<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006332.pub2" GROUP_ID="SYMPT" ID="591806010414574004" MERGED_FROM="" MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas" REVIEW_NO="157" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas">
<TITLE>Mu-opioid antagonists for opioid-induced bowel dysfunction</TITLE>
<CONTACT MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas"><PERSON ID="15659" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ewan</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>McNicol</LAST_NAME><POSITION>Clinical Pharmacist</POSITION><EMAIL_1>ewanmcnicol@comcast.net</EMAIL_1><ADDRESS><DEPARTMENT>Pharmacy and Anesthesiology</DEPARTMENT><ORGANISATION>Tufts Medical Center</ORGANISATION><ADDRESS_1>Box #420</ADDRESS_1><ADDRESS_2>800 Washington Street</ADDRESS_2><CITY>Boston</CITY><ZIP>02111</ZIP><REGION>MA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 617 636 2685</PHONE_1><PHONE_2>+1 617 636 5389</PHONE_2><FAX_1>+1 617 636 4633</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas"><PERSON ID="15659" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ewan</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>McNicol</LAST_NAME><POSITION>Clinical Pharmacist</POSITION><EMAIL_1>ewanmcnicol@comcast.net</EMAIL_1><ADDRESS><DEPARTMENT>Pharmacy and Anesthesiology</DEPARTMENT><ORGANISATION>Tufts Medical Center</ORGANISATION><ADDRESS_1>Box #420</ADDRESS_1><ADDRESS_2>800 Washington Street</ADDRESS_2><CITY>Boston</CITY><ZIP>02111</ZIP><REGION>MA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 617 636 2685</PHONE_1><PHONE_2>+1 617 636 5389</PHONE_2><FAX_1>+1 617 636 4633</FAX_1></ADDRESS></PERSON><PERSON ID="EC78107F82E26AA2017A33F26828F433" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Boyce</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>david.boyce@tufts.edu</EMAIL_1><ADDRESS><ORGANISATION>Tufts University School of Medicine</ORGANISATION><ADDRESS_1>145 Harrison Avenue</ADDRESS_1><CITY>Boston</CITY><ZIP>02111</ZIP><REGION>MA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>914-261-9180</PHONE_1></ADDRESS></PERSON><PERSON ID="EEFE6A4382E26AA2009C393D2C7C5933" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roman</FIRST_NAME><LAST_NAME>Schumann</LAST_NAME><POSITION>Associate Professor of Anesthesiology, Tufts University School of Medicine</POSITION><EMAIL_1>RSchumann@tuftsmedicalcenter.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anesthesiology</DEPARTMENT><ORGANISATION>Tufts Medical Center</ORGANISATION><ADDRESS_1>800 Washington Street</ADDRESS_1><ADDRESS_2>Box #298</ADDRESS_2><CITY>Boston</CITY><ZIP>02111</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 617-636-6044</PHONE_1><FAX_1>+1 617-636-8384</FAX_1></ADDRESS></PERSON><PERSON ID="15608" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Daniel</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Carr</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Saltonstall Professor of Pain Research</POSITION><EMAIL_1>daniel.carr@tufts.edu</EMAIL_1><EMAIL_2>dcarr@javelinpharma.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Anesthesia</DEPARTMENT><ORGANISATION>Tufts Medical Center</ORGANISATION><ADDRESS_1>Box #298, 800 Washington Street</ADDRESS_1><CITY>Boston</CITY><ZIP>MA 02111</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 617 636 9710</PHONE_1><FAX_1>+1 617 636 9709</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-30 18:55:58 +0000" MODIFIED_BY="Jessica Thomas">
<UP_TO_DATE>
<DATE DAY="8" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="1" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="8" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas"><DATE DAY="11" MONTH="5" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-11 17:05:57 +0200" MODIFIED_BY="Jessica Thomas"><DATE DAY="24" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-24 12:35:18 +0200" MODIFIED_BY="Jessica Thomas">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Further RM5 changes</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-30 18:55:24 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Minor update to references</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-30 18:55:19 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="11" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="8" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Evenor Armington Fund</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Richard Saltonstall Charitable Foundation</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-30 18:58:30 +0000" MODIFIED_BY="Jessica Thomas">
<SUMMARY>
<TITLE>Mu-opioid antagonists in the treatment of bowel dysfunction as a result of previous treatment by opioids</TITLE>
<SUMMARY_BODY>
<P>There is insufficient evidence to show that new opioid antagonists are effective in treating constipation due to strong analgesics. Opioids (morphine-like drugs) are substances used to treat severe pain. They cause many side effects, and frequently affect the stomach and bowels. Opioid-induced bowel dysfunction (OBD) is a recently coined term used to describe constipation, incomplete evacuation of the bowels, bloating, and increased reflux of stomach contents. OBD occurs both with short and long term use of opioids, in patients with many types of diseases, and causes increased disease and reduced quality of life. Traditional opioid antagonists (drugs that block the receptors which opioids bind to) can be used to reverse many of the side effects of opioids, including constipation, but because they block opioid receptors in the brain, they may also reverse reduction of pain. The search for opioid antagonists that act only in the gut ("peripherally active" antagonists), therefore not reversing reduction of pain, has produced two new drugs, methylnaltrexone and alvimopan, which are at an advanced phase of development. There is not enough information to make firm conclusions about the safety or effectiveness of traditional opioid antagonists in the treatment of OBD. Alvimopan and methylnaltrexone both show promise in treating OBD, but further data will be required to fully assess their effectiveness.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Opioid-induced bowel dysfunction (OBD) is characterized by constipation, incomplete evacuation, bloating, and increased gastric reflux. OBD occurs both acutely and chronically, in multiple disease states, resulting in increased morbidity and reduced quality of life. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the efficacy and safety of traditional and peripherally active opioid antagonists versus conventional interventions for OBD. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE in January 2007. Additional reports were identified from the reference lists of retrieved papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Studies were included if they were randomized controlled trials that investigated the efficacy of mu-opioid antagonists for OBD. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted by two independent review authors and included demographic variables, diagnoses, interventions, efficacy, and adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty-three studies met inclusion criteria and provided data on 2871 opioid antagonist-treated patients. The opioid antagonists investigated were alvimopan (nine studies), methylnaltrexone (six), naloxone (seven), and nalbuphine (one). Meta-analysis demonstrated that methylnaltrexone and alvimopan were better than placebo in reversing opioid-induced increased gastrointestinal transit time and constipation, and that alvimopan appears to be safe and efficacious in treating postoperative ileus. The incidence of adverse events with opioid antagonists was similar to placebo and generally reported as mild-to-moderate.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Insufficient evidence exists for the safety or efficacy of naloxone or nalbuphine in the treatment of OBD. Long-term efficacy and safety of any of the opioid antagonists is unknown, as is the incidence or nature of rare adverse events. Alvimopan and methylnaltrexone both show promise in treating OBD, but further data will be required to fully assess their place in therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-30 18:58:30 +0000" MODIFIED_BY="Jessica Thomas">
<BACKGROUND>
<P>Opioids can delay gastric emptying, decrease peristalsis and slow bowel motility, thereby causing constipation (<LINK REF="REF-Pasero-1999" TYPE="REFERENCE">Pasero 1999</LINK>). Opioid-induced bowel dysfunction (OBD) describes not only constipation, but also a constellation of symptoms including incomplete evacuation; bloating; abdominal distention; and increased gastric reflux (<LINK REF="REF-Pappagallo-2001" TYPE="REFERENCE">Pappagallo 2001</LINK>). Constipation, in turn, is defined as "the evacuation of hard stools less frequently than is normal for the individual" (<LINK REF="REF-Dickerson-1999" TYPE="REFERENCE">Dickerson 1999</LINK>), or as "a symptom (that is, a subjective phenomenon) characterized by diminished frequency of defecation associated with difficulty or discomfort" (<LINK REF="REF-Portenoy-1994" TYPE="REFERENCE">Portenoy 1994</LINK>). Constipation is the most commonly occurring adverse effect of chronic opioid therapy in patients with advanced cancer (<LINK REF="REF-McNicol-2003" TYPE="REFERENCE">McNicol 2003</LINK>). It is an almost inevitable consequence of opioid use in cancer and nonmalignant disease states, and one of the side effects of opioids to which few patients develop tolerance. </P>
<P>Postoperative ileus, a temporary impairment of gastrointestinal tract motility after abdominal or other surgery, is characterized by abdominal distension, lack of bowel sounds, accumulation of gas and fluids in the bowel, and delayed passage of flatus and defecation (<LINK REF="REF-Kehlet-2001" TYPE="REFERENCE">Kehlet 2001</LINK>). It has multifactorial etiologies, including the common use of opioids perioperatively. Postoperative ileus can contribute to pain and discomfort, reduce the ability for patients to take oral nutrition, increase the risk for pulmonary complications (due to gastric reflux and immobility) and increase the length of hospital stay (<LINK REF="REF-Kehlet-2000" TYPE="REFERENCE">Kehlet 2000</LINK>). Opioids, therefore, can precipitate bowel dysfunction both acutely and chronically, in patients with cancer and non-malignant disease, and may increase morbidity and reduce quality of life. </P>
<P>Traditional treatment of opioid-induced constipation in patients with chronic or cancer pain includes the use of a stimulant and a stool softener. The long-term effectiveness and safety of such a regimen is unclear. A prokinetic drug, such as metoclopramide, may also be employed to reduce gastric stasis (<LINK REF="REF-McNicol-2003" TYPE="REFERENCE">McNicol 2003</LINK>). There are currently no pharmacological agents licensed for the treatment of postoperative ileus. Multimodal interventions, such as the introduction of early enteral nutrition and the use of epidural anesthetics, combined with a reduction in opioid use, have been shown to reduce duration of ileus, but are labor intensive (<LINK REF="REF-Kehlet-2000" TYPE="REFERENCE">Kehlet 2000</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>). </P>
<P>The use of opioid antagonists such as naloxone may directly reduce opioid-induced adverse effects. However, analgesia may also be reversed, therefore titration to a balance between reduced adverse effects and satisfactory analgesia is challenging. The search for opioid antagonists that act locally in the gut, without reversing analgesia has involved the reformulation, or oral administration of existing antagonists, such as naloxone, and the development of new compounds. To date no new compound is commercially available. However, two new drugs, methylnaltrexone and alvimopan, are at an advanced phase of development. </P>
</BACKGROUND>
<OBJECTIVES>
<P>The purpose of this review was to compare the efficacy of both existing and new opioid antagonists versus conventional pharmacological or non pharmacological treatments for OBD and to evaluate adverse events reported in clinical trials.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-30 18:58:30 +0000" MODIFIED_BY="Jessica Thomas">
<SELECTION_CRITERIA MODIFIED="2008-10-30 18:57:57 +0000" MODIFIED_BY="Jessica Thomas">
<CRIT_STUDIES>
<P>Trials were included in this review if they were randomized controlled trials (RCTs) which investigated the efficacy of mu-opioid antagonists for OBD. Reports were excluded if they were non-randomized, case reports, or clinical observations.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants of any age and either sex were included. Patients receiving opioids for chronic cancer and noncancer pain and those receiving opioids as part of a postoperative regimen were included. </P>
<P>Since two of the opioid antagonists included in the review were at the developmental phase, studies employing healthy volunteers were also included, assuming that participants received both an opioid and an opioid antagonist, and fulfilled all other inclusion criteria. The results of the studies including healthy volunteers were analyzed separately through sub group analysis from those studies that enrolled patients.<I> </I>Future updates of this review will exclude studies with healthy volunteers once additional data in clinical models are available. Symptoms investigated included constipation, gastric stasis and postoperative ileus.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Mu receptor opioid antagonists, agonist/antagonists, or partial agonists, either peripherally or systemically acting, administered at any dose and by any route versus any comparator, such as a different opioid antagonist; an alternative pharmacological or non-pharmacological intervention; a placebo or versus no treatment. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-30 18:57:57 +0000" MODIFIED_BY="Jessica Thomas">
<P>Information about the indication for opioid, number of patients studied, opioid and opioid antagonist drug and dosing regimen, study design (placebo or active control, parallel or crossover), study duration and follow-up, OBD outcome measures and results, withdrawals and adverse events were included.<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-30 18:56:50 +0000" MODIFIED_BY="Jessica Thomas">
<OL>
<LI>in experimental models, gastrointestinal transit time;</LI>
<LI>in studies of constipation, bowel movements (BM): time to, number per time period, total number, immediate laxation, global assessment, proportion of patients having BM within given time period, weight and ease of;</LI>
<LI>in studies of postoperative ileus, combined endpoints such as: flatus/BM: time to latter; flatus/BM/solid food: time to latter; or solid food/BM: time to latter.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-30 18:57:57 +0000" MODIFIED_BY="Jessica Thomas">
<OL>
<LI>flatus: time to;</LI>
<LI>opioid withdrawal symptoms;</LI>
<LI>pain;</LI>
<LI>analgesic requirements;</LI>
<LI>constipation assessment scales;</LI>
<LI>length of stay: intensive care unit, overall, time to readiness for discharge, time until actual discharge;</LI>
<LI>requirement for postoperative chest X-ray;</LI>
<LI>nasogastric tube insertion;</LI>
<LI>gastric tube reflux volume;</LI>
<LI>overall satisfaction.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-04-11 22:24:04 +0100" MODIFIED_BY="Ewan McNicol">
<P>We identified trials for inclusion in the review by searching the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 1, 2007), EMBASE (1974 to 2006) and MEDLINE (1950 to April Week 1, 2007). Additional reports were identified from the reference lists of retrieved papers. No language restriction was applied. Both the Food and Drug Administration (FDA) and European Medicine Evaluation Agency websites were searched for additional trials. We contacted the manufacturers of methylnaltrexone and alvimopan for information on unpublished trials.<BR/>
<BR/>The strategy employed for searching MEDLINE via OVID is detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We adapted this search strategy for the CENTRAL and EMBASE databases.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-30 18:58:30 +0000" MODIFIED_BY="Jessica Thomas">
<SUBSECTION>
<HEADING LEVEL="4">Selection of studies</HEADING>
<P>Eligibility was initially determined by reading the titles and abstracts retrieved from each search. Full-length articles of potentially eligible studies were obtained and assessed. All abstracts and potentially eligible articles were read by two review authors (EM and DB). Disagreements were resolved by discussion, or if persistent, by a third review author (DC). The reports were not anonymized in any way prior to assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data extraction and management</HEADING>
<P>Data (as detailed in 'Types of outcome measures') were independently extracted from each study by two review authors (EM and DB) using a data extraction sheet. Disagreements were resolved by discussion, or if persistent, by a third review author (DC).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of methodological quality of included studies</HEADING>
<P>Each report was scored for quality by two review authors (EM and DB). The three-item Oxford Quality Score scale (<LINK REF="REF-Jadad-1996a" TYPE="REFERENCE">Jadad 1996a</LINK>) was used to assess study quality. This scoring system employs the following five questions, yielding a maximum possible score of five points:<BR/>1a) is the study randomized? If yes, add one point;<BR/>1b) is there a description of an adequate generation of the random sequence? If yes, add one point. If not, deduct one point;<BR/>2a) is the study double blind? If yes, add one point;<BR/>2b) is there an explicit statement that the patients and evaluators were blinded and the treatment was indistinguishable? If yes, add one point. If not, deduct one point;<BR/>3) are withdrawals and dropouts described? If yes, add one point.</P>
<P>Disagreement between review authors regarding the score allocated to each trial was resolved by discussion or a third review author (DC). Quality scores were not, however, used to weight the studies in any way. Studies with a score of three or more were termed "high quality"; those with two or less were described as "low quality".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Measures of treatment effect</HEADING>
<P>
<B>
<I>Dichotomous data</I>
</B>
<BR/>Discrete events such as preference for opioid antagonist versus conventional treatment regimens, or the number of patients reporting adverse events were used to calculate absolute risk reduction (ARR, also known as risk difference) using RevMan 4.2.8<I> </I>software (<LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>; <LINK REF="REF-McQuay-1998" TYPE="REFERENCE">McQuay 1998</LINK>). When a statistically significant ARR existed between interventions, numbers-needed-to-treat-to-benefit (NNTBs) or numbers needed-to-treat-to-harm (NNTHs) were derived. Dichotomous outcomes were also presented in terms of both raw numbers and percentages of patients in each study arm benefiting from therapy or suffering adverse events.</P>
<P>
<B>
<I>Continuous data</I>
</B>
<BR/>Continuous outcomes (e.g., time to first BM, pain intensity, analgesic consumption, intensity of a specific adverse event) were combined using weighted mean differences (WMDs). Meta-analyses were undertaken when appropriate comparable data were available. We applied a fixed-effect model to assess outcomes data unless significant heterogeneity was present, in which case we applied a random-effects model.</P>
<P>
<B>
<I>Time-to-event data</I>
</B>
<BR/>Hazard ratios (HRs) derived from time-to-event data, such as time to first BM/solid food, were combined if appropriate using methods described by Sutton <I>et al.</I> (<LINK REF="REF-Sutton-2000" TYPE="REFERENCE">Sutton 2000</LINK>).</P>
<P>
<B>
<I>Unit of analysis issues</I>
</B>
<BR/>Crossover trials were combined in analyses with parallel trials. Sensitivity analyses, where crossover trials were removed, were conducted where possible.</P>
<P>
<B>
<I>Dealing with missing data</I>
</B>
<BR/>No attempts were made to contact authors for missing patient data. If patient data was missing, analyses were based on patient populations in which outcomes were reported. Discrepancies between number of patients enrolled and number of patients in whom outcomes were reported were noted in the 'Characteristics of included studies' table. Where studies reported statistics based on intention-to-treat (ITT) or modified ITT populations, available case analyses were performed (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>).</P>
<P>
<B>
<I>Assessment of heterogeneity</I>
</B>
<BR/>We assessed statistical heterogeneity using the I<SUP>2</SUP> statistic. The I<SUP>2</SUP> statistic is a reliable and robust test to quantify heterogeneity, since it does not depend on the number of trials or on the between-study variance. I<SUP>2</SUP> measures the extent of inconsistency among studies' results, and can be interpreted as the proportion of total variation in study estimates that is due to heterogeneity rather than sampling error. An I<SUP>2</SUP> value of greater than 50% is considered to indicate substantial heterogeneity (<LINK REF="REF-Deeks-2006" TYPE="REFERENCE">Deeks 2006</LINK>). We also assessed heterogeneity by visually studying forest plots. Where possible, subanalyses or sensitivity analyses were performed in an attempt to explain heterogeneity.</P>
<P>
<B>
<I>Assessment of reporting biases</I>
</B>
<BR/>No attempt was made to assess reporting bias. The inclusion of abstracts, searching of FDA and European Medicine Evaluation Agency websites, and direct contact with manufacturers for unpublished studies was undertaken in an attempt to minimize publication bias.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-13 13:36:21 +0100" MODIFIED_BY="Laila Tyrrell">
<STUDY_DESCRIPTION>
<P>The literature search generated 418 citations (MEDLINE, 131; CENTRAL, 57; EMBASE, 230), of which 48 were selected for retrieval of the full article. Neither EMBASE nor CCRCT provided additional articles to those generated by the MEDLINE search. Neither the FDA nor the European Medicine Evaluation Agency websites provided information relevant to our search.</P>
<P>Twenty-three of the 48 retrieved articles met our inclusion criteria and provided data on 2871 opioid antagonist-treated participants. One included study was published as an abstract only (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>). All included studies are presented in the 'Characteristics of included studies' table. </P>
<P>The opioid antagonist investigated was alvimopan in nine studies (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>; <LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Gonenne-2005" TYPE="STUDY">Gonenne 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Liu-2000" TYPE="STUDY">Liu 2000</LINK>; <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>), methylnaltrexone in six studies (<LINK REF="STD-Murphy-1997" TYPE="STUDY">Murphy 1997</LINK>;<I> </I>
<LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>;<I> </I>
<LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>;<I> </I>
<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>;<I> </I>
<LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>;<I> </I>
<LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>), naloxone in seven studies (<LINK REF="STD-Hawkes-2001" TYPE="STUDY">Hawkes 2001</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>;<I> </I>
<LINK REF="STD-Meissner-2003" TYPE="STUDY">Meissner 2003</LINK>;<I> </I>
<LINK REF="STD-Meissner-2004" TYPE="STUDY">Meissner 2004</LINK>;<I> </I>
<LINK REF="STD-Nimmo-1979" TYPE="STUDY">Nimmo 1979</LINK>;<I> </I>
<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>), and nalbuphine in one (<LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>)<I>.</I> All studies were placebo-controlled trials and none employed an active control. The study population included healthy volunteers in ten studies<I> </I>(157 subjects, 5.5% of the overall population studied) (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>; <LINK REF="STD-Gonenne-2005" TYPE="STUDY">Gonenne 2005</LINK>; <LINK REF="STD-Hawkes-2001" TYPE="STUDY">Hawkes 2001</LINK>; <LINK REF="STD-Liu-2000" TYPE="STUDY">Liu 2000</LINK>; <LINK REF="STD-Murphy-1997" TYPE="STUDY">Murphy 1997</LINK>; <LINK REF="STD-Nimmo-1979" TYPE="STUDY">Nimmo 1979</LINK>; <LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>; <LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>; <LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>; <LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>) (all measured GI transit time), postoperative patients in seven studies (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>), patients receiving chronic opioid therapy in four studies (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>
<I>; </I>
<LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>
<I>; </I>
<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>
<I>; </I>
<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>)<I> </I>(malignant or non-malignant pain and methadone maintenance), and mechanically ventilated, intensive care patients in two studies (<LINK REF="STD-Meissner-2003" TYPE="STUDY">Meissner 2003</LINK>; <LINK REF="STD-Meissner-2004" TYPE="STUDY">Meissner 2004</LINK>) (receiving opioids, but not having undergone GI surgery). </P>
<P>Thirteen studies (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>; <LINK REF="STD-Gonenne-2005" TYPE="STUDY">Gonenne 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>; <LINK REF="STD-Meissner-2003" TYPE="STUDY">Meissner 2003</LINK>; <LINK REF="STD-Meissner-2004" TYPE="STUDY">Meissner 2004</LINK>; <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>; <LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>) had a parallel design and ten (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>; <LINK REF="STD-Hawkes-2001" TYPE="STUDY">Hawkes 2001</LINK>; <LINK REF="STD-Liu-2000" TYPE="STUDY">Liu 2000</LINK>; <LINK REF="STD-Murphy-1997" TYPE="STUDY">Murphy 1997</LINK>; <LINK REF="STD-Nimmo-1979" TYPE="STUDY">Nimmo 1979</LINK>; <LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>; <LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>; <LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>; <LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>; <LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>) were crossover studies. Study duration varied from less than 24 hours (single-dose trials) to 35 days, and was related to the populations and outcomes studied: those conducted in healthy volunteers measuring GI transit were mostly short single-dose trials; those involving surgical patients and measuring postoperative ileus lasted approximately one week; and studies enrolling patients receiving chronic opioid therapy and measuring resolution of constipation were routinely carried out over a week or longer. Numbers of patients enrolled also varied according to the populations and outcomes measured, and to the drug intervention. Trials assessing alvimopan use in postoperative ileus enrolled on average 412 patients, whereas those investigating naloxone reversal of opioid-related constipation enrolled 18 patients on average.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The quality of studies as assessed by the Oxford Quality Scale score varied widely from one (lowest quality) to five (highest quality). </P>
<P>In the studies of healthy volunteers, one open (i.e. non-blinded) study scored one point (<LINK REF="STD-Nimmo-1979" TYPE="STUDY">Nimmo 1979</LINK>), one study scored two points (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>), three scored three points (<LINK REF="STD-Gonenne-2005" TYPE="STUDY">Gonenne 2005</LINK>; <LINK REF="STD-Murphy-1997" TYPE="STUDY">Murphy 1997</LINK>), four studies scored four points (<LINK REF="STD-Hawkes-2001" TYPE="STUDY">Hawkes 2001</LINK>; <LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>; <LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>; <LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>), and one study scored five points (<LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>). </P>
<P>For the studies involving patients, two studies scored one point (<LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>) (<LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK> was an open study), one scored two points (<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>), five scored three points<I> </I>(<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>;<I> </I>
<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>;<I> </I>
<LINK REF="STD-Meissner-2003" TYPE="STUDY">Meissner 2003</LINK>;<I> </I>
<LINK REF="STD-Meissner-2004" TYPE="STUDY">Meissner 2004</LINK>;<I> </I>
<LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>)<I>,</I> four scored four points (<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>; <LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>), and one study scored five points<I> </I>(<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>).<I> </I>Quality was not related to disease state studied, but was related to opioid antagonist administered: studies employing methylnaltrexone had the highest quality (median score = 4), followed by alvimopan and naloxone (median score = 3) and nalbuphine (one study, Oxford score = 1).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-13 13:36:21 +0100" MODIFIED_BY="Laila Tyrrell">
<SUBSECTION>
<HEADING LEVEL="4">Meta-analyses of efficacy outcomes</HEADING>
<P>In the studies where alvimopan was administered, means and standard deviations were not routinely reported. Attempts were made to obtain them by contacting both the authors of each study and the manufacturer of the drug. No further data were supplied by either, therefore the following meta-analyses are based only on data reported in the original papers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gastrointestinal transit time </HEADING>
<P>Eight studies<I> </I>(<LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>; <LINK REF="STD-Liu-2000" TYPE="STUDY">Liu 2000</LINK>; <LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>; <LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>; <LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>; <LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>; <LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>; <LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>) enrolling 127 subjects assessed GI transit time by measuring breath hydrogen levels post ingestion of lactulose.</P>
<P>Three studies enrolled 72 patients in the immediate postoperative period (<LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>), subjects receiving methadone maintenance (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>) and patients with cancer (<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>). The intervention in these studies was methylnaltrexone (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>), nalbuphine (<LINK REF="STD-Freye-1988" TYPE="STUDY">Freye 1988</LINK>) or naloxone (<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>). The three studies were not combined as the different intervention drugs and populations produced clearly heterogenous outcomes; methylnaltrexone reduced transit time (54 minutes versus 125 minutes; 95% Confidence Interval (CI) = -100 to - 42); nalbuphine increased transit time (380 minutes versus placebo 270 minutes; 95% CI = 64 to 156); and naloxone did not produce a statistically significant change (Comparison 01, Outcome 01).</P>
<P>Five studies enrolled 55 healthy volunteers and administered methylnaltrexone (<LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>; <LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>; <LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>; <LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>) or alvimopan (<LINK REF="STD-Liu-2000" TYPE="STUDY">Liu 2000</LINK>). We had sufficient data to combine the four studies where methylnaltrexone was administered (Comparison 01, Outcome 02 02). On average, GI transit time in patients receiving methylnaltrexone was reduced by 52 minutes versus placebo (95% CI: -73 to -32). Mean transit times ranged from 93 to 110 minutes in the methylnaltrexone arms, whereas in the placebo arms times ranged from 140 to 163 minutes. The single alvimopan study demonstrated a reduced transit time for the intervention group (76 minutes versus placebo 103 minutes, 95% CI = -52 to -2).</P>
<P>Two studies assessed time to empty 50% of gastric contents in a total of 15 healthy volunteers and tested either methylnaltrexone (<LINK REF="STD-Murphy-1997" TYPE="STUDY">Murphy 1997</LINK>) or naloxone (<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>) (Comparison 01, Outcome 03). Both were crossover studies. Methylnaltrexone and naloxone accelerated opioid-delayed emptying time by 14 minutes (95% CI: -20 to -8) and 70 minutes (95% CI: -107 to -32) respectively versus placebo. In both studies combined, using a fixed-effect model, emptying time was reduced by 15 minutes (95% CI: -21 to -10). However, the I<SUP>2</SUP> statistic (87.8%) and inspection of the forest plot suggest considerable heterogeneity between the studies. When a random-effects model was employed the aggregate effect from both studies was no longer statistically significant.</P>
<P>Four studies in healthy volunteers presented data on outcomes (e.g., positioning of colonic markers) that we were not able to meta-analyze (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>; <LINK REF="STD-Gonenne-2005" TYPE="STUDY">Gonenne 2005</LINK>; <LINK REF="STD-Hawkes-2001" TYPE="STUDY">Hawkes 2001</LINK>; <LINK REF="STD-Nimmo-1979" TYPE="STUDY">Nimmo 1979</LINK>). Two studies demonstrated that alvimopan reversed opioid-induced increases in GI transit (<LINK REF="STD-Barr-2000" TYPE="STUDY">Barr 2000</LINK>; <LINK REF="STD-Gonenne-2005" TYPE="STUDY">Gonenne 2005</LINK>). The other two studies also demonstrated improvement in GI transit outcomes in patients administered the non-selective opioid antagonist naloxone (<LINK REF="STD-Hawkes-2001" TYPE="STUDY">Hawkes 2001</LINK>; <LINK REF="STD-Nimmo-1979" TYPE="STUDY">Nimmo 1979</LINK>). Given the heterogeneity of the interventions and outcomes data and the limited information provided on adverse events, it was not possible to make any firm conclusions based on these four studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Postoperative Ileus</HEADING>
<P>Six studies investigated opioid antagonist use in patients at risk of developing postoperative ileus. Five studies enrolling a total of 2225 patients administered alvimopan (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) and one naloxone (43 patients) (<LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>). All studies had a parallel group design. In the alvimopan studies the primary outcome was either time to first BM or flatus (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>) or a composite measure of time to passage of flatus or stool and tolerating solid food (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Similarly, the naloxone study investigated time to first postoperative passage of flatus and feces. The alvimopan studies reported most outcomes as hazard ratios derived from time-to-event variables, whereas the naloxone study presented means and standard deviations.</P>
<P>Secondary outcomes included pain (Visual Analogue Scale (VAS) intensity), opioid consumption, time to readiness for hospital discharge, insertion of a nasogastric tube, and need for chest x-ray.</P>
<P>The alvimopan studies reported sufficient information to allow us to combine the following outcomes for both a 6 mg and 12 mg dose: GI-3 (the later of two events: time that participant first tolerates solid food, or time the participant first passes flatus or has a BM); GI-2 (the later of the participant tolerating solid food or having a BM); time to first BM; time to first solid food, time to readiness for discharge; and time to actual discharge order written. We used a random-effects model since I<SUP>2</SUP> values for two of the outcomes (GI-2 and time to first bowel movement) suggested the presence of heterogeneity. The results of these meta-analyses are shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. The combined outcomes demonstrate that alvimopan is superior to placebo for all outcomes except for first solid food, where alvimopan shows a trend towards superiority. The results also indicate that there is no advantage to increasing the dose of alvimopan from 6 to 12 mg. <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK> reported outcomes (time to first flatus, BM, liquids and solids, and time to readiness for and actual discharge) for 26 patients receiving a 1 mg dose of alvimopan. Due to the small sample size in the <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK> study, the CI around the point estimate for each outcome were too wide to show significant differences between this dose and 6 or 12 mg. However, there is a trend towards superior efficacy in both the 6 and 12 mg doses versus 1 mg for most outcomes.</P>
<P>The alvimopan studies also reported the numbers of participants requiring chest x-ray or insertion of a nasogastric tube. In the former outcome, a dose of 6 mg resulted in a 6% ARR (95% CI: -11 to -1), whereas the 12 mg dose produced a non-statistically significant reduction of 4% (Comparison 04, Outcome 01). In total, 77 of 720 (11%) participants receiving alvimopan required an x-ray versus 57 of 369 (15%) receiving placebo. The 6 and 12 mg doses resulted in a 4% and 3% ARR for insertion of nasogastric tube respectively (Comparison 05, Outcome 01). In the 6 mg analysis, 6% of those receiving alvimopan required insertion versus 10% of those who were administered placebo. The nasogastric data for 12 mg of alvimopan appeared heterogenous (I<SUP>2</SUP> = 68%). Using a random-effects model for this outcome, the data were no longer statistically significant.</P>
<P>The single study of epidural naloxone reported earlier flatus and first BM versus placebo (<LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>). It was not possible to compare measures of efficacy for oral alvimopan and epidural naloxone due to the different manner in which outcomes were presented. However, one study for each intervention presented postoperative maximum VAS pain scores versus placebo in a manner that permitted meta-analysis (<LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>) (Comparison 03, Outcome 01). The respective studies demonstrated no difference in pain scores between epidural naloxone and placebo or oral alvimopan and placebo, suggesting that neither intervention antagonized analgesia. In addition, the four other studies administering alvimopan to postoperative patients all reported no difference in maximum or average VAS scores for all doses versus placebo. All five alvimopan studies measured opioid consumption. In all but two cases, opioid consumption was similar between active and placebo groups. <LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK> reported a statistically significant difference between placebo and 12 mg alvimopan (25.6 mg versus 31.6 mg) and <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK> reported a statistically significant difference between placebo and 6 mg alvimopan (27 mg versus 33.6 mg). The studies were not combinable due to non-reporting of standard deviations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Constipation</HEADING>
<P>Four studies enrolling a total of 147 patients investigated opioid antagonist use in patients with constipation due to chronic opioid usage. Two studies administered naloxone (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>; <LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>), one alvimopan (<LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>) and one methylnaltrexone (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>). All were parallel studies except for <LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>, which employed a crossover design. Indications for opioid use included cancer pain, non-cancer pain and methadone maintenance. Assessment of constipation varied amongst studies and included composite scales, proportion of patients with a BM within a specified time period, small bowel transit time, stool frequency, and overall satisfaction. Possible reversal of analgesia was assessed by using the Short Form Brief Pain Inventory, VAS pain intensity, and withdrawal scales.</P>
<P>The studies reported sufficient data to allow us to analyze three separate measures of efficacy; number of patients with a BM within a specified time period; BMs per week; and number of patients satisfied with BMs (Comparison 02, Outcomes 01, 02 and 03 respectively).</P>
<P>The studies by <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK> and <LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK> investigated the number of patients reporting a BM within 8 hours or immediate laxation respectively (Comparison 02, Outcome 01). The former study enrolled patients with cancer pain, non-cancer pain, and opioid dependency and administered alvimopan. The latter study enrolled patients receiving methadone maintenance and administered methylnaltrexone. Both the study populations and the outcome measures, therefore, appeared heterogenous. The meta-analysis also demonstrated significant heterogeneity (I<SUP>2</SUP> = 98%). However, individually both studies showed statistically significant improvement for antagonist versus placebo. Fifty-four percent of patients receiving alvimopan had a BM versus 30% of those receiving placebo, which translates to an NNTB of 4.2 (95% CI: 2.4 to 16.7). One-hundred percent of patients receiving methylnaltrexone had immediate laxation versus none in the placebo group, which translates to an NNTB of 1 (95% CI: 0.86 to 1.2). When both studies are combined using a fixed-effect model the use of an opioid antagonist produces an NNTB of 2.7 (95% CI: 1.9 to 4.8). However, when a random-effects model is employed to adjust for between study heterogeneity the combined effect observed in the two studies is no longer statistically significant.</P>
<P>Three studies assessed number of BMs per week (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>; <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>; <LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>) (Comparison 02, Outcome 02). Only the study by <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK> enrolled more than ten patients. Each of the three studies demonstrated a statistically insignificant trend towards improvement with opioid antagonist versus placebo. When the three studies are combined, the improvement achieves statistical significance, with patients receiving an opioid antagonist having 1.4 BMs more per week than those receiving placebo (95% CI: 0.2 to 2.5). When sensitivity analysis is performed to remove the crossover study by <LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK> the improvement is still statistically significant (WMD: 1.2; 95% CI: 0.03 to 2.9).</P>
<P>Lastly, three studies assessed patient satisfaction (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>; <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>; <LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>) (Comparison 02, Outcome 03). All three studies showed a significant improvement in patients' satisfaction with their BMs when receiving opioid antagonist versus placebo, with methylnaltrexone appearing to demonstrate the greatest improvement (100% of patients satisfied versus 22% of patients receiving placebo) (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>). Using a fixed-effect model, the three studies combined demonstrated a statistically significant improvement in satisfaction, with 75% of patients receiving opioid antagonist satisfied versus 44% of those receiving placebo. This translates to a NNTB of 3.1 (95% CI: 2.1 to 6.2). Both the forest plot and the I<SUP>2</SUP> statistic (85%) suggest that considerable between-study heterogeneity exists. However, the combination of studies using a random-effects model continues to show a significant improvement in satisfaction for patients receiving an opioid antagonist.</P>
<P>Two studies assessed numbers of patients reporting reversal of analgesia by capturing any increases in baseline pain intensity (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>; <LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>) (Comparison 03, Outcome 02). Neither study defined the increment in pain intensity VAS that was considered to indicate reversal. Separately and in combination neither study showed any difference between opioid antagonist and placebo in number of patients reporting reversal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Meta-analyses of safety data</HEADING>
<P>Twenty-nine different adverse events were reported, of which 19 were reported in a similar manner by more than one paper, thereby making meta-analysis possible. Safety data were meta-analyzed by incidence or severity of adverse event, and where possible sub-analyzed by intervention and disease state. Where data for different dosage strengths were provided, incidence or severity was analyzed for each strength. Where papers reported an absence of adverse events they were not added to the analysis. Although most data were reported as incidence rather than severity, authors often described severity as mild-to-moderate, or not serious. Analysis failed to show a difference between opioid antagonist and placebo except for the following adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nausea (Comparison 06)</HEADING>
<P>Meta-analysis using a fixed-effect model did not demonstrate significant reductions in the incidence of nausea for any drug at any strength, nor was there evidence of an overall class effect (Comparison 06, Outcome 01). On the other hand, a single study of alvimopan 6 mg administered to 26 postoperative patients demonstrated a reduction in severity of nausea (WMD of 20% (95% CI: -35 to -5)) (<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>). A single study of methylnaltrexone administered to healthy volunteers (<LINK REF="STD-Murphy-1997" TYPE="STUDY">Murphy 1997</LINK>) did not demonstrate a statistically significant difference versus placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vomiting (Comparison 07)</HEADING>
<P>As with the analysis of the incidence of nausea, there was no significant reduction in the number of patients that vomited for any drug at any strength (Comparison 07, Outcome 01). However, there was evidence of an overall class effect, with a 4% ARR (95% CI: -7 to -1). Class effect statistical significance disappeared when a random-effects model was used to account for between study heterogeneity (I<SUP>2</SUP> = 66%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Abdominal Cramping (Comparison 11)</HEADING>
<P>In a single study enrolling 22 patients with opioid-induced constipation all eleven of those administered methylnaltrexone reported mild abdominal cramping versus none of eleven administered placebo (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>). No overall class effect was seen in the ten trials that reported incidence of cramping, and no other drug in any other condition produced an increase in abdominal symptoms versus placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Diarrhea (Comparison 12)</HEADING>
<P>A single study of alvimopan administered to patients with constipation showed an increase in the incidence of diarrhea in those patients versus patients receiving placebo (<LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>). Six of 56 (11%) patients receiving alvimopan complained of diarrhea versus none of 54 receiving placebo. This translates to an absolute increase in risk of 11% (95% CI: 2 to 19) and an NNTH of nine (95% CI: 5 to 50). There was no difference in incidence of diarrhea in any other populations (postoperative ileus, healthy volunteers) or with different antagonists (methylnaltrexone, naloxone).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Constipation (Comparison 13)</HEADING>
<P>In postoperative patients, meta-analysis demonstrated that both alvimopan 6 mg and 12 mg reduced the risk of incidence of constipation. Twenty-two of 370 (6%) patients administered alvimopan 6 mg reported suffering from constipation versus 39 of 377 (10%) administered placebo, translating to an ARR of 4% (95% CI: - 8 to -1). Similarly, 120 of 780 (15%) patients administered alvimopan 12 mg reported constipation versus 72 of 483 (15%) patients administered placebo, translating to an ARR of 5% (95% CI: -9 to -1). The 12 mg analysis appeared to be statistically heterogenous (I<SUP>2</SUP> = 54%). When a random-effects model was employed, neither strength continued to show a statistically significant reduction in constipation, but an overall class effect remained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Postoperative Ileus (Comparison 14)</HEADING>
<P>When a fixed-effect model was used to combine four studies of alvimopan 12 mg administered to postoperative patients a statistically significant reduction in the incidence of ileus was seen (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Thirty-nine of 956 patients (4%) receiving alvimopan versus 63 of 648 (10%) receiving placebo reported suffering from ileus, translating to an ARR of 4% (95% CI: -7 to -1). When data for a dose of 6 mg from the same three studies were combined, the reduction was in ileus was not significant. The higher dose data appeared to be borderline heterogenous (I<SUP>2</SUP> = 50%) and when a random-effects model was employed the analysis was no longer statistically significant. The authors from these four studies did not report how ileus was defined.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anxiety/jitteriness (Comparison 17)</HEADING>
<P>If the outcomes anxiety and jitteriness are combined, a single study (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>) showed an increased incidence in patients with constipation administered naloxone versus those administered placebo. The study population was very small, however. Three of six patients (50%) receiving naloxone versus none of three receiving placebo reported this combined outcome. The small sample size is reflected in the wide CIs for increase in absolute risk of 50% (95% CI: 1 to 99) and NNTH of 2 (95% CI: 1.01 to 100).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oliguria (Comparison 25)</HEADING>
<P>Meta-analysis of data from two studies (<LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) demonstrated a tendency towards reduction in incidence of oliguria (decreased production of urine). When data from both doses were combined an overall effect of ARR of 4% (95% CI: -7 to -1) was observed. Seventy-six of 786 patients (10%) receiving alvimopan suffered from oliguria versus 104 of 778 (13%) receiving placebo. The results appeared to be homogenous (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment-related withdrawals (Comparison 31)</HEADING>
<P>Postoperative patients administered 6 mg of alvimopan were less likely to withdraw from the study due to their treatment than those receiving placebo (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>). Thirty-one of 539 patients (6%) receiving 6 mg of alvimopan withdrew versus 59 of 542 (11%) receiving placebo, which translates to an ARR of 5% (-8 to -2). Differences on treatment-related withdrawals did not differ significantly for the higher dose of 12 mg versus placebo, or for alvimopan or naloxone in other conditions, although analysis showed a marginal overall class effect. However, when a random-effects model was employed reductions in both the 6 mg alvimopan analysis and the overall analysis no longer achieved statistical significance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serious adverse events (Comparison 32)</HEADING>
<P>Alvimopan 6 mg (n = 539) and 12 mg (n = 956) demonstrated a 5% and 4% ARR respectively in serious adverse events versus placebo in postoperative patients when a fixed-effect model was used. However, in both cases there was evidence of heterogeneity of data (I<SUP>2</SUP> &gt; 60%). When a random-effects model was employed the reduction at both doses was no longer statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rehospitalization (Comparison 33)</HEADING>
<P>An overall reduction in rehospitalization was seen when data from both 6 mg and 12 mg doses of alvimopan were combined in postoperative patients. Fifty-one of 1199 patients receiving alvimopan (4%) were rehospitalized versus 77 of 884 (9%) receiving placebo.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-13 13:36:27 +0100" MODIFIED_BY="Laila Tyrrell">
<P>Our objective in this review was to compare the efficacy and safety of both traditional nonselective opioid antagonists and newer, peripherally selective antagonists versus placebo or other existing pharmacological or nonpharmacological treatments for OBD. We hypothesized that the newly developed peripherally acting opioid antagonists would have similar efficacy to that of nonselective antagonists in reversing opioid-induced constipation or postoperative ileus, but would be less likely than nonselective antagonists to reverse centrally mediated opioid effects such as analgesia.</P>
<SUBSECTION>
<HEADING LEVEL="4">Efficacy</HEADING>
<P>
<BR/>
<I>
<B>Gastrointestinal transit time<BR/>
</B>
</I>Our analyses demonstrate that opioid-induced increases in GI transit time are reversed by methylnaltrexone in healthy volunteers (<LINK REF="STD-Yuan-1996" TYPE="STUDY">Yuan 1996</LINK>; <LINK REF="STD-Yuan-1997" TYPE="STUDY">Yuan 1997</LINK>; <LINK REF="STD-Yuan-2000b" TYPE="STUDY">Yuan 2000b</LINK>; <LINK REF="STD-Yuan-2002" TYPE="STUDY">Yuan 2002</LINK>). The clinical significance of a 52 minute reduction in GI transit time in this population is unclear. In addition, it is not possible to assess reversal of analgesia in a non-pain population. The one methylnaltrexone study that enrolled patients in a methadone maintenance program with chronic constipation demonstrated that reductions in GI transit time were accompanied by a laxation response in all patients (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>). It is not possible to make firm conclusions regarding the efficacy of any other opioid antagonist in reducing transit time, or to make comparisons between antagonists because there was insufficient trial data available. Also, we could not compare overall results in studies that involved healthy volunteers versus those that enrolled patients due, in part, to the fact that different antagonists were used in the two populations. Only methylnaltrexone was assessed in both populations; it demonstrated a similar reversal of opioid-induced increase in GI transit time in both healthy volunteers and in a single study of patients in a methadone maintenance program. Adverse event data in healthy volunteers were also insufficient to make any overall comparisons versus patients for drug safety profiles.<BR/>
<B>
<BR/>
<I>Postoperative ileus</I>
</B>
<BR/>Evaluating the effectiveness of therapeutic agents for postoperative ileus is challenging because the definition of ileus and methods for assessing it are not clear (<LINK REF="REF-Kurz-2003" TYPE="REFERENCE">Kurz 2003</LINK>). Our meta-analyses of hazard ratios derived from multiple outcomes from the five studies of alvimopan<I> </I>(<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) demonstrated that alvimopan was more effective than placebo for all outcomes except time to solid food (<LINK REF="REF-Spruance-2004" TYPE="REFERENCE">Spruance 2004</LINK>). However, the clinical significance of these differences is unclear. It is also unclear what is the most effective dose of alvimopan. The results of the outcomes 'requirement for postoperative x-ray' (Comparison 04, Outcome 01) or 'Nasogastric tube insertion' (Comparison 05, Outcome 01) suggest that alvimopan reduces the incidence of postoperative complications.</P>
<P>If ileus (or constipation) is a primarily peripherally mediated adverse effect of opioids, and analgesia mostly centrally mediated, we should expect both peripherally selective and non-selective opioid antagonists to reverse OBD, but only non-selective antagonists to reverse analgesia. However, while data from the alvimopan studies (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>
<I>; </I>
<LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>
<I>; </I>
<LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>
<I>; </I>
<LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>
<I>; </I>
<LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>)<I> </I>seem to confirm this hypothesis, the one study of epidural naloxone (<LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>)<I> </I>surprisingly showed no difference in analgesia between the naloxone and placebo groups. This could be a result of chance in a small sample size, or may be due to naloxone having dose-dependent effects, i.e., reversal of ileus at a lower dose than that required to reverse analgesia.</P>
<P>The studies that measured postoperative ileus did so in only three different surgeries: bowel resection (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>), hysterectomy (<LINK REF="STD-Delaney-2005" TYPE="STUDY">Delaney 2005</LINK>; <LINK REF="STD-Herzog-2006" TYPE="STUDY">Herzog 2006</LINK>; <LINK REF="STD-Taguchi-2001" TYPE="STUDY">Taguchi 2001</LINK>; <LINK REF="STD-Viscusi-2006" TYPE="STUDY">Viscusi 2006</LINK>; <LINK REF="STD-Wolff-2004" TYPE="STUDY">Wolff 2004</LINK>) and gastrectomy (<LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>). It remains to be determined whether the positive results seen in these studies translate to other postoperative populations. A limitation of many reports included in this review is their restriction of study populations to receive systemic opioids for postoperative pain management. Major abdominal and thoracic surgeries increasingly employ epidural mixtures containing local anesthetics, whose use is known to accelerate return of intestinal function (<LINK REF="REF-Carr-1998" TYPE="REFERENCE">Carr 1998</LINK>; <LINK REF="REF-Liu-1995" TYPE="REFERENCE">Liu 1995</LINK>; <LINK REF="REF-Person-2006" TYPE="REFERENCE">Person 2006</LINK>). Therefore, the advantage achieved by opioid antagonists observed in these studies might be reduced if it were compared to currently employed epidural analgesic mixtures.</P>
<P>
<I>
<B>Constipation</B>
</I>
<BR/>A small number of heterogenous studies with low participant enrollment were available and used for the meta-analysis of constipation outcomes <I>(</I>
<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>
<I>; </I>
<LINK REF="STD-Paulson-2005" TYPE="STUDY">Paulson 2005</LINK>
<I>; </I>
<LINK REF="STD-Sykes-1996" TYPE="STUDY">Sykes 1996</LINK>
<I>; </I>
<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>
<I>)</I>. These comparisons, therefore, should be interpreted with caution due to the small sample size. Additionally, in one study, methylnaltrexone was administered intravenously (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>). One would anticipate that once marketed, methylnaltrexone will be available in oral formulation. It should also be noted that participants receiving alvimopan actually had more mean BMs per week than those in either of the naloxone studies: the WMD was less because participants receiving placebo had a relatively high number of BMs per week in the alvimopan study.</P>
<P>When assessing the number of participants reporting reversal of analgesia the study administering naloxone is too small for us to ascertain whether there is no difference between naloxone and placebo or whether the study is insufficiently powered to demonstrate a difference (<LINK REF="STD-Liu-2002" TYPE="STUDY">Liu 2002</LINK>). The larger numbers enrolled in the alvimopan trial suggest that alvimopan does not cause reversal of analgesia in this population.</P>
<P>It is possible that our analyses of efficacy may have been confounded by the different opioids administered in each trial. Different opioids may have varying effects on the GI system (<LINK REF="REF-Fakata-2005" TYPE="REFERENCE">Fakata 2005</LINK>; <LINK REF="REF-Radbruch-2000" TYPE="REFERENCE">Radbruch 2000</LINK>). The heterogeneity of dosage regimens and routes of administration amongst studies prevented us from performing any subanalyses based upon the opioids administered. However, in all studies that reported the opioid and dose used, the same regimen was administered to both active and placebo arms.</P>
<P>Two studies that assessed outcomes or data that we were not able to include in our analyses merit discussion, as they assessed mechanically ventilated participants in the intensive care unit receiving opioids for analgesia/sedation (<LINK REF="STD-Meissner-2003" TYPE="STUDY">Meissner 2003</LINK>; <LINK REF="STD-Meissner-2004" TYPE="STUDY">Meissner 2004</LINK>). Both studies employed naloxone and assessed various outcomes including gastric reflux, constipation and pneumonia (<I>see</I> 'Characteristics of included studies'). Based on limited data, the studies suggest that naloxone reduces both gastric reflux and the incidence of pneumonia without reversing analgesia or causing an increase in opioid requirements. Further investigation in this critical population is merited.</P>
<P>
<B>Safety</B>
<BR/>One would usually expect incidence or severity of adverse events to be equivalent or higher in active treatment groups versus placebo. The results from many of the safety analyses show the opposite, suggesting that these outcomes are in fact measures of efficacy rather than of safety. This assumption would particularly seem to hold for GI-related adverse events. The majority of studies show a reduction, or trend to reduction, in incidence and severity of nausea and in the incidence of constipation, postoperative ileus, and vomiting. Conversely, and as might be expected, GI symptoms such as diarrhea and abdominal cramping occur more commonly in some of the arms receiving opioid antagonist than in those receiving placebo. It is possible that patients would be willing to risk the occurrence of diarrhea and cramping in order to obtain relief from those adverse events related to constipation. Interestingly, a prior study in which ultra-low doses of the nonselective opioid antagonist naloxone were co-administered with morphine during postoperative patient-controlled analgesia also demonstrated a reduction in nausea (<LINK REF="REF-Cepeda-2004" TYPE="REFERENCE">Cepeda 2004</LINK>). Adverse events such as treatment-related withdrawals, serious adverse events, rehospitalization, and death may also reflect an intervention's efficacy as much as its safety. Meta-analyses of the first three of these outcomes, where incidence is lower in the treatment group, appear to confirm this for certain populations (<I>see </I>analyses, Comparisons 31, 32 and 33). A meta-analysis of the numbers of participants dying during a study period, did not demonstrate a difference between the alvimopan treated participants and those receiving placebo. This could be because no difference exists between opioid antagonist and placebo, but equally could be a result of study populations being too small to adequately describe a rare event, or because duration of studies was insufficient to capture long-term toxicity.</P>
<P>Participants administered naloxone had an increased incidence of anxiety or jitteriness, perhaps demonstrating centrally mediated opioid antagonism, but the number of participants enrolled was insufficient to make firm conclusions regarding naloxone or to extrapolate any conclusion to other antagonists. The possibility also exists that if one analyzes multiple adverse events, by chance one analysis will show a difference when none exists.</P>
<P>Most of the safety data comes from the alvimopan studies. Many of the methylnaltrexone papers reported "no serious adverse events" or "no adverse events of clinical importance" in either group. The lack of adverse event data in these studies may reflect a milder adverse event profile for methylnaltrexone over alvimopan. However, the absence of data in both the methylnaltrexone and placebo arms suggests that differences may be due to the investigators in the methylnaltrexone studies using different criteria or thresholds for defining events, or because most methylnaltrexone trials enrolled healthy volunteers. Adverse events were rarely reported in naloxone studies. Again, this may be a consequence of limited participant enrollments, or because of the generally low quality of these studies, rather than any actual differences in adverse event profiles.</P>
<P>Some general observations can be made from the included studies. Measures of both efficacy and safety do not consistently show a class effect for opioid antagonists. Even in those analyses where a statistically significant overall effect is demonstrated, heterogeneity clearly exists between studies with different drugs or study populations, or both. It may be inappropriate to combine such heterogenous data. Equally, there is insufficient evidence for us to make comparisons between any of the antagonists for either safety or efficacy. Therefore we cannot confirm our hypothesis that antagonists whose site of action is restricted to the periphery have similar efficacy to that of non-specific antagonists, but a lower incidence of adverse effects.</P>
<P>None of the studies compared an opioid antagonist with another antagonist, an alternative pharmacological regimen, or a non-pharmacological intervention. Therefore, the efficacy or safety of these compounds relative to other interventions is unknown. We can only make comparisons based on similar studies with alternative interventions. Studies involving alternative pharmacotherapies for participants with constipation due to cancer pain and chronic non-cancer pain are too heterogenous to make any meaningful comparisons within these alternative therapies, or between them and opioid antagonists (<LINK REF="REF-McNicol-2003" TYPE="REFERENCE">McNicol 2003</LINK>). Other compounds currently being developed, such as the chloride channel activator lubiprostone, may also show efficacy in both opioid-induced constipation and in postoperative ileus, but have thus far not been tested in these populations (<LINK REF="REF-Winpenny-2005" TYPE="REFERENCE">Winpenny 2005</LINK>).</P>
<P>Alvimopan is the first drug whose manufacturers have sought FDA approval for use in postoperative ileus. However, small studies with prokinetic agents, laxatives, nonsteroidal anti-inflammatory drugs (NSAIDs), and GI hormone analogues, have been conducted in this setting (<LINK REF="REF-Person-2006" TYPE="REFERENCE">Person 2006</LINK>). The majority of these studies either failed to show a benefit, were non-randomized, or reported unacceptable side effect profiles. One small study involving ketorolac demonstrated a benefit in postoperative ileus, but since NSAIDs are a standard component of postoperative regimens, the use of an opioid antagonist in place of an NSAID is unlikely (<LINK REF="REF-Ferraz-1995" TYPE="REFERENCE">Ferraz 1995</LINK>). Comparison with non-pharmacological interventions, such as nasogastric decompression, early ambulation and early feeding or multimodal accelerated care pathways is also difficult, given that such interventions are increasingly considered standard postoperative practice and that trials investigating such interventions studied different populations and measured widely different outcomes (<LINK REF="REF-Person-2006" TYPE="REFERENCE">Person 2006</LINK>). In addition, the alvimopan studies incorporated these accelerated care pathways for both intervention and placebo arms, suggesting that alvimopan will be used in addition to, rather than instead of, such pathways.</P>
<P>Both efficacy and adverse event profiles can change over time. None of the study durations exceeded 35 days. Clearly, for investigation of GI transit time or in postoperative participants a short study duration is appropriate. However, although the studies involving participants with constipation were generally carried out over the longest time period, patients with chronic pain may require treatment for months or years. It is not possible from the available studies to determine whether efficacy or safety varies over time for these patients. Additionally, these studies enrolled few participants. Results from multi-center, long-term, post-marketing studies of COX-2 inhibitors have demonstrated that rare adverse events may only be seen with chronic administration in large populations. Therefore, despite the seemingly mild adverse event profile demonstrated with opioid antagonists, it is not prudent to claim that this class of drugs is safe for all patients or with chronic use.</P>
<P>Finally, our systematic review and meta-analysis shares limitations common to all analyses of heterogenous data (<LINK REF="REF-Jadad-1996b" TYPE="REFERENCE">Jadad 1996b</LINK>; <LINK REF="REF-Naylor-1997" TYPE="REFERENCE">Naylor 1997</LINK>; <LINK REF="REF-Sacks-1987" TYPE="REFERENCE">Sacks 1987</LINK>). Negative studies often go unpublished and we are only able to analyze the data which investigators chose to assess and present. As detailed in our 'Methods of the Review' section, we attempted to minimize potential bias by contacting authors for unpublished studies and clarification of data, and by searching drug regulatory websites.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Insufficient evidence exists for either a class effect of opioid antagonists (with the exception of the outcomes BMs per week and patient satisfaction) or for the superiority of any antagonist over another in opioid-induced bowel dysfunction. Insufficient evidence exists regarding the safety or efficacy of the non-selective opioid antagonist naloxone or the mixed agonist/antagonist nalbuphine in the treatment of opioid-induced constipation or postoperative ileus. Limited data in patients with constipation and in experimental models demonstrates that methylnaltrexone is efficacious in reversing the opioid-induced increase in GI transit time and constipation. Data from three large phase III trials support the efficacy and short-term safety of alvimopan use in several outcomes related to postoperative ileus, although the clinical significance of these improved outcomes is unclear. Limited data also support the efficacy of alvimopan in treating opioid-induced constipation. Long-term efficacy and safety of any of the opioid antagonists is unknown, as is the incidence or nature of rare adverse events. </P>
<P>Based on the evidence from our review, the effectiveness or safety of the currently available non-selective opioid antagonist has not been confirmed. Given the lack of high-quality evidence supporting other treatments for any aspect of OBD, it would seem reasonable to suggest that traditional opioid antagonists be considered on a trial-and-error basis, although whether they should be considered as first-line treatments is less certain. Due to the lack of long-term safety or efficacy data, therapy should be closely monitored and used for the shortest period possible.</P>
<P>It should be noted that the manufacturers of alvimopan and methylnaltrexone have not obtained marketing approval for either drug. The companies responsible for the production of alvimopan have been concentrating on its development as an agent for postoperative ileus, following their suspension of development for its role in improving opioid-induced constipation. The suspension was linked to a higher risk of cardiovascular events, fractures and skin cancers in this population. The manufacturers of methylnaltrexone recently (2007) submitted a new drug application in both Europe and the United States for its subcutaneous formulation and are conducting Phase I trials of a reformulation of the oral compound. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Alvimopan and methylnaltrexone both show promise in treating opioid-induced bowel dysfunction, but further data including that from postmarketing and cost effectiveness studies and from trials in wider populations will be required to fully assess their place in therapy. While further research into the use of traditional opioid antagonists, such as naloxone, would be helpful, it is unlikely that large, well-designed, RCTs will be performed. Traditional antagonists have been off-patent for several years, therefore, pharmaceutical industry interest in further research is likely to be minimal. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We wish to thank John L Plummer, PhD, AStat, Chief Medical Scientist, Pain Management Unit, Flinders Medical Centre, Bedford Park, South Australia for both technical assistance and expert clinical perspective with statistical analysis<B>, </B>and Dr Roman Schumann for translation and extraction of articles Freye 1988 and Meissner 2004.<B>
<BR/>
</B>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>EM: conceived, designed and coordinated the review, screened search results, organized retrieval of papers, screened retrieved papers against inclusion criteria, appraised quality of papers, extracted data from papers, wrote to authors of papers for additional information, entered data into RevMan, analysed data, and wrote the review.</P>
<P>DB: co-designed the review, screened search results, organized retrieval of papers, screened retrieved papers against inclusion criteria, appraised quality of papers, extracted data from papers, and analyzed data.</P>
<P>DC: co-ordinated the review and developed the search strategy. Provided methodological, clinical, policy and consumer perspective. Provided general and editorial advice on the review. Secured funding for the review. </P>
<P>RS: translated and extracted data from foreign language studies. Provided editorial advice on the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-13 13:39:34 +0100" MODIFIED_BY="Laila Tyrrell">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-2000" NAME="Barr 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr WH, Nguyen P, Slattery M, Russell R, Carpenter RL</AU>
<TI>ADL 8-2698 reverses opioid induced delay in colonic transit</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>67</VL>
<PG>91 (abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delaney-2005" NAME="Delaney 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, et al</AU>
<TI>Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2005</YR>
<VL>48</VL>
<PG>1114-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freye-1988" NAME="Freye 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freye E, Helle G</AU>
<TI>The agonist-antagonist nalbuphine prolongs gastro-cecal transit time and induces short-term pain following neuroleptanesthesia using fentanyl. A comparative study using a placebo</TI>
<TO>Der Agonist-Antagonist Nalbuphin verlangert die gastro-coekale Transitzeit und induziert kurzfristig Schmerzen nach Neuroleptanaesthesie mit Fentanyl. Eine Vergleichsuntersuchung zu Plazebo</TO>
<SO>Anaesthesist</SO>
<YR>1988</YR>
<VL>67</VL>
<PG>440-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonenne-2005" NAME="Gonenne 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonenne J, Camilleri M, Ferber I, Burton D, Baxter K, Keyashian K, et al</AU>
<TI>Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>784-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkes-2001" NAME="Hawkes 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkes ND, Richardson C, Evans BK, Rhodes J, Lewis SJ, Thomas GAO</AU>
<TI>Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>625-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herzog-2006" NAME="Herzog 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herzog TJ, Coleman RL, Guerrieri JP, Gabriel K, Du W, Techner L, et al</AU>
<TI>A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2006</YR>
<VL>195</VL>
<NO>2</NO>
<PG>445-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2001" NAME="Lee 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee J, Shim JY, Choi JH, Kim ES, Kwon OK, Moon DE, et al</AU>
<TI>Epidural naloxone reduces intestinal hypomotility but not analgesia of epidural morphine</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2001</YR>
<VL>48</VL>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2000" NAME="Liu 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr</AU>
<TI>ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>68</VL>
<PG>66-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2002" NAME="Liu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu M, Wittbrodt E</AU>
<TI>Low-dose oral naloxone reverses opioid-induced constipation and analgesia</TI>
<SO>Journal of Pain &amp; Symptom Management</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>48-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meissner-2003" NAME="Meissner 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meissner W, Dohrn B, Reinhart K</AU>
<TI>Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>776-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meissner-2004" NAME="Meissner 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meissner W, Hartmann M, Kahler G, Brauer M</AU>
<TI>Effect of enteral naloxone on the incidence of gastritis and esophagitis in mechanically ventilated patients</TI>
<TO>Der Einfluss von enteralem Naloxon auf die Inzidenz von Gastritis und Osophagitis bei opioidbehandelten Intensivpatienten: Doppelblinde plazebokontrollierte Studie</TO>
<SO>Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>538-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1997" NAME="Murphy 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy DB, Sutton JA, Prescott LF, Murphy MB</AU>
<TI>Opioid-induced delay in gastric emptying: a peripheral mechanism in humans</TI>
<SO>Anesthesiology</SO>
<YR>1997</YR>
<VL>87</VL>
<PG>765-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nimmo-1979" NAME="Nimmo 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nimmo WS, Heading RC, Wilson J, Prescott LF</AU>
<TI>Reversal of narcotic-induced delay in gastric emptying and paracetamol absorption by naloxone</TI>
<SO>BMJ</SO>
<YR>1979</YR>
<VL>2</VL>
<PG>1189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paulson-2005" NAME="Paulson 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paulson DM, Kennedy DT, Donovick RA, Carpenter RL, et al</AU>
<TI>Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial</TI>
<SO>Journal of Pain</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>184-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sykes-1996" NAME="Sykes 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sykes NP</AU>
<TI>An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer</TI>
<SO>Palliative Medicine</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>135-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taguchi-2001" NAME="Taguchi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taguchi A, Sharma N, Saleem RM, Sessler DI, et al</AU>
<TI>Selective postoperative inhibition of gastrointestinal opioid receptors</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>245</VL>
<PG>935-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viscusi-2006" NAME="Viscusi 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viscusi ER, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K, et al</AU>
<TI>Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery</TI>
<SO>Surgical Endoscopy</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>64-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-2004" NAME="Wolff 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, et al</AU>
<TI>Alvimopan, a novel, peripherally acting mu opioid antagonist - results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus</TI>
<SO>Annals of Surgery</SO>
<YR>2004</YR>
<VL>240</VL>
<PG>728-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-1996" NAME="Yuan 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen M, Moss J</AU>
<TI>Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1996</YR>
<VL>59</VL>
<PG>469-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-1997" NAME="Yuan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF, Osinski J, Toledano A, Roizen M, Moss J</AU>
<TI>The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1997</YR>
<VL>61</VL>
<PG>467-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2000a" NAME="Yuan 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, et al</AU>
<TI>Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<PG>367-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2000b" NAME="Yuan 2000b" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF, O'Connor M, Karrison T</AU>
<TI>Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>67</VL>
<PG>398-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2002" NAME="Yuan 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J</AU>
<TI>Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>2002</YR>
<VL>300</VL>
<PG>118-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Callaghan-1998" NAME="Callaghan 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Callaghan JT, Cerimele B, Nowak TV, DeLong A, Nyhart E, Oldham S</AU>
<TI>Effect of the opioid antagonist LY 246736 on gastrointestinal transit in human subjects</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>A730 (abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheskin-1995" NAME="Cheskin 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheskin LJ, Chami TN, Johnson RE, Jaffe JH</AU>
<TI>Assessment of nalmefene glucuronide as a selective gut opioid antagonist</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1995</YR>
<VL>39</VL>
<PG>151-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Culpepper_x002d_Morga-1989" NAME="Culpepper-Morga 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culpepper-Morgan JA, Inturissi C, Portnoy R, Kreek MJ</AU>
<TI>Oral naloxone treatment of narcotic induced constipation: dose response</TI>
<SO>NIDA Research Monograph</SO>
<YR>1989</YR>
<VL>95</VL>
<PG>399-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Culpepper_x002d_Morga-1992" NAME="Culpepper-Morga 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, et al</AU>
<TI>Treatment of opioid-induced constipation with oral naloxone: a pilot study</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1992</YR>
<VL>52</VL>
<PG>90-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foss-1997" NAME="Foss 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foss JF, O'Connor MF, Yuan CS, Murphy M, Moss J, Roizen MF</AU>
<TI>Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>37</VL>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gowan-1988" NAME="Gowan 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gowan JD, Hurtig JB, Fraser RA, Torbicki E, Kitts J</AU>
<TI>Naloxone infusion after prophylactic epidural morphine: effects on incidence of postoperative side-effects and quality of analgesia</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1988</YR>
<VL>35</VL>
<PG>143-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2000" NAME="Jones 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones HE, Johnson RE, Fudala PJ, Henningfield JE, Heishman SJ</AU>
<TI>Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>60</YR>
<VL>60</VL>
<PG>29-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joshi-1999" NAME="Joshi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER</AU>
<TI>Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia</TI>
<SO>Anesthesiology</SO>
<YR>1999</YR>
<VL>90</VL>
<PG>1007-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaufman-1988" NAME="Kaufman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman PN, Krevsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA, et al</AU>
<TI>Role of opiate receptors in the regulation of colonic transit</TI>
<SO>Gastroenterology</SO>
<YR>1988</YR>
<VL>94</VL>
<PG>1351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreek-1983" NAME="Kreek 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreek MJ, Schaefer RA, Hahn EF, Fishman J</AU>
<TI>Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Latasch-1997" NAME="Latasch 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Latasch L, Zimmermann M, Eberhardt B, Jurna I</AU>
<TI>Treament of morphine-induced constipation with oral naloxone</TI>
<TO>Aufhebung einer morphin-induzierten obstipation durch orales naloxon</TO>
<SO>Anaesthesist</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1999" NAME="Lewis 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis TD</AU>
<TI>Morphine and gastroduodenal motility</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1999</YR>
<VL>44</VL>
<PG>2178-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meissner-2000" NAME="Meissner 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K</AU>
<TI>Oral naloxone reverses opioid-associated constipation</TI>
<SO>Pain</SO>
<YR>2000</YR>
<VL>84</VL>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mittal-1986" NAME="Mittal 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mittal RK, Frank EB, Lange RC, McCallum RW</AU>
<TI>Effects of morphine and naloxone on esophageal motility and gastric emptying in man</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1986</YR>
<VL>31</VL>
<PG>936-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narducci-1986" NAME="Narducci 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narducci F, Bassotti G, Granata MT, Gaburri M, Farroni F, Palumbo R, et al</AU>
<TI>Functional dyspepsia and chronic idiopathic gastric stasis. Role of endogenous opiates</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<PG>716-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1983" NAME="Rees 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees WDW, Sharpe GR, Christofides ND, Bloom SR, Turnberg LA</AU>
<TI>The effects of an opiate agonist and antagonist on the human upper gastrointestinal tract</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1991" NAME="Robinson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson BA, Johansson L, Shaw J</AU>
<TI>Oral naloxone in opioid-associated constipation [comment]</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>581-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schang-1985" NAME="Schang 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schang JC, Devroede G</AU>
<TI>Beneficial effects of naloxone in a patient with intestinal pseudoobstruction</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1985</YR>
<VL>80</VL>
<PG>407-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sykes-1991" NAME="Sykes 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sykes NP</AU>
<TI>Oral naloxone in opioid-associated constipation</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>1475</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-2003" NAME="Thomas 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas MC, Erstad BL</AU>
<TI>Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation</TI>
<SO>American Journal of Health-system Pharmacy</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>1264-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welch-1987" NAME="Welch 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welch IM, Baxter AJ, Read NW</AU>
<TI>Effect of naloxone, domperidone and idazoxan on the delay in gastric emptying induced by ileal lipid</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>425-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-1999a" NAME="Yuan 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF, O'Connor M, Osinski J</AU>
<TI>Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study</TI>
<SO>Pain</SO>
<YR>1999</YR>
<VL>83</VL>
<PG>631-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-1999b" NAME="Yuan 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J</AU>
<TI>Methylnaltrexone (MTNX) reverses chronic opioid constipation: a double-blind, randomized, placebo-controlled trial</TI>
<SO>Anesthesiology</SO>
<YR>1999</YR>
<VL>91</VL>
<PG>A973</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2000c" NAME="Yuan 2000c" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Foss JF</AU>
<TI>Oral methylnaltrexone for opioid-induced constipation</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>248</VL>
<PG>1383-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2005" NAME="Yuan 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, et al</AU>
<TI>Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>538-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-13 13:39:34 +0100" MODIFIED_BY="Laila Tyrrell">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-13 13:39:34 +0100" MODIFIED_BY="Laila Tyrrell">
<REFERENCE ID="REF-Carr-1998" NAME="Carr 1998" TYPE="BOOK_SECTION">
<AU>Carr DB, Cousins MJ</AU>
<TI>Spinal route of analgesia. Opioids and future options</TI>
<SO>Neural Blockade in Clinical Anesthesia and Management of Pain</SO>
<YR>1998</YR>
<PG>915-83</PG>
<EN>3rd</EN>
<ED>Cousins MJ, Bridenbaugh PO</ED>
<PB>Lippincott-Raven Publishers</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cepeda-2004" NAME="Cepeda 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cepeda MS, Alvarez H, Morales O, Carr DB</AU>
<TI>Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>107</VL>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" NAME="Cook 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cook RJ, Sackett DL</AU>
<TI>The number needed to treat: a clinically useful measure of treatment effect</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>452-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2006" MODIFIED="2008-08-13 13:39:34 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Deeks 2006" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT, Altman DG, editors</AU>
<TI>Analysing and presenting results</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [Updated September 2006]; Section 8. In: The Cochrane Library, Issue 4, 2006</SO>
<YR>2006</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickerson-1999" NAME="Dickerson 1999" TYPE="BOOK">
<AU>Dickerson ED, Benedetti C, Davis MP, Grauer PA, Santa-Emma PH, Zafirides P</AU>
<SO>Palliative Care Pocket Consultant</SO>
<YR>1999</YR>
<PB>Janoski Advertising Design</PB>
<CY>Columbus</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fakata-2005" NAME="Fakata 2005" TYPE="BOOK_SECTION">
<AU>Fakata KL, Lipman AG</AU>
<TI>Gastrointestinal opioid physiology and pharmacology</TI>
<SO>Handbook of Opioid Bowel Syndrome</SO>
<YR>2005</YR>
<PG>7-28</PG>
<ED>Yuan CS</ED>
<PB>The Haworth Medical Press</PB>
<CY>Binghamton</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferraz-1995" NAME="Ferraz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ferraz AA, Cowles VE, Condon RE, Carilli S, Ezberci F, Frantzides CT, et al</AU>
<TI>Nonopioid analgesics shorten the duration of postoperative ileus</TI>
<SO>American Surgeon</SO>
<YR>1995</YR>
<VL>61</VL>
<PG>1079-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2008-08-13 13:39:26 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Higgins 2006" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Guide to the contents of a protocol and review</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [Updated September 2006]; Section 3. In: The Cochrane Library, Issue 4, 2006</SO>
<YR>2006</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-04-11 22:40:24 +0100" MODIFIED_BY="Ewan McNicol"/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996a" NAME="Jadad 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996b" NAME="Jadad 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR</AU>
<TI>Meta-analysis in pain relief: a valuable but easily misused tool</TI>
<SO>Current Opinion in Anaesthesiology</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>426</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kehlet-2000" NAME="Kehlet 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kehlet H</AU>
<TI>Postoperative ileus</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47 (Suppl)</VL>
<PG>iv85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kehlet-2001" NAME="Kehlet 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kehlet H, Holte K</AU>
<TI>Review of postoperative ileus</TI>
<SO>American Journal of Surgery</SO>
<YR>2001</YR>
<VL>182 (suppl)</VL>
<PG>3S-10S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurz-2003" NAME="Kurz 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kurz A, Sessler DI</AU>
<TI>Opioid-induced bowel dysfunction: pathophysiology and potential new therapies</TI>
<SO>Drugs</SO>
<YR>2003</YR>
<VL>63</VL>
<PG>649-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-1995" NAME="Liu 1995" TYPE="JOURNAL_ARTICLE">
<AU>Liu SS, Carpenter RL, Mackey DC, Thirlby RC, Rupp SM, Shine TS, et al</AU>
<TI>Effects of perioperative analgesic technique on rate of recovery after colon surgery</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>83</VL>
<PG>757-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNicol-2003" NAME="McNicol 2003" TYPE="JOURNAL_ARTICLE">
<AU>McNicol E, Horowicz-Mehler N, Fisk R, Bennett K, Gialeli-Goudas M, Chew P, et al</AU>
<TI>Management of opioid side effects in cancer-related and chronic noncancer pain - a systematic review</TI>
<SO>Journal of Pain</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>231-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1998" NAME="McQuay 1998" TYPE="BOOK">
<AU>McQuay H, Moore R</AU>
<SO>An evidence-based resource for pain relief</SO>
<YR>1998</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naylor-1997" NAME="Naylor 1997" TYPE="JOURNAL_ARTICLE">
<AU>Naylor CD</AU>
<TI>Meta-analysis and the meta-epidemiology of clinical research: meta-analysis is an important contribution to research and practice but it's not a panacea (Editorial)</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>317</VL>
<PG>617-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pappagallo-2001" NAME="Pappagallo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Pappagallo M</AU>
<TI>Incidence, prevalence, and management of opioid bowel dysfunction</TI>
<SO>American Journal of Surgery</SO>
<YR>2001</YR>
<VL>182 (Suppl)</VL>
<PG>11S-18S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasero-1999" NAME="Pasero 1999" TYPE="BOOK_SECTION">
<AU>Pasero C, Portenoy RK, McCaffery M</AU>
<TI>Opioid analgesics</TI>
<SO>Pain</SO>
<YR>1999</YR>
<PG>165-299</PG>
<EN>2nd</EN>
<ED>McCaffery M, Pasero C</ED>
<PB>Mosby</PB>
<CY>St. Louis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Person-2006" NAME="Person 2006" TYPE="JOURNAL_ARTICLE">
<AU>Person B, Wexner SD</AU>
<TI>The management of postoperative ileus</TI>
<SO>Current Problems in Surgery</SO>
<YR>2006</YR>
<VL>43</VL>
<PG>12-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Portenoy-1994" NAME="Portenoy 1994" TYPE="JOURNAL_ARTICLE">
<AU>Portenoy RK</AU>
<TI>Management of common opioid side effects during long-term therapy of cancer pain</TI>
<SO>Annals of the Academy of Medicine, Singapore</SO>
<YR>1994</YR>
<VL>23</VL>
<PG>160-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radbruch-2000" NAME="Radbruch 2000" TYPE="JOURNAL_ARTICLE">
<AU>Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, et al</AU>
<TI>Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine</TI>
<SO>Palliative Medicine</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>111-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacks-1987" NAME="Sacks 1987" TYPE="JOURNAL_ARTICLE">
<AU>Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC</AU>
<TI>Meta-analyses of randomized controlled trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>316</VL>
<PG>450-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spruance-2004" NAME="Spruance 2004" TYPE="JOURNAL_ARTICLE">
<AU>Spruance SL, Reid JE, Grace M, Samore M</AU>
<TI>Hazard ratio in clinical trials</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>2004</YR>
<VL>48</VL>
<PG>2787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutton-2000" NAME="Sutton 2000" TYPE="BOOK_SECTION">
<AU>Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F</AU>
<TI>Meta-analysis of survival data</TI>
<SO>Methods for meta-analysis in medical research</SO>
<YR>2000</YR>
<PG>277-85</PG>
<ED>Cressie NAC, Fisher NI, Johnstone IM, Kadane JB, Scott DW, Silverman BW, et al</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winpenny-2005" NAME="Winpenny 2005" TYPE="JOURNAL_ARTICLE">
<AU>Winpenny JP</AU>
<TI>Lubiprostone</TI>
<SO>Idrugs</SO>
<YR>2005</YR>
<VL>8</VL>
<PG>416-22</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-30 19:00:30 +0000" MODIFIED_BY="Jessica Thomas">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-13 13:46:03 +0100" MODIFIED_BY="Laila Tyrrell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Barr-2000">
<CHAR_METHODS>
<P>Crossover, 4 days each treatment (10 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: not listed<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed:Alvimopan period: ?/?/11; Placebo period: ?/?/11<BR/>Age (mean+/-SD, median, or range): not listed<BR/>% male: not listed<BR/>Primary diagnosis: healthy volunteers<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine oral sustained-release 30 mg twice daily<BR/>Alvimopan oral 3 mg three times daily<BR/>Placebo unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others): <BR/>Colonic motility: 24 radio-opaque markers ingested orally on days 1 to 3. Number of markers in each colonic segment on day 5 multiplied by factors: cecum/ascending = 6, hepatic flexure = 5, transverse = 4, splenic flexure = 3, descending = 2, recto-sigmoid = 1, and summed. BMs weighed (days 1 to 4). <BR/>Pupil diameter measured before and 4 h after first dose of morphine<BR/>Results:<BR/>Total marker score: alvimopan 140+/-88 vs. placebo 248+/-88 (P &lt; 0.01); stool weight: alvimopan 223+/-178 g vs. placebo 35+/-63 g (P &lt; 0.05). <BR/>Alvimopan did not antagonize pupil constriction after morphine: alvimopan 0.7+/-0.8 mm vs. placebo 0.7+/-1 mm.<BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: not listed<BR/>Reasons for dropout: not listed<BR/>Concurrent medications: not listed<BR/>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Delaney-2005">
<CHAR_METHODS>
<P>Parallel, 7 days maximum</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: males or females ages 18-80 scheduled for laparotomy: partial colectomy with primary anastomosis (excluding low anterior resection) or total abdominal hysterectomy (radical or simple; simple hysterectomy limited to approximately 20% of enrollment).<BR/>Exclusion criteria: opioids within 4 weeks of surgery (except a one-time parenteral opioid use at colonoscopy); current severe cardiovascular, pulmonary, renal, hepatic, hematologic, or systemic disease; pregnancy; clinically significant laboratory abnormalities on screening; complete bowel obstruction or inflammatory bowel disease; and patients scheduled to receive total colectomy, colostomy, or ileostomy, or expected to receive epidural opioids, local anesthetics, or nonsteroidal anti-inflammatory drugs for postoperative pain management.<BR/>Number of patients screened/enrolled/completed: Alvimopan 6 mg group: ?/152/128; Alvimopan 12 mg group: ?/146/107; Placebo group: ?/153/121<BR/>Age (mean+/-SD, median, or range): Alvimopan 6 mg group: 58.2 (range 29-87); Alvimopan 12 mg group: 57.1 (30-93); Placebo group: 58.6 (30-88)<BR/>% male: Alvimopan 6 mg group: 35; Alvimopan 12 mg group: 34; Placebo group: 29<BR/>Primary diagnosis: not listed<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Opioid: PCA unspecified<BR/>Alvimopan oral 6 or 12 mg 2 h prior to surgery, then twice daily beginning on postoperative day 1<BR/>Placebo unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Primary efficacy endpoint: time to recovery of GI function, defined as the later of time of first tolerating solid food or time to pass first flatus or BM (h)<BR/>Secondary efficacy endpoint: also representing time to recovery of GI function, defined as the later of time of first tolerated solid food, or time to first BM (h)<BR/>Pain: postoperative VAS (anchors not defined); opioid consumption (morphine equivalents [mg])<BR/>Time to hospital discharge readiness or actual discharge (h)<BR/>Results:<BR/>Primary efficacy endpoint: mean time to GI recovery: alvimopan 12 mg, 92.8 h (HR = 1.28, P = 0.059 vs. placebo); alvimopan 6 mg, 86.2 h (HR = 1.45, P = 0.003 vs. placebo); placebo group 100.3 h. Bowel resection or radical hysterectomy patients only: alvimopan 12 mg, 101.3 h (HR = 1.29, P = 0.073 vs. placebo); alvimopan 6 mg, 94.5 h (HR = 1.51, P = 0.004 vs. placebo); Placebo group, 111.4 h. Simple hysterectomy patients only: similar times to recovery in all groups (53 h vs 56 h vs. 58 h, alvimopan 12 mg, 6 mg, placebo respectively). <BR/>Secondary efficacy endpoint: alvimopan 12 mg, 104 h (HR = 1.31, P = 0.057 vs. placebo); alvimopan 6 mg, 100 h (HR = 1.46, P = 0.007 vs. placebo); placebo group, 115 h. <BR/>Time to first BM: alvimopan 12 mg, 87 h (HR = 1.47, P = 0.006 vs. placebo); alvimopan 6 mg, 85 h (HR = 1.55, P = 0.002 vs. placebo); Placebo group, 102 h.<BR/>Readiness for discharge: alvimopan 12 mg, 98 h (HR = 1.54, P = 0.004 vs. placebo); alvimopan 6 mg, 97 h (HR = 1.61, P &lt; 0.001 vs placebo); Placebo group, 112 h.<BR/>Time to hospital discharge: alvimopan 12 mg, 115 h (HR = 1.18, P = 0.17 vs. placebo); alvimopan 6 mg, 108 h (HR = 1.50, P &lt; 0.001 vs. placebo); Placebo group, 122 h. <BR/>Pain: VAS: similar amongst all groups (data displayed graphically, P values not listed). Postoperative opioid consumption: alvimopan 12 mg, 31.6 mg (P = 0.045 vs. placebo); alvimopan 6 mg, 25 mg (P not listed vs. placebo); Placebo group, 25.6 mg. <BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: mean maximum VAS scores for nausea, vomiting, and abdominal distension similar amongst all groups (not listed). Most common treatment emergent adverse events: nausea and vomiting. Vomiting reduced by 53% (P &lt; 0.001), constipation reduced by 53% (P = 0.04) in alvimopan 12 mg group vs. placebo. Nausea the only adverse event leading to discontinuation of study drug that occurred with &gt; = 2% higher frequency in alvimopan groups vs. placebo group.<BR/>Discontinuations (due to adverse events): 26.7% (17.8%) alvimopan 12 mg vs. 15.8% (6.6%) alvimopan 6 mg vs. 20.9% (14.4%) Placebo group; other reasons: withdrawal of consent (n = 5); protocol violations (n = 21); administrative/other reasons (n = 11) - did not differ among groups<BR/>Concurrent medications: not listed<BR/>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Freye-1988">
<CHAR_METHODS>
<P>Parallel, single dose study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: No prior intestinal disease, no laxative abuse, no abdominal procedures potentially leading to adhesions, non-abdominal surgical interventions, no full enemas the night before surgery, no beans or plums on the day prior to surgery (increase in hydrogen production), no nicotine prior to surgery, women included in first half of menstrual cycle only, anesthetic technique that avoids the need for neuromuscular blockade reversal at end of surgery. <BR/>Exclusion criteria: oral antibiotics immediately prior to surgery, receiving beta blockade or L-dopa medication<BR/>Number of patients screened/enrolled/completed: Nalbuphine group: ?/?/20; Placebo group: ?/?/20<BR/>Age (mean+/-SD, median, or range): Nalbuphine group: 35+/-14; Placebo group: 36+/-11<BR/>% male: Nalbuphine group: 70; Placebo group: 55<BR/>Primary diagnosis: various peripheral surgical lesions<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fentanyl IV 7 mcg/kg, meperidine 1 mg/kg IM for surgery<BR/>Nalbuphine 0.1 mg/kg at end of surgery<BR/>Placebo: normal saline at end of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Constipation: gastro-cecal transit time: lactulose hydrogen breath test - transit complete when 3-fold increase in exhaled hydrogen compared to preoperative measurement. <BR/>Pain: VAS (scale not specified)<BR/>Results:<BR/>Gastro-cecal transit time (min): nalbuphine 380+/-89.6 vs. placebo 270+/-53.5 (P &lt; 0.01).<BR/>Pain: increased in nalbuphine group at 10 and 20 min vs. placebo (3.5 vs. 1.8 and 2.5 vs. 1.4, P &lt; 0.005), lower at 120 and 240 min (0.7 vs. 1.4 and 0.7 vs. 1.1, P &lt; 0.05).<BR/>Antagonism of analgesia: yes, from 0 to 20 mins</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: vomiting, agitation/anxiety, hypoventilation, blood pressure, and heart rate changes measured, but not listed or discussed.<BR/>Reasons for dropout: not listed<BR/>Concurrent medications: not listed<BR/>QS = 1<BR/>Somewhat paradoxical conclusion with regards to nalbuphine's peripheral antinociception and intestinal dysmotility properties. Authors do not specify route of administration of nalbuphine. No elaboration on side effects</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gonenne-2005">
<CHAR_METHODS>
<P>Parallel, 72 h study with intervention on days 2-3<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: healthy men and non-pregnant, nonlactating women between ages of 18 and 65 y, body mass index between 19 and 30 kg/m2<BR/>Exclusion criteria: 3 or more yes answers on bowel disease questionnaire, score of 11 or more on Hospital Anxiety Depression scale, non-prescription or prescription medication use within 7 days of study.<BR/>Number of patients screened/enrolled/completed: Alvimopan plus codeine group: ?/18/18; Codeine plus placebo group: ?/20/18; Alvimopan plus placebo group: ?/17/17; Placebo group: ?/19/19<BR/>Age (mean+/-SD, median, or range): Alvimopan plus codeine group: 34 (range 19-62); Codeine plus placebo group: 34 (20-61); Alvimopan plus placebo group: 30 (18-62); Placebo group: 33 (20-54)<BR/>% male: Alvimopan plus codeine group: 44; Codeine plus placebo group: 40; Alvimopan plus placebo group: 41; Placebo group: 42<BR/>Primary diagnosis: healthy volunteers<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Codeine oral 30 mg four times daily<BR/>Alvimopan oral 12 mg twice daily<BR/>Placebo unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Gastric emptying: Placebo group 130 min vs. codeine group 160 min (P &lt; 0.05 vs. placebo) vs. alvimopan/codeine group 180 min (P &lt; 0.05 vs. placebo)<BR/>Small bowel transit 10%: codeine delayed (P &lt; 0.05); alvimopan reversed. <BR/>Mean colonic geometric center at 4 h: placebo/placebo 0.67+/-0.13 (SE) vs. alvimopan/placebo 0.79+/-0.13 vs. placebo/codeine 0.15+/-0.13 (P &lt; 0.05 vs. placebo) vs. alvimopan/codeine 0.69+/-0.12; Similar results at 24 and 48 h.<BR/>Antagonism of analgesia: not measured - healthy volunteers</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: all adverse events mild to moderate. Number of participants with any adverse event (n/N): Placebo group 8/18; Alvimopan group 8/17; Codeine group 14/18; Alvimopan/codeine group 15/19.<BR/>Reasons for dropout: Placebo/codeine group: n = 1 adverse event (unspecified), n = 1 other (unspecified)<BR/>Concurrent medications: not listed<BR/>QS = 3<BR/>some results displayed graphically - data obtained by measuring figures with ruler</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hawkes-2001">
<CHAR_METHODS>
<P>Crossover, 9 days each treatment (2 week washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: healthy, non-smoking men with normal bowel frequency (not greater than 3 BM daily, but more than 3 BM weekly), who had not taken the following within previous month: laxatives, anti-diarrheal medication, antacids, antibiotics<BR/>Exclusion criteria: history of sensitivity to codeine or naloxone; known gastrointestinal disorder; previous vagotomy or bowel resection; significant medical or psychiatric illness<BR/>Number of patients screened/enrolled/completed: Baseline period: ?/12/12; Codeine period: ?/12/12; Naloxone period: ?/12/12; Naloxone + Codeine period: ?/12/12<BR/>Age (mean+/-SD, median, or range): 37.8+/-11.6<BR/>% male: 100<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Codeine oral 30 mg twice daily<BR/>Naloxone oral 10 mg twice daily<BR/>Placebo: identical capsules</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Whole-gut transit time (h): 20 encapsulated markers swallowed each day for 4 days and time to BM noted. Mean whole-gut transit time = (s1t1 + s2t2 + s3t3 + s4t4)/(s1 + s2 + s3 + s4), where s1 = number of first set of markers in stool, t1 = time lapse in hours between ingestion of these markers and passage of stool, and so on for each set of markers.<BR/>Results:<BR/>GI transit: codeine increased transit time in 8/12 subjects.<BR/>Overall:<BR/>Control period 53.1+/-3.03 (SEM); codeine 57.3+/-5.18 (P = 0.46 vs. control); naloxone 42.1+/-3.69 (P = 0.005 vs. control); naloxone plus codeine 40.7+/-3.96 (P = 0.024 vs. control)<BR/>For 8 "codeine responders":<BR/>Control period 50.4+/-3.02; codeine 66.2+/-4.21 (P = 0.001 vs. control); naloxone 41.4+/-5.08 (P = 0.034 vs. control); naloxone plus codeine 42.4+/-5.44 (P = 0.2 vs. control)<BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: mild abdominal pain (control n = 2, codeine n = 5, naloxone n = 1, codeine plus naloxone n = 2); abdominal swelling (codeine plus naloxone n = 2); urgency to defecate (naloxone n = 2, codeine plus naloxone n = 3) (n/12 in each case)<BR/>Reasons for dropout: no dropout<BR/>Concurrent medications: not listed<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herzog-2006">
<CHAR_METHODS>
<P>Parallel, 7 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: females aged 18 years or over, who underwent simple total abdominal hysterectomies and who were scheduled for opioid-based patient-controlled analgesia.<BR/>Exclusion criteria: Opioid exposure within 2 weeks before study entry, complete bowel obstruction, previous or planned colectomy, colostomy or ileostomy, or presence of any other condition known/suspected to be associated with increased risk of postoperative morbidity.<BR/>Number of patients screened/enrolled/completed: Alvimopan 12 mg group: ?/413/380; Placebo group: ?/106/94<BR/>Age (mean+/-SD, median, or range): Alvimopan 12 mg group: 44.1+/-8.3; Placebo group: 43.1+/-8.1<BR/>% male: 0<BR/>Primary diagnosis: Uterine fibroids (placebo group 50.0% vs. alvimopan group 50.1%), abnormal bleeding (19.8% vs. 22.8%), pelvic pain (6.6% vs. 7.0%).<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Opioid: PCA unspecified<BR/>Alvimopan oral 12 mg, 2 h prior to surgery, then twice daily for 7 days (hospital and home)<BR/>Placebo: identical appearance to active treatment, unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Constipation: time to recovery of GI function, determined by 3-component composite endpoint (the latest of time of first tolerating solid food or time to pass first flatus or BM); and two-component composite endpoint (the later of time of first tolerated solid food, or time to first BM), proportion of patients who met definition of responder (three component endpoint recovery 60 hours or less after end of surgery). Post-hospital discharge: use of laxatives, BM frequency and hardness, presence of straining during BM. <BR/>Time to: discharge order written, first flatus, first BM, first tolerance of solid food. <BR/>Postoperative pain: VAS (anchors not specified), opioid consumption (morphine equivalents). Post-hospital discharge: consumption of pain medication.<BR/>Incidence of postoperative insertion of nasogastric tube. <BR/>Post-hospital discharge: daily ambulation, ongoing appetite, and hospital readmission.<BR/>Patients assessed for 7 days postoperatively (hospital and home)<BR/>Results:<BR/>Constipation: No significant differences in time to 3-component GI recovery (HR, 1.16; P = 0.18), toleration of first solid food (HR, 1.09; P = 0.46). Alvimopan accelerated 2-component recovery vs. placebo (71.8 hrs vs. 92.0 hrs; HR, 2.23; P &lt; 0.001), time to first BM (69.4 hrs vs. 91.6 hrs; HR, 2.33; P &lt; 0.001), time to first flatus (42.4 hrs vs. 46.7 hrs; HR, 1.26; P = 0.039). Proportion of responders in each treatment group similar (alvimopan group 75.0% vs. placebo group 71.6%).<BR/>Proportion of patients who used laxatives (in or out of hospital) lower in alvimopan group on each postoperative day. Alvimopan group had increased numbers of daily BMs on postoperative days 2 through 7. Proportion of patients with hard stools: alvimopan group 11.4% on first day<BR/>postoperatively and decreased each day thereafter; placebo group 25% still experienced hard stools on postoperative days 4 to 6.<BR/>No significant differences in written hospital discharge order (HR, 1.31; P = 0.27).<BR/>Nasogastric tube insertion: alvimopan group, n = 0 vs. placebo group, n = 1.<BR/>Hospital readmission: alvimopan group, n = 2 vs. placebo group, n = 1.<BR/>Opioid consumption and VAS pain scores comparable between groups.<BR/>Proportion of patients ambulatory for &gt; 2 hour on postoperative day 7: alvimopan group 32% vs. placebo group 22%.<BR/>Post-hospital discharge: appetite and use of pain medication similar between groups.<BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: most common treatment emergent adverse events were gastrointestinal related. Nausea: alvimopan group 72.2% vs. placebo group 63.2%; vomiting: 31.2% vs. 25.5%; constipation 22.8% vs. 31.1%; flatulence 18.4% vs. 18.9%; postoperative ileus: 0.7% vs. 2.8%. <BR/>Proportion of patients with &gt; = 1 treatment emergent adverse event: alvimopan group 96.1% vs. placebo group 94.3%; serious adverse events: 5.6% vs, 6.6%.<BR/>More than 50% and 20% of nausea and vomiting episodes, respectively, occurred on day of surgery, with no significant differences between treatment groups on subsequent postoperative days.<BR/>Discontinuations: adverse events: 3.9% vs. 4.7%; withdrawal of consent 1.0% vs. 0; protocol violations 1.9% vs. 1.9%; other 1.2% vs. 4.7%, alvimopan and placebo groups respectively.<BR/>Concurrent medications: not listed<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-13 13:46:01 +0100" MODIFIED_BY="Laila Tyrrell" STUDY_ID="STD-Lee-2001">
<CHAR_METHODS>
<P>Parallel, 48 h</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-13 13:46:01 +0100" MODIFIED_BY="Laila Tyrrell">
<P>Inclusion criteria: ASA I or II patients with stomach cancer, administered combined thoracic epidural and general anaesthesia for subtotal gastrectomy; no pre-existing cardio-pulmonary, endocrine, hepatic, or renal disease.<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed: Placebo group: ?/18/?; Naloxone group: ?/25/?<BR/>Age (mean+/-SD, median, or range): Placebo group: 52.5+/-11.2; Naloxone group: 53.4+/-10.8<BR/>% male: not listed<BR/>Primary diagnosis: stomach cancer<BR/>Comorbidities: not listed - all ASA I or II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine epidural 3 mg at beginning of surgery, followed by continuous epidural infusion - 3 mg morphine in 100 ml bupivacaine 0.125% at 2 ml/hr <BR/>Naloxone epidural 0.208 mcg/kg/h (added to existing epidural)<BR/>Control: no naloxone added</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Constipation: time to first postoperative passage of flatus and feces<BR/>Pain: VAS during rest and coughing. Scores assessed at 2, 4, 8, 16, 24, 36 and 48 h postoperatively<BR/>Results:<BR/>Constipation: time to first postoperative passage of flatus, naloxone group 51.9+/-16.6 h vs. placebo group 87.0+/-19.5 h (P &lt; 0.001 ); feces, 95.3+/-25.0 h vs 132.9+/-29.4 h (P &lt; 0.001). <BR/>Pain: No differences found in either resting or active VAS for naloxone vs. placebo.<BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: not listed<BR/>Reasons for dropout: no mention of dropouts<BR/>Concurrent medications: General anesthesia: induction - 4 mg/kg thiopental, 1 mg/kg succinylcholine; muscle relaxation - pancuronium 0.08 mg/kg; maintenance - 3 L/min N2O and 2 L/min O2. Bupivacaine 0.33%, 5 ml each hour until end of surgery.<BR/>QS = 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2000">
<CHAR_METHODS>
<P>Crossover, &lt; 24 h each treatment (minimum 5 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: healthy, aged 18-45, within 30% of ideal body weight and more than 45 kg, no use of medications within previous seven days, no narcotics or laxatives in previous three months, normal bowel habits (defined as one or two bowel movements/day), no pregnancy<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed: Alvimopan plus morphine Period: ?/14/14; Placebo plus morphine Period: ?/14/14; Placebo Period: ?/14/14<BR/>Age (mean+/-SD, median, or range): 28+/-7; range = 18 to 45<BR/>% male: 50<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine IV 0.05 mg/kg over 1 min beginning 2 min before lactulose <BR/>Alvimopan oral 2 mg x 2 (2 h and 30 min before lactulose) <BR/>Placebo: oral unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>GI transit time: lactulose hydrogen breath test (oral lactulose 10 g suspended in 100 ml tap water collected every 15 min)<BR/>Results:<BR/>GI transit time (min): baseline 69+/-33; morphine 103+/-37 (P = 0.005 vs. baseline); morphine plus alvimopan 76+/-30 (P &gt; 0.3 vs. baseline) <BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: none<BR/>Reasons for dropout: no dropout<BR/>Concurrent medications: not listed<BR/>QS = 3<BR/>Each subject received oral and IV placebo treatment on the first day, because some people do not produce hydrogen after ingestion of lactulose. Thus this portion of the study was only single-blinded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2002">
<CHAR_METHODS>
<P>Parallel, 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: chronic pain (malignant and nonmalignant) and a complaint of opioid-induced constipation, onset of constipation corresponding to use of opioids, receiving stable dose of opioids for pain<BR/>Exclusion criteria: receiving tricyclic antidepressants or calcium channel blockers, history of bowel dysfunction (e.g., Crohn's disease, bowel adhesions, etc.)<BR/>Number of patients screened/enrolled/completed: Naloxone 2 mg group: ?/3/3; Naloxone 4 mg group: ?/3/2; Placebo group: ?/3/2<BR/>Age (mean+/-SD, median, or range): range = 33-72<BR/>% male: 44<BR/>Primary diagnosis: opioid-induced constipation<BR/>Comorbidities: chronic pain (malignant and non-malignant)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oxycodone or morphine oral (various doses)<BR/>Naloxone oral 2 mg or 4 mg three times daily (doses ranged from 1.7 to 10% of daily opioid dose)<BR/>Placebo: oral unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Constipation: Constipation Assessment Scale (0-2, 2 = most severe): 8 symptoms rated - abdominal distention/bloating, change in amount of gas passed rectally, less frequent bowel movements (BM/wk), oozing liquid stool, rectal fullness or pressure, rectal pain with bowel movement, smaller stool size, urge but inability to pass stool<BR/>Pain: Short Form Brief Pain Inventory: overall pain levels, analgesic requirements, interference of pain on quality of life<BR/>All data recorded for 3 days prior to intervention, then daily throughout intervention.<BR/>Results:<BR/>Constipation: frequency: 6/6 naloxone patients reported improved bowel frequency vs. baseline. 1/3 patients receiving placebo improved bowel frequency. Trend toward less constipating symptoms in naloxone patients. 4/6 naloxone patients satisfied with bowel habits vs 0/3 placebo.<BR/>Pain: naloxone 3/6 required increased analgesia (n = 1, complete reversal with naloxone 4 mg) vs. placebo 2/3 (due to increased tumor size and placebo effect)<BR/>Antagonism of analgesia: naloxone 2 mg group: 2/3; naloxone 4 mg group: 1/3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: diarrhea (naloxone n = 1), anxiety (naloxone n = 2), cramping (naloxone n = 1; placebo n = 1); jitteriness (naloxone n = 1)<BR/>Reasons for dropout: complete reversal of analgesia and diarrhea (n = 1); marked increase in pain (n = 1)<BR/>Concurrent medications: Prophylactic regimen of stool softener and bowel stimulant<BR/>QS = 3<BR/>None of the subjects in naloxone groups who experienced reversal of analgesia returned to their baseline opioid doses until several days after stopping the naloxone</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Meissner-2003">
<CHAR_METHODS>
<P>Parallel, 5-10 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: continuous administration of IV fentanyl as part of the analgesic-sedative regimen in mechanically ventilated patients<BR/>Exclusion criteria: any preexisting diseases, injury or surgery of the GI tract; pregnancy; age &lt; 18 years or analgesic-sedative therapy for &gt; 24 h prior to study<BR/>Number of patients screened/enrolled/completed: Naloxone group: ?/38/38; Placebo group: ?/43/43<BR/>Age (mean+/-SD, median, or range): Naloxone group: 50 median; 35-63 (interquartile range); Placebo group: 49 (34-58)<BR/>% male: not listed<BR/>Primary diagnosis: intracranial bleeding (n = 41); head injury (n = 27); trauma (n = 10); postoperative respiratory insufficiency (n = 3)<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fentanyl IV continuous infusion with boluses if required (adjusted at discretion of attending physician)<BR/>Naloxone via feeding tube 8 mg every 6 h (stopped 12 h after end of fentanyl administration)<BR/>Placebo: saccharin 0.336 g, vaniline 0.4 g, Na-EDTA 0.2 g, orange flavor, and potassium sorbate 2 g in 1000 g aqua dest (same formulation as naloxone group)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Constipation: time to first defecation <BR/>ICU and hospital stay time <BR/>Need for propulsive medication, fentanyl and norepinephrine<BR/>Gastric tube reflux: daily amount of fluid flowing passively back through gastric tube<BR/>Frequency of pneumonia<BR/>Results:<BR/>Constipation: time to defecation (hrs): naloxone 72 (62-84) (median [interquartile range]) vs. placebo 73 (50-81), P = 0.37.<BR/>Gastric tube reflux volume (ml): naloxone 54 (0-162) (median [interquartile range]) vs. placebo 129 (48-245), P = 0.03.<BR/>Pain: fentanyl requirements (mcg/kg/hr): naloxone 7 (6.2-8.6) (median [interquartile range]) vs. placebo 6.5 (5.2-7.9), P = 0.15.<BR/>Hospital stay (days): naloxone 24 (16-33) (median [interquartile range]) vs. placebo 23 (14-34), P = 0.92.<BR/>Pneumonia: naloxone, n = 13 vs. placebo, n = 24, P = 0.04.<BR/>Antagonism of analgesia? no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: see results<BR/>Reasons for dropout: protocol violation (n = 3)<BR/>Concurrent medications: droperidol IV (dose varied); colloids during hemodynamic resuscitation; norepinephrine if MAP &lt; 70 mm Hg; propulsive medication: neostigmine 15 mcg/kg, metoclopramide 0.3 mg/kg, dexpanthenol 15 mg/kg if bowel evacuation absent &gt; 3 days<BR/>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Meissner-2004">
<CHAR_METHODS>
<P>Parallel, 4-8 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: ICU patients 18 years and older, at least 72 h of mechanical ventilation under sedation, at least 1 esophagogastroduodensocopy during this time<BR/>Exclusion criteria: less than 72 h of ventilation, sedation/analgesia, diseases or injury or surgery of the intestinal tract<BR/>Number of patients screened/enrolled/completed: Naloxone group: ?/?/17; Placebo group: ?/?/22<BR/>Age (mean+/-SD, median, or range): Naloxone group: median 50 (range 40-63); Placebo group: 49 (37-62)<BR/>% male: not listed<BR/>Primary diagnosis: not listed<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fentanyl IV continuous infusion with boluses if required (adjusted at discretion of attending physician)<BR/>Naloxone via NGT 8 mg four times daily <BR/>Placebo: unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Incidence of esophago-gastric mucosal lesions: Savary-Miller score<BR/>Gastric reflux, enteral nutrition volume, frequency of prokinetic drug administration<BR/>Results:<BR/>Incidence of esophago-gastric mucosal lesions: naloxone, n = 4 (24%) gastritis vs. placebo, n = 9 gastritis, n = 1 esophagitis, n = 4 both (64% of group positive for lesions, P = 0.02).<BR/>Less prokinetic use in naloxone group (P = 0.03, see concurrent medications). <BR/>Trend for tolerance of greater enteral feedings in naloxone group.<BR/>Fentanyl consumption similar between groups.<BR/>Antagonism of analgesia? not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: not listed<BR/>Reasons for dropout: not listed<BR/>Concurrent medications: Ranitidine 50 mg IV three times daily, droperidol to effect; prokinetics (neostigmine 15 mcg/kg, metoclopramide 0.3 mg/kg, dexpanthenol 15 mg/kg) median times/day: naloxone group 0 (range 0-0.7) vs. placebo group 0.4 (0-1.6) (P = 0.03); norepinephrine: naloxone group 0.13 mcg/kg/min (0.05-0.35) vs placebo group 0.18 (0.14-0.30) (P = 0.15). <BR/>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Murphy-1997">
<CHAR_METHODS>
<P>Crossover, 3 h each treatment (minimum 7 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: no history of GI disease or drug hypersensitivity, and not taking medications<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed: Placebo period: ?/11/11; Morphine period: ?/11/10; Morphine plus methylnaltrexone period: ?/10/10<BR/>Age (mean+/-SD, median, or range): 26+/-4.4<BR/>% male: 45<BR/>Primary diagnosis: healthy volunteers<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine IV 0.09 mg/kg <BR/>Methylnaltrexone IV 0.3 mg/kg<BR/>Placebo: normal saline IV <BR/>all administered over 10 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>gastric emptying: directly by noninvasive electric bioimpedance method, indirectly by acetaminophen absorption technique (area under serum concentration curve determined by gastric emptying rate)<BR/>Results:<BR/>Gastric emptying: <BR/>bioimpedance, time to empty half the stomach (min): placebo 5.5+/-1.9; morphine 21.3+/-9.0 (P &lt; 0.03 vs. placebo); methylnaltrexone plus morphine 7.4+/-3.0 (P &lt; 0.04 vs. morphine)<BR/>acetaminophen absorption AUC (mg/l/h): placebo 1078+/-295; morphine 502+/-395 (P &lt; 0.05 vs. placebo); morphine plus methylnaltrexone 798+/-481 (P &lt; 0.05 vs. morphine)<BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: Nausea (VRS, 1 = no nausea, 10 = worst possible nausea): highest scores after morphine alone (P &lt; 0.014 at 50 min vs. saline). N = 3 vomited after morphine, n = 1 vomited with methylnaltrexone plus morphine. No nausea or vomiting with saline.<BR/>Reasons for dropout: vomiting (n = 1, morphine group)<BR/>Concurrent medications: not listed<BR/>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nimmo-1979">
<CHAR_METHODS>
<P>Crossover, 24 h each treatment (minimum 7 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: fasting healthy volunteers<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed: Pentazocine period: ?/4/4; Pentazocine plus naloxone period: ?/4/4; Baseline period: ?/4/4<BR/>Age (mean+/-SD, median, or range): range = 26-39<BR/>% male: not listed<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Pentazocine IM 60 mg <BR/>Naloxone IV 1.2 mg <BR/>Placebo: unspecified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>gastric emptying: time to empty half ingested dose of acetaminophen (method not specified); peak plasma acetaminophen concentration; time to peak plasma concentration<BR/>Results:<BR/>Mean time (minutes) to empty half ingested dose of acetaminophen: control 13.0+/-3.5 (SE); pentazocine 97.3+/-17.6 (P &lt; 0.02 vs. control); pentazocine plus naloxone 27.8+/-7.6 (NS vs. control, P value not specified)<BR/>Mean peak plasma acetaminophen concentration (mcg/ml): control 23.8+/-1.9 (SE); pentazocine 10.8+/-0.6 (P &lt; 0.05 vs. control); pentazocine plus naloxone 15.0+/-1.8 (P &lt; 0.05 vs. control)<BR/>Mean time to peak concentration (minutes): control 22.5+/-1.3 (SE); pentazocine 160.0+/-16.3 (P &lt; 0.01 vs. control); pentazocine plus naloxone 25.0+/-1.8 (NS vs. control, P value not specified)<BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: not listed<BR/>Reasons for dropout: not listed<BR/>Concurrent medications: not listed<BR/>QS = 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Paulson-2005">
<CHAR_METHODS>
<P>Parallel, 35 days (treatment and follow up)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: at least 18 years old, received opioid therapy for at least one month with stable dose (+/-20%) for at least one week, minimum equivalent daily dose of 10 mg oral morphine; had opioid-induced bowel dysfunction (&lt; 3 BM/wk, without aid of laxatives or enemas, and at least one associated symptom: lumpy or hard stools, straining, sensation or anorectal obstruction, or sensation of incomplete evacuation).<BR/>Exclusion criteria: patients with soft or loose stools; patients who could not give informed consent; could not use electronic diary; had a known organic cause of bowel dysfunction or obstruction; used manual maneuvers (e.g. digital evacuation or pelvic floor support) for more than 25% of their BMs; history of irritable bowel syndrome or intermittent loose stools; used opioids for cancer-related pain; had fecal incontinence; required the use of cathartic laxatives or enemas; had exposure to vinca alkaloids within 6 months or a history of vinca-associated gastrointestinal neurotoxicity (including paralytic ileus and intestinal pseudo-obstruction); or used illicit drugs or habitual alcohol<BR/>Number of patients screened/enrolled/completed: Alvimopan 0.5 mg group: ?/58/54; Alvimopan 1 mg group: ?/56/47; Placebo group: ?/54/51<BR/>Age (mean+/-SD, median, or range): Alvimopan 0.5 mg group: 52+/1.5; Alvimopan 1 mg group: 51+/-1.4; Placebo group: 48+/-1.2<BR/>% male: Alvimopan 0.5 mg group: 50; Alvimopan 1 mg group: 39; Placebo group: 35<BR/>Primary diagnosis: opioid-induced bowel dysfunction <BR/>Comorbidities: chronic opioid treatment, minimum of 1 month for nonmalignant pain (n = 148) or opioid dependence (n = 20)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Various: some patients took more than one opioid<BR/>Alvimopan oral capsule(s) 0.5 mg or 1 mg daily<BR/>Placebo: oral capsules (unspecified)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Constipation: proportion of patients with at least one BM within 8 h of intervention each day for 21 days averaged across all patients<BR/>Median time to BM (h)<BR/>Total weekly number of BMs during baseline, treatment and follow-up<BR/>Overall patient satisfaction: percentage of patients reporting improvement in quality of BMs (better or much better than usual)<BR/>Pain: VAS (0 to 100, anchors not specified); median opioid consumption (morphine equivalent doses)<BR/>Results:<BR/>Overall (21 days) proportion of patients having a BM within 8 hrs of study medication on each day: Alvimopan 1 mg group 54% vs. Alvimopan 0.05 mg group 43% vs. Placebo group 29% (P &lt; 0.001 both active groups vs. placebo)<BR/>Median time to BM: Alvimopan 1 mg group 3 hrs vs. Alvimopan 0.5 mg group 7 hrs vs. placebo group 21 hrs (hazard ratios: Alvimopan 1 mg group vs. Placebo group: 2.29; P &lt; 0.01; Alvimopan 0.5 mg group vs. Placebo group: 1.36; P = 0.12)<BR/>Mean (95% CI) weekly number of BMs (weeks 1, 2 and 3 respectively): Alvimopan 1 mg group: 8.4 (7.3 to 9.4), 6.9 (6.1 to 7.8), 6.4 (5.4 to 7.3) vs. Alvimopan 0.5 mg group: 5.8 (4.8 to 6.9), 5.6 (4.8 to 6.4), 5.2 (4.3 to 6.1) vs. Placebo group: 5.5 (4.4 to 6.6), 5.0 (4.2 to 5.9), 5.5 (4.5 to 6.4)<BR/>Overall patient satisfaction: Alvimopan 1 mg group 70% vs. Alvimopan 0.5 mg group 58% vs. Placebo group 50%, P = 0.046, Alvimopan 1 mg group vs. Placebo group).<BR/>'Modest' decreases in severity of straining, cramping, and rectal pain, softening of stool, and decreased frequency of anorectal obstruction, with incomplete evacuation vs. placebo (data not listed, dose not specified, P = 0.002). <BR/>Pain: Opioid consumption and VAS pain intensity scores remained consistent throughout the study for all groups.<BR/>Antagonism of analgesia: no (but see adverse events)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: At least one adverse event: alvimopan 0.5 mg group 37% vs. alvimopan 1 mg group 48% vs. placebo group 33%. Most common adverse events: cramping, nausea, vomiting, diarrhea, flatulence<BR/>Exacerbation of baseline pain: alvimopan 1 mg Group (n = 2)<BR/>Reasons for dropout: Alvimopan 0.5 mg group: adverse events (n = 2); lost to follow up (n = 1); withdrew consent (n = 1). Alvimopan 1 mg group: adverse events (n = 6); other (n = 1); withdrew consent (n = 2). Placebo group: adverse events (n = 1); insufficient responses (n = 1); other (n = 1)<BR/>Concurrent medications: Continuation of patients' regular medications (including opioid analgesics)<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sykes-1996">
<CHAR_METHODS>
<P>crossover, Phase I: 2 days each treatment arm (parallel washout), Phase II: unspecified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: patients with cancer receiving either morphine or diamorphine analgesia orally<BR/>Exclusion criteria: fecal stomas or history of constipation prior to using opioid analgesia<BR/>Number of patients screened/enrolled/completed: Phase I: ?/17/13; Phase II: ?/10/9 <BR/>Age (mean+/-SD, median, or range): mean 64, median 65, range 44-88 (for both randomized and non-randomized phase)<BR/>% male: 48 (for both randomized and non-randomized phase)<BR/>Primary diagnosis: opioid-related constipation<BR/>Comorbidities: cancer in all patients (9 breast, 5 bronchus, 3 prostate, 2 esophagus, 1 each of rectum, kidney, bladder, stomach, colon, fallopian tube, malignant melanoma, fibrosarcoma); 3 patients had liver metastases, 2 had hepatomegaly; no patient had constipation prior to using opioid analgesia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine or diamorphine oral (maintenance dose)<BR/>Phase I: naloxone oral 4-hourly for total daily dose of 0.5%, 1%, 2%, 5%, 10% or 20% of total daily dose of analgesic opioid; Phase II: naloxone oral at 10-80% of morphine dose <BR/>Placebo: chloroform water</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Constipation: Phase I: small bowel transit time - lactulose/hydrogen breath test; Phase II: stool frequency; subjective reports of ease of defecation<BR/>Pain: 4-point scale (0 = no pain, 3 = severe pain)<BR/>Results:<BR/>Constipation:<BR/>Phase 1: small bowel transit time (n = 10): naloxone period 164+/-43 min vs. placebo period 176+/-40 (P = 0.43)<BR/>Phase 2: 9/10 had BM.<BR/>Pain: <BR/>Phase I and II (n = 15): naloxone period 0.79+/-0.87 vs. placebo period 0.72+/-0.76 (P = 0.44)<BR/>Phase II: naloxone period 0.5 (no placebo comparison). Pain score did not increase except in patient whose pain returned (dropout), but 5 patients reported abdominal discomfort.<BR/>Overall: naloxone at doses of 10% or less of morphine dose produced no laxative effect in any of 14 patients, but produced laxation in 9/12 when used at 20% or more. 2 generalized withdrawals occurred. 5 mg of naloxone or less produced laxation in 6/8 patients in whom this represented at least 20% of the morphine dose. 6-10 mg dose was effective in 2/3 patients. Doses &gt; 10 mg caused withdrawal in one patient and laxation in another.<BR/>Antagonism of analgesia: yes (n = 1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: nausea (n = 1), withdrawal (n = 1), abdominal discomfort (n = 5): all after receiving naloxone, all in Phase II - no placebo comparison<BR/>Reasons for dropout: Phase I: severe diarrhea caused by lactulose taken for the transit time measurement (n = 1); general deterioration in health while taking naloxone (n = 1); diarrhea while receiving placebo (n = 1); nausea after two doses of naloxone at the 10% level (n = 1); No dropouts attributed to naloxone. Phase II: severe immediate withdrawal (n = 1)<BR/>Concurrent medications: all patients required laxatives prior to trial. Their use was continued during the trial except for lactulose.<BR/>QS = 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-13 13:46:03 +0100" MODIFIED_BY="Laila Tyrrell" STUDY_ID="STD-Taguchi-2001">
<CHAR_METHODS>
<P>Parallel, 7 days maximum</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-13 13:46:03 +0100" MODIFIED_BY="Laila Tyrrell">
<P>Inclusion criteria: 18 to 78 years old, healthy or well-controlled systemic disease, scheduled for partial colectomy or total abdominal hysterectomy (simple or radical) with general anaesthesia<BR/>Exclusion criteria: treatment with corticosteroids or immunosuppressive drugs within 2 weeks before surgery, opioid analgesics within 4 weeks, or likely to receive NSAIDs post surgery; Crohn's disease, history of abdominal radiation therapy, history of treatment with vinca alkaloids<BR/>Number of patients screened/enrolled/completed: Alvimopan 1 mg group: ?/27/18; Alvimopan 6 mg group: ?/26/26; Placebo group: ?/26/22<BR/>Age (mean+/-SD, median, or range): Alvimopan 1 mg group: 56+/-9; Alvimopan 6 mg group: 49+/-13; Placebo group: 54+/-12<BR/>% male: Alvimopan 1 mg group: 12; Alvimopan 6 mg group: 8; Placebo group: 12<BR/>Primary diagnosis: surgery: partial colectomy (n = 15); total abdominal hysterectomy (n = 63)<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine or meperidine IV PCA (doses unspecified)<BR/>Alvimopan oral 1 mg or 6 mg twice daily <BR/>Placebo: identical capsules <BR/>initial doses of interventions/placebo taken 2 h prior to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Constipation: Time to first flatus and first BM (h)<BR/>Pain: VAS 100 cm; total daily consumption of opioids (mg morphine equivalents)<BR/>Time to discharge readiness and time to actual discharge (h)<BR/>Results:<BR/>Constipation: Median time to first flatus: Alvimopan 6 mg 49 h (interquartile range 43-63) vs. placebo 70 h (48 to 88) (P = 0.03); median time to first BM: Alvimopan 6 mg 70 h (interquartile range 50 to 83) vs. placebo 111 h (70 to 171) (P = 0.01)<BR/>Pain: Maximum: Alvimopan 6 mg 53+/-21 vs. placebo 54+/-25 (P = 0.30); similar amounts of opioid consumed by all groups (P = 0.91).<BR/>Time until ready for discharge (median): Alvimopan 6 mg 68 h (interquartile range 65-68) vs. placebo 91 h (70 to 112) (P = 0.03)<BR/>Actual time to discharge: Alvimopan 6 mg 71 h (56 to 89) vs. placebo group 100 h (79 to 121) (P &lt; 0.001) <BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: Maximal itching and abdominal cramping scores (VAS, anchors not specified) similar amongst all 3 groups. Maximal nausea score (VAS, anchors not specified): Alvimopan 6 mg 18+/-26 vs. alvimopan 1 mg 38+/-33 vs. placebo 38+/-28 (P = 0.02). Frequency of vomiting: Alvimopan 6 mg 0% vs. alvimopan 1 mg 26% vs. placebo 23% (P = 0.03) <BR/>Reasons for dropout: Alvimopan 1 mg group: canceled surgery (n = 1); reasons for other dropouts unspecified<BR/>Concurrent medications: General anesthesia: all patients, not specified by protocol<BR/>QS = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Viscusi-2006">
<CHAR_METHODS>
<P>Parallel, 7 days maximum</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: adult patients (age = 18 years) undergoing laparotomy for partial small or large bowel resection with primary anastomosis, or simple or radical total abdominal hysterectomy, scheduled for postoperative pain management with opioid-based patient-controlled analgesia<BR/>Exclusion criteria: pregnancy; an acute course of opioids &lt; 1 week before study or chronic course of opioids &lt; 2 weeks before study; complete bowel obstruction or colectomy, colostomy, or ileostomy; presence of any other condition known or suspected to be associated with increased risk of postoperative morbidity.<BR/>Number of patients screened/enrolled/completed: Alvimopan 6 mg group: ?/220/187; Alvimopan 12 mg group: ?/222/184; Placebo group: ?/224/176<BR/>Age (mean+/-SD, median, or range): Alvimopan 6 mg group: 56 (range 21-91); Alvimopan 12 mg group: 58 (23-90); Placebo group: 57 (20-93)<BR/>% male: Alvimopan 6 mg group: 39.1; Alvimopan 12 mg group: 36.2; Placebo group: 35.7<BR/>Primary diagnosis: bowel resection (65.7%); radical total abdominal hysterectomy (16.4%); simple total abdominal hysterectomy (13.7%). Percentages balanced for all 3 treatment groups.<BR/>Comorbidities: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Opioid: IV PCA unspecified <BR/>Alvimopan oral 6 mg or 12 mg twice daily<BR/>Placebo: unspecified<BR/>initial doses of interventions/placebo taken 2 h prior to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Constipation: time to recovery of GI function, determined by three-component (flatus, BM, and toleration of solid food) composite endpoint; and two-component composite endpoint (BM, solid food). <BR/>Time to: readiness for hospital discharge based on recovery of GI function alone (determined by investigator), discharge order written, first flatus, first BM, first tolerance of solid food. <BR/>Postoperative pain: VAS (anchors not specified), opioid consumption (morphine equivalents)<BR/>Severity of GI symptoms: daily and maximum VAS scores for nausea and abdominal bloating/distension; incidence of postoperative insertion of nasogastric tube. <BR/>Patients assessed until hospital discharge or for maximum of 10 postoperative days if patient remained hospitalized.<BR/>Results:<BR/>Constipation: time to recovery of GI function, three-component composite endpoint; Alvimopan did not accelerate recovery compared with placebo (6 mg: hazard ratio = 1.20, P = 0.080; 12 mg: HR = 1.24, P = 0.038). After adjustment for significant covariates (sex/surgical duration), benefits significant for both doses (6 mg: HR = 1.24, P = 0.037; 12 mg: HR = 1.26, P = 0.028). Two-component composite endpoint: alvimopan accelerated time to recovery (6 mg: HR = 1.37, P = 0.008; 12 mg: HR = 1.33, P = 0.018)<BR/>Discharge order written: 6 mg: HR = 1.31 (14.2 h earlier) vs. placebo, P = 0.008; 12 mg: HR = 1.28 (15.2 h earlier) vs. placebo, P = 0.015. <BR/>Postoperative pain: No significant differences in opioid consumption or pain scores between groups<BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: similar between groups. NGT insertion (6 mg, 6.0%; 12 mg, 5.5%; placebo, 8.2%), postoperative chest x-rays (6 mg, 12.0%; 12 mg, 12.5%; placebo, 17.1%) and serious adverse events that required readmission (6 mg, 7.3%; 12 mg, 8.6%; placebo, 11.2%) or prolonged stay (6 mg, 5.9%; 12 mg, 6.8%; placebo, 11.6%) less common in alvimopan groups vs. placebo group.<BR/>Reasons for dropout: Alvimopan 6 mg group: adverse events (n = 17); withdrawn (n = 2); protocol violation (n = 12); other (n = 2). Alvimopan 12 mg group: adverse events (n = 17); withdrawn (n = 3); protocol violation (n = 14); other (n = 4). Placebo group: adverse events (n = 29); withdrawn (n = 4); protocol violation (n = 11); other (n = 4).<BR/>Concurrent medications: not listed<BR/>QS = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wolff-2004">
<CHAR_METHODS>
<P>Parallel, 7 days maximum</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: at least 18 years old, scheduled to undergo a partial small or large bowel resection with primary anastomosis or radical total abdominal hysterectomy, scheduled to receive postoperative pain management with IV PCA with opioids, and scheduled to have NGT removed at the end of surgery<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed: Alvimopan 6 mg Group: ?/169/155; Alvimopan 12 mg Group: ?/176/165; Placebo Group: ?/165/149<BR/>Age (mean+/-SD, median, or range): Alvimopan 6 mg Group: 59.3 (range 19-88); Alvimopan 12 mg Group: 61.3 (20-89); Placebo Group: 60.9 (20-87)<BR/>% male: Alvimopan 6 mg Group: 56; Alvimopan 12 mg Group: 47; Placebo Group: 47<BR/>Primary diagnosis: laparotomy for large bowel resection (n = 395), small bowel resection (n = 56) or radical hysterectomy (n = 18). Colon or rectal cancer (54%); diverticular disease (11%); Crohn's disease (7%); ostomy reversal (7%); intestinal polyps (6%); uterine cancer (4%)<BR/>Comorbidities: see "Primary diagnosis"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Opioid: IV PCA unspecified <BR/>Alvimopan oral 6 mg or 12 mg twice daily<BR/>Placebo: unspecified<BR/>initial doses of interventions/placebo taken 2 h prior to surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Primary efficacy endpoint: time to recovery of GI function, defined as the later of time of first tolerating solid food or time to pass first flatus or BM (h)<BR/>Secondary efficacy endpoint: also representing time to recovery of GI function, defined as the later of time of first tolerated solid food, or time to first BM (h)<BR/>Pain: postoperative VAS (anchors not defined); opioid consumption (mg [opioid not specified])<BR/>Time to hospital discharge (h)<BR/>Results:<BR/>Primary efficacy endpoint: mean time to GI recovery: alvimopan 12 mg, 98 h (HR = 1.54, P &lt; 0.001 vs. placebo); alvimopan 6 mg, 105 h (HR = 1.28, P &lt; 0.05 vs. placebo); placebo group 120 h. <BR/>Secondary efficacy endpoint: alvimopan 12 mg, 105 h (HR = 1.67, P &lt; 0.001 vs. placebo); alvimopan 6 mg, 113 h (HR = 1.38, P = 0.013 vs. placebo); placebo group, 133 h. <BR/>Time to hospital discharge: alvimopan 12 mg, 126 h (HR = 1.42, P = 0.003 vs. placebo); alvimopan 6 mg, 133 h (HR = 1.25, P = 0.070 vs. placebo); Placebo group, 146 h. <BR/>Pain: VAS: similar amongst all groups (data not listed). Postoperative opioid consumption: alvimopan 12 mg, 27.1 mg; alvimopan 6 mg, 33.6 mg (statistically significant, but P not listed vs. placebo); Placebo group, 27.0 mg. <BR/>Antagonism of analgesia: no (although data not reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: most common treatment emergent adverse events: nausea and vomiting; similar amongst all groups. Treatment emergent postoperative ileus: Placebo group, 15.8% vs. alvimopan 6 mg, 8.3% (P = 0.043 vs. placebo) vs. alvimopan 12 mg, 6.3% (P = 0.005 vs. placebo). Treatment emergent adverse events leading to discontinued treatment: Placebo group 4.2% vs. alvimopan 6 mg, 2.4% vs. alvimopan 12 mg, 3.4%, of which nausea and vomiting were the most common reasons.<BR/>Reasons for dropout: lack of postoperative efficacy evaluations because of use of epidural anesthesia, NGT insertion, ileostomy or colostomy (n = 21); surgical procedure not specified by protocol (n = 14); cancellation of surgery (n = 6). Adverse events (attributed to drug): placebo group, n = 26 (n = 7); alvimopan 6 mg group, n = 18 (n = 4); alvimopan 12 mg group, n = 14 (n = 6)<BR/>Concurrent medications: not listed<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yuan-1996">
<CHAR_METHODS>
<P>Crossover, 7 h each treatment (minimum 7 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: healthy, non-pregnant subjects<BR/>Exclusion criteria: drug abuse, medical contraindications<BR/>Number of patients screened/enrolled/completed: Placebo plus placebo period: ?/14/12; Placebo plus morphine period: ?/12/12; Methylnaltrexone plus morphine 0.05 mg/kg period: ?/12/12; Methylnaltrexone plus morphine 0.10 mg/kg period: ?/6/6<BR/>Age (mean+/-SD, median, or range): 25.8+/-8.4 (range: 18-43)<BR/>% male: 50<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine IV 0.05-0.1 mg/kg single dose<BR/>Methylnaltrexone IV 0.45 mg/kg single dose<BR/>Placebo: not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others):<BR/>Oral-cecal transit time: lactulose hydrogen breath test <BR/>Pain: cold-pressor test assessed at 30, 70, 110 and 170 seconds after forearm immersed in cold water; VRS (0 = not painful or bothersome at all; 10 = extreme pain or bothersomeness)<BR/>pharmacokinetic data<BR/>Results:<BR/>Oral-cecal transit time (min): baseline 104.6+/-31.1; morphine 163.3+/-39.8 min (P &lt; 0.01 vs. baseline); methylnaltrexone plus morphine 106.3+/-39.8 (P = 0.56 vs. baseline)<BR/>Pain: Differences in pain intensity and pain bothersomeness ratings in all four immersion time points statistically significant for both morphine and morphine plus methylnaltrexone vs. control (P &lt; 0.001). Differences between morphine and methylnaltrexone plus morphine not significant. <BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: not listed<BR/>Reasons for dropout: high and unstable baseline hydrogen level (n = 1); low peak hydrogen value 2 h post lactulose (n = 1)<BR/>Concurrent medications: not listed<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yuan-1997">
<CHAR_METHODS>
<P>Crossover, 7 h each treatment (minimum 7 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: not listed<BR/>Exclusion criteria: drug abuse disorders or medical contraindications<BR/>Number of patients screened/enrolled/completed: Placebo plus placebo period: ?/14/14; Placebo plus morphine period: ?/14/14; Methylnaltrexone plus morphine period: ?/14/14<BR/>Age (mean+/-SD, median, or range): 23.4+/-3.9 (range: 20 to 34) <BR/>% male: 36<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine IV 0.05 mg/kg <BR/>Methylnaltrexone oral 19.2 mg/kg <BR/>Placebo: capsule or saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Constipation: gastrointestinal (oral-cecal) transit time - lactulose hydrogen breath test<BR/>Plasma and urine methylnaltrexone levels, vital signs<BR/>Results:<BR/>Gastrointestinal transit time: <BR/>Placebo plus placebo period: 114.6+/-37.0 min<BR/>Placebo plus morphine period: 158.6+/-50.2 minutes (P &lt; 0.001 vs. placebo period)<BR/>Methylnaltrexone plus morphine period: 110.4+/-45.0 min (P = 0.28 vs. baseline, P &lt; 0.005 vs. placebo plus morphine)<BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: no adverse events occurred at any dose of methylnaltrexone<BR/>Reasons for dropout: no dropouts<BR/>Concurrent medications: not listed<BR/>QS = 4<BR/>Initial dose finding study produced dose used in main part of trial (19.2 mg/kg)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yuan-2000a">
<CHAR_METHODS>
<P>Parallel, 2 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: enrollment in a methadone maintenance program for 1 month or longer; methadone-induced constipation, i.e., no or 1 BM in previous 3 days, or 2 or fewer BM in previous week; no laxative use 2 days before the study or during the study<BR/>Exclusion criteria: history or current evidence of significant CV, respiratory, endocrine, renal, hepatic, hematological, or psychiatric disease; any laboratory findings indicating hepatic or renal impairment, or abnormal physical examination findings; current use of other medications, including street drugs; known hypersensitivity to lactose or lactulose; and participation in any investigational new drug study in the previous 30 d.<BR/>Number of patients screened/enrolled/completed: Methylnaltrexone group:?/11/11; Placebo group: ?/11/11<BR/>Age (mean+/-SD, median, or range): 43.2+/-5.5<BR/>% male: 41<BR/>Primary diagnosis: methadone-induced constipation<BR/>Comorbidities: all subjects enrolled in methadone maintenance program</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Methadone oral maintenance (range 30-100 mg/day)<BR/>Methylnaltrexone IV up to 0.365 mg/kg in 4 syringes. Syringes contained 0.015, 0.05, 0.1 and 0.2 mg/kg each in 35 ml saline, administered 1 min apart.<BR/>Placebo: IV saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Oral-cecal transit time change from baseline: hydrogen breath test (oral lactulose 10 g suspended in 100 ml tap water), conducted every 15 min until oral-cecal transit time determined; immediate laxation: defecation during or within 1 min of infusion; BM frequency and consistency; overall satisfaction with respect to bowel movement.<BR/>Withdrawal symptom questionnaire: items included yawning, lacrimation, rhinorrhea, perspiration, tremor, piloerection, and restlessness (VRS 0 = none, 3 = severe).<BR/>Results:<BR/>Oral-cecal transit time (change from baseline, min): methylnaltrexone -77.7+/-37.2 vs. placebo -1.4+/-12.0 (P &lt; 0.001); immediate laxation: day 1, methylnaltrexone n = 10 vs. placebo n = 0 (P &lt; 0.001); day 2, methylnaltrexone n = 11 vs. placebo n = 0 (P &lt; 0.001); 7/9 placebo group disappointed with BM satisfaction vs. 0/11 in methylnaltrexone group.<BR/>No opioid withdrawal observed in any subject.<BR/>Antagonism of analgesia: no</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: no significant adverse events. Mild to moderate abdominal cramping without discomfort: 11/11 methylnaltrexone group vs. 0/11 placebo group; mild lightheadedness (n = 1 methylnaltrexone group); mild diarrhea (n = 1 methylnaltrexone group).<BR/>Reasons for dropout: no dropout<BR/>Concurrent medications: not listed<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yuan-2000b">
<CHAR_METHODS>
<P>Crossover, 7 h each treatment (minimum 7 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: not listed<BR/>Exclusion criteria: not listed<BR/>Number of patients screened/enrolled/completed: Control period: ?/9/9; Methylnaltrexone plus placebo period: ?/9/9; Methylnaltrexone plus morphine period: ?/9/9<BR/>Age (mean+/-SD, median, or range): 25.1+/-6.8<BR/>% male: 42<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine IV 0.05 mg/kg<BR/>Methylnaltrexone oral enteric-coated 3.2 mg/kg capsule <BR/>Placebo: oral cornstarch capsule; IV saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Oral-cecal transit time change from baseline: hydrogen breath test (oral lactulose, unspecified dose), conducted every 15 min until time was determined.<BR/>Results:<BR/>Oral-cecal transit time (min): baseline (placebo) 96.7+/-54.1; morphine 155.0+/-53.6 (P = 0.014 vs. baseline); morphine plus methylnaltrexone 93.3+/-56.0 (P = 0.009 vs. morphine only; P = 0.55 vs. baseline). <BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: not listed<BR/>Reasons for dropout: no dropout<BR/>Concurrent medications: not listed<BR/>QS = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yuan-2002">
<CHAR_METHODS>
<P>Crossover, 7 h each treatment (minimum 7 day washout)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: healthy subjects<BR/>Exclusion criteria: drug abuse or medical contraindications<BR/>Number of patients screened/enrolled/completed: Placebo period: ?/13/12; Morphine period: ?/13/12; Morphine plus methylnaltrexone period: ?/13/12<BR/>Age (mean+/-SD, median, or range): 24.8+/-5.9 (range: 19-38)<BR/>% male: 67<BR/>Primary diagnosis: healthy volunteers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Morphine IV 0.05 mg/kg<BR/>Methylnaltrexone SC methylnaltrexone 0.1 mg/kg or 0.3 mg/kg<BR/>Placebo: IV or SC saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes measured (constipation; others)<BR/>Constipation: oral-cecal transit time: lactulose hydrogen breath test (min)<BR/>Unpleasant subjective effects: 12 item questionnaire (flushing, stimulated, numb, drunken, difficulty in concentrating, drowsy (sleepy), coasting or spaced out, turning of stomach, skin itch, dry mouth, dizzy, and nauseous). 5-point scale (0 = not at all, 4 = extremely) completed at 0 h, 5 min, post-morphine injection (~20 min) and 180 min post-morphine. Ratings of 12 items summed to give a score.<BR/>Results:<BR/>Results displayed graphically<BR/>Constipation: Oral-cecal transit time (min): <BR/>0.1 mg/kg methylnaltrexone: baseline 85+/-20.5; morphine 155+/-27.9 (P &lt; 0.01 vs. baseline); methylnaltrexone plus morphine 110+/-41.0. <BR/>0.3 mg/kg methylnaltrexone: baseline 98+/-49.1; morphine 140+/-58.2 (P &lt; 0.01 vs. baseline); methylnaltrexone plus morphine 108+/-59.6 (P &lt; 0.05 vs. morphine).<BR/>Subjective ratings: methylnaltrexone significantly decreased morphine-induced changes.<BR/>Antagonism of analgesia: healthy volunteers - analgesia not measured</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events: see 'Results'<BR/>Reasons for dropout: low hydrogen value with no peak up to 4 h after lactulose administration (n = 1)<BR/>Concurrent medications: not listed<BR/>QS = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ASA = American Society of Anesthesiologists;<BR/>BM = bowel movement; <BR/>ICU = intensive care unit; <BR/>NS = non significant; <BR/>PCA = patient controlled analgesia; <BR/>SD = standard deviation; <BR/>VAS = visual analog scale; <BR/>VRS = verbal rating scale<BR/>vs. = versus<BR/>h = hour</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-30 19:00:30 +0000" MODIFIED_BY="Jessica Thomas" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Callaghan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Loperamide is the opioid agonist used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cheskin-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Culpepper_x002d_Morga-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Culpepper_x002d_Morga-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foss-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No opioid administered</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gowan-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No constipation outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joshi-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No constipation outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaufman-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients administered naloxone or morphine, but not both</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kreek-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Latasch-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lewis-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meissner-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mittal-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients administered naloxone or morphine, but not both</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Narducci-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of endogenous opioids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rees-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Loperamide is the opioid agonist used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schang-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sykes-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomas-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Welch-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lipid-induced constipation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yuan-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-30 19:00:30 +0000" MODIFIED_BY="Jessica Thomas" STUDY_ID="STD-Yuan-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 19:00:30 +0000" MODIFIED_BY="Jessica Thomas">
<P>Duplicate study (<LINK REF="STD-Yuan-2000a" TYPE="STUDY">Yuan 2000a</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yuan-2000c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yuan-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>No opioid administered</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Barr-2000">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Delaney-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Freye-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gonenne-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hawkes-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Herzog-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Meissner-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Meissner-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Murphy-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nimmo-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Paulson-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sykes-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Taguchi-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Viscusi-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolff-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yuan-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yuan-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yuan-2000a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yuan-2000b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yuan-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-04-11 22:43:52 +0100" MODIFIED_BY="Ewan McNicol">
<COMPARISON ID="CMP-001" MODIFIED="2008-04-11 22:43:52 +0100" MODIFIED_BY="Ewan McNicol" NO="1">
<NAME>GI transit</NAME>
<CONT_OUTCOME CHI2="42.97302831276375" CI_END="3.3929636149414186" CI_START="-37.20244622115102" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.904741303104803" ESTIMABLE="YES" I2="95.34591794312536" I2_Q="95.34591794312536" ID="CMP-001.01" MODIFIED="2008-04-11 22:43:52 +0100" MODIFIED_BY="Ewan McNicol" NO="1" P_CHI2="4.661606656242157E-10" P_Q="4.661606656242157E-10" P_Z="0.10260862309901485" Q="42.97302831276375" RANDOM="NO" SCALE="180.71509153745686" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="41" UNITS="" WEIGHT="100.0" Z="1.6323364762581907">
<NAME>Oral-cecal transit time (minutes) vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-41.86455600977495" CI_START="-99.73544399022504" DF="0.0" EFFECT_SIZE="-70.8" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="1.621149667608413E-6" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="49.20775683084511" Z="4.795691061533858">
<NAME>Methylnaltrexone</NAME>
<CONT_DATA CI_END="-41.864556009774944" CI_START="-99.73544399022505" EFFECT_SIZE="-70.8" ESTIMABLE="YES" MEAN_1="54.5" MEAN_2="125.3" ORDER="1" SD_1="19.3" SD_2="45.0" SE="14.763252905902425" STUDY_ID="STD-Yuan-2000a" TOTAL_1="11" TOTAL_2="11" WEIGHT="49.20775683084511"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="155.73568713569063" CI_START="64.26431286430939" DF="0.0" EFFECT_SIZE="110.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="2.4295258589652523E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="19.696245666747643" Z="4.713956470354678">
<NAME>Nalbuphine</NAME>
<CONT_DATA CI_END="155.73568713569063" CI_START="64.26431286430939" EFFECT_SIZE="110.0" ESTIMABLE="YES" MEAN_1="380.0" MEAN_2="270.0" ORDER="2" SD_1="89.6" SD_2="53.5" SE="23.334963038325128" STUDY_ID="STD-Freye-1988" TOTAL_1="20" TOTAL_2="20" WEIGHT="19.696245666747643"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.399438831627663" CI_START="-48.39943883162766" DF="0.0" EFFECT_SIZE="-12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="0.5181809681815344" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="31.095997502407247" Z="0.6461519344645603">
<NAME>Naloxone</NAME>
<CONT_DATA CI_END="24.399438831627663" CI_START="-48.39943883162766" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="164.0" MEAN_2="176.0" ORDER="3" SD_1="43.0" SD_2="40.0" SE="18.571483516402235" STUDY_ID="STD-Sykes-1996" TOTAL_1="10" TOTAL_2="10" WEIGHT="31.095997502407247"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.025506118818795" CI_END="-26.4806237502602" CI_START="-58.06771436413948" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-42.27416905719984" ESTIMABLE="YES" I2="0.0" I2_Q="58.36318658359207" ID="CMP-001.02" NO="2" P_CHI2="0.5535661974535141" P_Q="0.12120205665693973" P_Z="1.5528160490365026E-7" Q="2.4017207801160096" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="99.99999999999999" Z="5.246184261874541">
<NAME>Oral-cecal transit time (minutes) vs. placebo in healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.787785049339208E-32" CI_END="-2.048232149440551" CI_START="-51.951767850559456" DF="0.0" EFFECT_SIZE="-27.000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.0" P_Z="0.03393418882446671" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="40.064213262895564" Z="2.120852834938305">
<NAME>Alvimopan</NAME>
<CONT_DATA CI_END="-2.0482321494405475" CI_START="-51.95176785055945" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="103.0" ORDER="4" SD_1="30.0" SD_2="37.0" SE="12.73072773141538" STUDY_ID="STD-Liu-2000" TOTAL_1="14" TOTAL_2="14" WEIGHT="40.064213262895564"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6237853387027852" CI_END="-32.08392352571185" CI_START="-72.88452083357132" DF="3.0" EFFECT_SIZE="-52.484222179641584" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.890966332231065" P_Z="4.5964429108329585E-7" STUDIES="4" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="59.93578673710442" Z="5.042435259097561">
<NAME>Methylnaltrexone</NAME>
<CONT_DATA CI_END="-25.153952546843126" CI_START="-88.8460474531569" EFFECT_SIZE="-57.000000000000014" ESTIMABLE="YES" MEAN_1="106.3" MEAN_2="163.3" ORDER="5" SD_1="39.8" SD_2="39.8" SE="16.248281960461746" STUDY_ID="STD-Yuan-1996" TOTAL_1="12" TOTAL_2="12" WEIGHT="24.595076935334443"/>
<CONT_DATA CI_END="-12.885510866736254" CI_START="-83.51448913326372" EFFECT_SIZE="-48.19999999999999" ESTIMABLE="YES" MEAN_1="110.4" MEAN_2="158.6" ORDER="6" SD_1="45.0" SD_2="50.2" SE="18.017927580210614" STUDY_ID="STD-Yuan-1997" TOTAL_1="14" TOTAL_2="14" WEIGHT="20.001078074892636"/>
<CONT_DATA CI_END="-11.056175768413802" CI_START="-112.34382423158621" EFFECT_SIZE="-61.7" ESTIMABLE="YES" MEAN_1="93.3" MEAN_2="155.0" ORDER="7" SD_1="56.0" SD_2="53.6" SE="25.839160633082148" STUDY_ID="STD-Yuan-2000b" TOTAL_1="9" TOTAL_2="9" WEIGHT="9.725373193193288"/>
<CONT_DATA CI_END="34.65510650645959" CI_START="-98.65510650645959" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="108.0" MEAN_2="140.0" ORDER="8" SD_1="59.6" SD_2="58.2" SE="34.008332312341736" STUDY_ID="STD-Yuan-2002" TOTAL_1="6" TOTAL_2="6" WEIGHT="5.614258533684058"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.226435908477313" CI_END="-9.550742012553673" CI_START="-20.694591617533273" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.122666815043473" ESTIMABLE="YES" I2="87.84406745368909" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.004128488477506687" P_Q="1.0" P_Z="1.0404990685974737E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="5.319505082774942">
<NAME>Time to empty half stomach contents (minutes): naloxone vs. placebo in healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-8.265781438380328" CI_START="-19.534218561619674" EFFECT_SIZE="-13.9" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="21.3" ORDER="9" SD_1="3.0" SD_2="9.0" SE="2.874654129393024" STUDY_ID="STD-Murphy-1997" TOTAL_1="10" TOTAL_2="11" WEIGHT="97.80095896574915"/>
<CONT_DATA CI_END="-31.92590059919592" CI_START="-107.07409940080407" EFFECT_SIZE="-69.5" ESTIMABLE="YES" MEAN_1="27.8" MEAN_2="97.3" ORDER="10" SD_1="15.2" SD_2="35.2" SE="19.170811146114815" STUDY_ID="STD-Nimmo-1979" TOTAL_1="4" TOTAL_2="4" WEIGHT="2.19904103425085"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Patients with chronic constipation: bowel movements</NAME>
<DICH_OUTCOME CHI2="62.29346091140852" CI_END="0.5178481328103139" CI_START="0.21458504437348325" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.3662165885918986" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" I2="98.39469506852065" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.2857975853372096" LOG_CI_START="-0.6684005497158544" LOG_EFFECT_SIZE="-0.4362619872578245" METHOD="MH" NO="1" P_CHI2="1.9984014443252818E-15" P_Q="0.0" P_Z="2.205130907663568E-6" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="65" WEIGHT="100.0" Z="4.7336543849170365">
<NAME>Number of patients with bowel movement within specified time period vs. placebo</NAME>
<GROUP_LABEL_1>Opoid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.41800834141777926" CI_START="0.060827637418199576" EFFECT_SIZE="0.23941798941798942" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" O_E="0.0" SE="0.09111920086720356" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.00830270876667779" WEIGHT="83.32874069991733"/>
<DICH_DATA CI_END="1.1598914135979508" CI_START="0.8401085864020492" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" O_E="0.0" SE="0.08157875086438007" STUDY_ID="STD-Yuan-2000a" TOTAL_1="11" TOTAL_2="11" VAR="0.006655092592592593" WEIGHT="16.671259300082667"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.374559095586271" CI_END="2.4861208868254687" CI_START="0.22634835827102928" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.356234622548249" ESTIMABLE="YES" I2="15.77383760557846" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.30505006624265196" P_Q="1.0" P_Z="0.018642650123304558" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="65" UNITS="" WEIGHT="99.99999999999999" Z="2.3526005216828225">
<NAME>Bowel movements per week vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors antagonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.422536838984124" CI_START="-0.02253683898412362" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="2.0" ORDER="13" SD_1="1.5" SD_2="2.6" SE="1.6441816606851365" STUDY_ID="STD-Liu-2002" TOTAL_1="5" TOTAL_2="3" WEIGHT="12.29344709616594"/>
<CONT_DATA CI_END="2.1709616818344104" CI_START="-0.3709616818344099" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="5.5" ORDER="14" SD_1="3.4" SD_2="3.4" SE="0.6484617533075065" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" WEIGHT="79.03228593701245"/>
<CONT_DATA CI_END="6.736351014542905" CI_START="-0.9363510145429044" EFFECT_SIZE="2.9" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="3.1" ORDER="15" SD_1="5.2" SD_2="1.9" SE="1.9573579131063383" STUDY_ID="STD-Sykes-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="8.6742669668216"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="13.171319233064029" CI_END="0.4756293777954704" CI_START="0.15823686174032697" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.3169331197678987" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="28" I2="84.81549217196567" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.3227313285267903" LOG_CI_START="-0.8006923388812104" LOG_EFFECT_SIZE="-0.4990323743128289" METHOD="MH" NO="3" P_CHI2="0.0013800254498638198" P_Q="0.0" P_Z="9.068404854992497E-5" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="64" WEIGHT="100.00000000000001" Z="3.914254236196787">
<NAME>Number of patients satisfied with bowel movements vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1473279394063818" CI_START="0.18600539392695137" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16" O_E="0.0" SE="0.24523984957433403" STUDY_ID="STD-Liu-2002" TOTAL_1="6" TOTAL_2="3" VAR="0.06014258381924198" WEIGHT="6.165190848922603"/>
<DICH_DATA CI_END="0.38601795362137287" CI_START="0.013982046378627044" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17" O_E="0.0" SE="0.09490886316721062" STUDY_ID="STD-Paulson-2005" TOTAL_1="50" TOTAL_2="52" VAR="0.009007692307692307" WEIGHT="78.57596179999396"/>
<DICH_DATA CI_END="1.068999317089674" CI_START="0.48655623846588153" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="18" O_E="0.0" SE="0.1485851483032416" STUDY_ID="STD-Yuan-2000a" TOTAL_1="11" TOTAL_2="9" VAR="0.022077546296296297" WEIGHT="15.258847351083444"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Pain</NAME>
<CONT_OUTCOME CHI2="0.01431990785411897" CI_END="7.463346113342252" CI_START="-8.163939649600659" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35029676812920363" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.9047478821469608" P_Q="1.0" P_Z="0.9299816030448922" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="0.08786798422309308">
<NAME>Postoperative ileus: VAS maximum vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.693844404019254" CI_START="-9.693844404019254" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="32.0" ORDER="19" SD_1="16.0" SD_2="16.0" SE="4.945929864264375" STUDY_ID="STD-Lee-2001" TOTAL_1="25" TOTAL_2="18" WEIGHT="64.97032318707963"/>
<CONT_DATA CI_END="12.201871246010855" CI_START="-14.201871246010855" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="54.0" ORDER="20" SD_1="21.0" SD_2="25.0" SE="6.735772366301386" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="22" WEIGHT="35.029676812920364"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.516927367432337" CI_END="0.09380682330477028" CI_START="-0.04982819609556354" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.02198931360460337" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-1.0277655708337863" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.65778832690959" METHOD="MH" NO="2" P_CHI2="0.47215539549188423" P_Q="0.0" P_Z="0.5484342589289095" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="57" WEIGHT="100.0" Z="0.600108008335453">
<NAME>Constipation: reversal of analgesia vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5001266217160154" CI_START="-0.8334599550493487" EFFECT_SIZE="-0.16666666666666663" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21" O_E="0.0" SE="0.34020690871988585" STUDY_ID="STD-Liu-2002" TOTAL_1="6" TOTAL_2="3" VAR="0.11574074074074073" WEIGHT="6.781750924784217"/>
<DICH_DATA CI_END="0.09449705225091096" CI_START="-0.02306848082233954" EFFECT_SIZE="0.03571428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="22" O_E="0.0" SE="0.029991758522246434" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="8.995055792567416E-4" WEIGHT="93.21824907521578"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Requirement for postoperative x-ray</NAME>
<DICH_OUTCOME CHI2="0.5744158974631389" CI_END="-0.013282060192657548" CI_START="-0.08212925171855345" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.047705655955605504" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9022634704285168" P_Q="0.0" P_Z="0.006603603165346331" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="720" TOTAL_2="738" WEIGHT="100.0" Z="2.7161999047318086">
<NAME>Postoperative ileus: Alvimopan incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11034477956889649" CI_END="-0.009881723587237663" CI_START="-0.10537562094483299" DF="1.0" EFFECT_SIZE="-0.05762867226603533" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="57" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.7397519898859916" P_Z="0.018000941979594298" STUDIES="2" TAU2="0.0" TOTAL_1="361" TOTAL_2="369" WEIGHT="50.07207821856615" Z="2.365598750155269">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="9.465594395787619E-4" CI_START="-0.13535595048873506" EFFECT_SIZE="-0.06720469552457815" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23" O_E="0.0" SE="0.03477168738901598" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" VAR="0.0012090702438794531" WEIGHT="19.615914258852914"/>
<DICH_DATA CI_END="0.013619264285918989" CI_START="-0.11654134220799693" EFFECT_SIZE="-0.05146103896103897" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0332048464973352" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="0.0011025618309115934" WEIGHT="30.456163959713237"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07001889786978623" CI_END="0.011851216311098312" CI_START="-0.08735919433090293" DF="1.0" EFFECT_SIZE="-0.03775398900990231" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="57" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-1.926237074962705" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.7913092720478199" P_Z="0.1357758319693082" STUDIES="2" TAU2="0.0" TOTAL_1="359" TOTAL_2="369" WEIGHT="49.92792178143386" Z="1.4917075386199996">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.044940663197856015" CI_START="-0.10411107799045972" EFFECT_SIZE="-0.029585207396301855" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25" O_E="0.0" SE="0.038024102066164696" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" VAR="0.0014458323379381104" WEIGHT="19.40207262532659"/>
<DICH_DATA CI_END="0.022924886514005982" CI_START="-0.10881693564134926" EFFECT_SIZE="-0.042946024563671636" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.033608225251718374" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="0.0011295128045702408" WEIGHT="30.52584915610727"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Nasogastric tube insertion</NAME>
<DICH_OUTCOME CHI2="11.999337840662067" CI_END="-0.016321516746069853" CI_START="-0.05606589029387027" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.03619370351997006" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="101" I2="49.9972408505089" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.061983678450048485" P_Q="0.0" P_Z="3.573483850311687E-4" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1453" TOTAL_2="1142" WEIGHT="100.00000000000001" Z="3.5697307082193457">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1321243855853627" CI_END="-0.008958825415024428" CI_START="-0.07318435743801363" DF="2.0" EFFECT_SIZE="-0.041071591426519026" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="50" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.5677569175544377" P_Z="0.012184509966387603" STUDIES="3" TAU2="0.0" TOTAL_1="516" TOTAL_2="518" WEIGHT="42.85700233002454" Z="2.506755100289624">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="-6.0996815118251335E-5" CI_START="-0.09531684617827865" EFFECT_SIZE="-0.047688921496698455" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27" O_E="0.0" SE="0.024300408097936082" STUDY_ID="STD-Delaney-2005" TOTAL_1="141" TOTAL_2="145" VAR="5.905098337262375E-4" WEIGHT="11.854157833875949"/>
<DICH_DATA CI_END="0.026042995949949035" CI_START="-0.06857546348241658" EFFECT_SIZE="-0.021266233766233773" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="0.024137805637936195" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="5.826336610147843E-4" WEIGHT="18.405064878885597"/>
<DICH_DATA CI_END="0.007975854223154125" CI_START="-0.13553593216210197" EFFECT_SIZE="-0.06378003896947392" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="29" O_E="0.0" SE="0.036610822320526995" STUDY_ID="STD-Wolff-2004" TOTAL_1="155" TOTAL_2="149" VAR="0.0013403523109851974" WEIGHT="12.597779617263003"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.460145006546762" CI_END="-0.007448920063549774" CI_START="-0.057621697101839925" DF="3.0" EFFECT_SIZE="-0.03253530858269485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="51" I2="68.28801252069718" ID="CMP-005.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.023759221969564925" P_Z="0.01102398673900861" STUDIES="4" TAU2="0.0" TOTAL_1="937" TOTAL_2="624" WEIGHT="57.14299766997547" Z="2.5419375530803583">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.06326499441013339" CI_START="-0.05626849266100794" EFFECT_SIZE="0.003498250874562722" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.030493796828412717" STUDY_ID="STD-Delaney-2005" TOTAL_1="138" TOTAL_2="145" VAR="9.298716450125135E-4" WEIGHT="11.724930491126381"/>
<DICH_DATA CI_END="0.013092226780084459" CI_START="-0.03196015130838634" EFFECT_SIZE="-0.009433962264150943" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="31" O_E="0.0" SE="0.01149316478359761" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="1.320928367429283E-4" WEIGHT="13.98743826472796"/>
<DICH_DATA CI_END="0.020416392955237728" CI_START="-0.07253339360165015" EFFECT_SIZE="-0.02605850032320621" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="0.023712115959799242" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="5.622644432909659E-4" WEIGHT="18.44717656972186"/>
<DICH_DATA CI_END="-0.033449394741518035" CI_START="-0.1648829217116038" EFFECT_SIZE="-0.09916615822656091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="0.03352957707560359" STUDY_ID="STD-Wolff-2004" TOTAL_1="165" TOTAL_2="149" VAR="0.0011242325388688419" WEIGHT="12.983452344399264"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Nausea</NAME>
<DICH_OUTCOME CHI2="19.436472780254753" CI_END="-0.004280576410253999" CI_START="-0.07561657026113697" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.03994857333569548" ESTIMABLE="YES" EVENTS_1="933" EVENTS_2="773" I2="43.405369254164526" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.05369479395993615" P_Q="0.0" P_Z="0.028150504438306575" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1632" TOTAL_2="1324" WEIGHT="99.99999999999999" Z="2.1951825647902194">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.30001485892323987" CI_START="-0.223091782000163" DF="0.0" EFFECT_SIZE="0.038461538461538436" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-0.5228572353184576" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4149733479708182" NO="1" P_CHI2="1.0" P_Z="0.7731832215299256" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="1.8747611117607188" Z="0.28821362329313494">
<NAME>Alvimopan 1 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.30001485892323987" CI_START="-0.223091782000163" EFFECT_SIZE="0.038461538461538436" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34" O_E="0.0" SE="0.1334480238028865" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" VAR="0.017808375056895767" WEIGHT="1.8747611117607188"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.313049848800299" CI_END="-0.004262468203911629" CI_START="-0.11750353153321441" DF="3.0" EFFECT_SIZE="-0.06088299986856302" ESTIMABLE="YES" EVENTS_1="311" EVENTS_2="347" I2="43.53525591939612" ID="CMP-006.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.15025790475736944" P_Z="0.035073165913019594" STUDIES="4" TAU2="0.0" TOTAL_1="565" TOTAL_2="568" WEIGHT="40.84406318801465" Z="2.107512654948064">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.06687405535511609" CI_START="-0.14635117953812266" EFFECT_SIZE="-0.03973856209150328" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="104" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" O_E="0.0" SE="0.05439519209922534" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0029588369235116264" WEIGHT="10.923017901728484"/>
<DICH_DATA CI_END="-0.0930947927138292" CI_START="-0.5992128995938633" EFFECT_SIZE="-0.3461538461538462" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36" O_E="0.0" SE="0.1291141344617118" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" VAR="0.016670459717796994" WEIGHT="1.8747611117607188"/>
<DICH_DATA CI_END="0.029916205035564566" CI_START="-0.1557278933472528" EFFECT_SIZE="-0.0629058441558441" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="121" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="37" O_E="0.0" SE="0.04735905859677889" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="0.0022428804311731367" WEIGHT="16.00627643582263"/>
<DICH_DATA CI_END="0.07076583380285784" CI_START="-0.13667940740873918" EFFECT_SIZE="-0.032956786802940674" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="106" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.0529206768205688" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.002800598035147088" WEIGHT="12.040007738702819"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.14818852386351" CI_END="0.017697591853436265" CI_START="-0.08355344097641305" DF="3.0" EFFECT_SIZE="-0.032927924561488395" ESTIMABLE="YES" EVENTS_1="591" EVENTS_2="398" I2="63.18200062242137" ID="CMP-006.01.03" LOG_CI_END="-1.7520858249328888" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.0430463762266049" P_Z="0.2023791018804456" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="51.262593713427194" Z="1.2748027239311897">
<NAME>Alvimopan 12 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.018091343361626017" CI_START="-0.19948627576381064" EFFECT_SIZE="-0.09069746620109231" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="104" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.055505514601712366" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0030808621512009044" WEIGHT="10.773968025343693"/>
<DICH_DATA CI_END="0.19094663264117143" CI_START="-0.011998302429649638" EFFECT_SIZE="0.0894741651057609" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="67" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40" O_E="0.0" SE="0.05177261844391652" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.002680404020539365" WEIGHT="12.164412620521823"/>
<DICH_DATA CI_END="0.05484760729261359" CI_START="-0.13067986327192835" EFFECT_SIZE="-0.03791612798965738" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="121" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="41" O_E="0.0" SE="0.047329306055610955" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="0.002240063211705692" WEIGHT="16.042899581089475"/>
<DICH_DATA CI_END="0.006759059727955569" CI_START="-0.20069845366734965" EFFECT_SIZE="-0.09696969696969704" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="106" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42" O_E="0.0" SE="0.052923807537205686" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0028009294042351893" WEIGHT="12.281313486472202"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.1754416390734356" CI_START="-0.036552750184546706" DF="0.0" EFFECT_SIZE="0.06944444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="-0.7558673238908202" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.1583624920952496" NO="4" P_CHI2="1.0" P_Z="0.19911484856749148" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="3.964529791583506" Z="1.2840774750115593">
<NAME>Alvimopan, constipation</NAME>
<DICH_DATA CI_END="0.1754416390734356" CI_START="-0.036552750184546706" EFFECT_SIZE="0.06944444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" O_E="0.0" SE="0.054081195095972937" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.0029247756630086876" WEIGHT="3.964529791583506"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.2843007698126345" CI_START="-0.31938848911088014" DF="0.0" EFFECT_SIZE="-0.017543859649122806" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-006.01.05" LOG_CI_END="-0.5462219643513213" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="5" P_CHI2="1.0" P_Z="0.9093033308137629" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.332990229152112" Z="0.11391732602107707">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.2843007698126345" CI_START="-0.31938848911088014" EFFECT_SIZE="-0.017543859649122806" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="44" O_E="0.0" SE="0.15400519185182443" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.02371759911731725" WEIGHT="1.332990229152112"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.13947572022285157" CI_START="-0.5394757202228515" DF="0.0" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-006.01.06" LOG_CI_END="-0.8555013873077879" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="6" P_CHI2="1.0" P_Z="0.24821309871315478" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.7210619660618149" Z="1.1547005383792515">
<NAME>Naloxone, healthy volunteers</NAME>
<DICH_DATA CI_END="0.13947572022285157" CI_START="-0.5394757202228515" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="45" O_E="0.0" SE="0.17320508075688773" STUDY_ID="STD-Murphy-1997" TOTAL_1="10" TOTAL_2="10" VAR="0.03" WEIGHT="0.7210619660618149"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>VAS maximum vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.31283936141525" CI_START="-34.68716063858475" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="38.0" ORDER="46" SD_1="26.0" SD_2="28.0" SE="7.493587001820033" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>VAS maximum vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.978023739083103" CI_START="-23.978023739083103" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="30.0" ORDER="47" SD_1="12.0" SD_2="22.0" SE="7.64198926981712" STUDY_ID="STD-Murphy-1997" TOTAL_1="10" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Vomiting</NAME>
<DICH_OUTCOME CHI2="26.418719450173896" CI_END="-0.011752105375262091" CI_START="-0.07469930242322503" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.04322570389924356" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="333" I2="65.93324662471194" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.0017442071073721088" P_Q="0.0" P_Z="0.0071066260679668435" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1603" TOTAL_2="1296" WEIGHT="100.0" Z="2.6918060476737833">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.27361335047834845" CI_START="-0.19669027355527155" DF="0.0" EFFECT_SIZE="0.038461538461538436" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-0.5628627158056396" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4149733479708182" NO="1" P_CHI2="1.0" P_Z="0.7485342973455111" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="1.914077257690399" Z="0.32057261021330596">
<NAME>Alvimopan 1 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.27361335047834845" CI_START="-0.19669027355527155" EFFECT_SIZE="0.038461538461538436" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.11997761891119299" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" VAR="0.014394629039599455" WEIGHT="1.914077257690399"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.105044682064786" CI_END="-0.0018862806816914157" CI_START="-0.10132521890437274" DF="3.0" EFFECT_SIZE="-0.05160574979303208" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="153" I2="41.23459858167941" ID="CMP-007.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.16426510776251024" P_Z="0.04191913812067421" STUDIES="4" TAU2="0.0" TOTAL_1="565" TOTAL_2="568" WEIGHT="41.70061559812568" Z="2.034322023089697">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.03461002274349928" CI_START="-0.16846623189382598" EFFECT_SIZE="-0.06692810457516335" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="49" O_E="0.0" SE="0.0518061189489105" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0026838739605486634" WEIGHT="11.152087601928068"/>
<DICH_DATA CI_END="-0.06167793308426375" CI_START="-0.39986052845419784" EFFECT_SIZE="-0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.08627265552772276" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" VAR="0.007442971091805112" WEIGHT="1.914077257690399"/>
<DICH_DATA CI_END="0.027519643049938633" CI_START="-0.12751964304993862" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="51" O_E="0.0" SE="0.03955156506007441" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="0.0015643262987012985" WEIGHT="16.341948589567373"/>
<DICH_DATA CI_END="0.08076404575269501" CI_START="-0.10464785425188809" EFFECT_SIZE="-0.011941904249596541" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.0472998232281533" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0022372732774145502" WEIGHT="12.292502148939837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.30363655883464" CI_END="-0.00437220550676809" CI_START="-0.09243448134973616" DF="3.0" EFFECT_SIZE="-0.04840334342825212" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="174" I2="73.45986856189856" ID="CMP-007.01.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.01019237335774914" P_Z="0.031194358471713177" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="52.3376360761729" Z="2.154584558315685">
<NAME>Alvimopan 12 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="-0.07559208869910151" CI_START="-0.2635609241041933" EFFECT_SIZE="-0.1695765064016474" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" O_E="0.0" SE="0.04795211465306657" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.002299405299700842" WEIGHT="10.99991195839674"/>
<DICH_DATA CI_END="0.15185221879333918" CI_START="-0.036588844495746814" EFFECT_SIZE="0.057631687148796185" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" O_E="0.0" SE="0.048072583163641026" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.0023109732520251824" WEIGHT="12.419515960748523"/>
<DICH_DATA CI_END="0.03612200403968223" CI_START="-0.11983241127950121" EFFECT_SIZE="-0.04185520361990949" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55" O_E="0.0" SE="0.03978502068133189" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="0.0015828478706140065" WEIGHT="16.379339769179865"/>
<DICH_DATA CI_END="0.03317228227653639" CI_START="-0.14453591864017273" EFFECT_SIZE="-0.055681818181818166" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="56" O_E="0.0" SE="0.045334557756787554" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0020552221270035064" WEIGHT="12.538868387847774"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.1457906173216519" CI_START="-0.0029334744645090616" DF="0.0" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-007.01.04" LOG_CI_END="-0.8362704251027636" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.1461280356782382" NO="4" P_CHI2="1.0" P_Z="0.05974832300335508" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="4.047671068011026" Z="1.8826462583942127">
<NAME>Alvimopan, constipation</NAME>
<DICH_DATA CI_END="0.1457906173216519" CI_START="-0.0029334744645090616" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="0.03794051649909836" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.0014394827922183547" WEIGHT="4.047671068011026"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2697120872066253" CI_END="0.09537593170912254" CI_START="-0.30245022961171764" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.10353714895129754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-1.0205612064771235" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="2" P_CHI2="0.6035250227720874" P_Q="0.0" P_Z="0.30763849923407516" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.020189734796467">
<NAME>Incidence vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.18819848717530868" CI_START="-0.3168534579355426" DF="0.0" EFFECT_SIZE="-0.06432748538011696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="-0.7253838719505058" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.6175866438807005" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="63.82865268396729" Z="0.49927361247320234">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.18819848717530868" CI_START="-0.3168534579355426" EFFECT_SIZE="-0.06432748538011696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="58" O_E="0.0" SE="0.128842149420764" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.016600299467362477" WEIGHT="63.82865268396729"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.14951581291342983" CI_START="-0.4949703583679752" DF="0.0" EFFECT_SIZE="-0.1727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="-0.8253128735744782" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.29345569138675076" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="36.1713473160327" Z="1.0505709781799617">
<NAME>Naloxone, healthy volunteers</NAME>
<DICH_DATA CI_END="0.14951581291342983" CI_START="-0.4949703583679752" EFFECT_SIZE="-0.1727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="59" O_E="0.0" SE="0.16441275869481015" STUDY_ID="STD-Murphy-1997" TOTAL_1="10" TOTAL_2="11" VAR="0.027031555221637867" WEIGHT="36.1713473160327"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Dyspepsia</NAME>
<DICH_OUTCOME CHI2="2.036806799769964" CI_END="0.016927594140970607" CI_START="-0.050252133074053094" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.016662269466541244" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" I2="1.8070835080735625" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-1.7714047622423756" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.3611712574580672" P_Q="0.0" P_Z="0.33093059932505764" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="709" TOTAL_2="412" WEIGHT="100.0" Z="0.9722411628911446">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.009124217437493524" CI_START="-0.11160787756821247" DF="0.0" EFFECT_SIZE="-0.05124183006535948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-2.03980437368272" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.09616859337424061" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="153" WEIGHT="32.258023502412634" Z="1.6637190206180008">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.009124217437493524" CI_START="-0.11160787756821247" EFFECT_SIZE="-0.05124183006535948" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="60" O_E="0.0" SE="0.0307995697773085" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="9.486134984672953E-4" WEIGHT="32.258023502412634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.006099439121821716" CI_END="0.040206614954427185" CI_START="-0.04059830084211593" DF="1.0" EFFECT_SIZE="-1.9584294384437202E-4" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-1.3957024891576357" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.9377493775404963" P_Z="0.9924197808493606" STUDIES="2" TAU2="0.0" TOTAL_1="559" TOTAL_2="259" WEIGHT="67.74197649758736" Z="0.009500538742661263">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.06727712957933203" CI_START="-0.07094800432192315" EFFECT_SIZE="-0.001835437371295559" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="61" O_E="0.0" SE="0.03526216170081629" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.001243420047814515" WEIGHT="31.817847128199112"/>
<DICH_DATA CI_END="0.04661517979639486" CI_START="-0.04410250219577355" EFFECT_SIZE="0.0012563388003106538" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" O_E="0.0" SE="0.023142691066707834" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="5.355841498090785E-4" WEIGHT="35.924129369388254"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Flatulence</NAME>
<DICH_OUTCOME CHI2="0.5454909054230983" CI_END="0.014226124908812768" CI_START="-0.04318689455223395" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.01448038482171059" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="112" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-1.8469133824109805" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9903627773581091" P_Q="0.0" P_Z="0.322828597892326" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1206" TOTAL_2="914" WEIGHT="99.99999999999999" Z="0.9886619097638307">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2844325594787854" CI_END="0.028313186566519585" CI_START="-0.06165686954263101" DF="1.0" EFFECT_SIZE="-0.016671841488055714" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-1.5480112493076157" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.5938106364634234" P_Z="0.46760606929976833" STUDIES="2" TAU2="0.0" TOTAL_1="370" TOTAL_2="377" WEIGHT="38.53918299759108" Z="0.7263796486445996">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.03495428216635303" CI_START="-0.09717650438857524" EFFECT_SIZE="-0.031111111111111103" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="63" O_E="0.0" SE="0.03370745268718177" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0011361923666585976" WEIGHT="15.632202631231623"/>
<DICH_DATA CI_END="0.05397183919450304" CI_START="-0.06760820283086669" EFFECT_SIZE="-0.0068181818181818205" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="64" O_E="0.0" SE="0.031015886767404292" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="9.619852319684447E-4" WEIGHT="22.906980366359456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.22695696206449734" CI_END="0.024120833709741968" CI_START="-0.05033328487596961" DF="3.0" EFFECT_SIZE="-0.013106225583113822" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="67" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="-1.6176076853675827" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.9731245170420224" P_Z="0.4901762995044946" STUDIES="4" TAU2="0.0" TOTAL_1="836" TOTAL_2="537" WEIGHT="61.46081700240891" Z="0.6900284525318461">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.0458560333278637" CI_START="-0.089996063769264" EFFECT_SIZE="-0.02207001522070015" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="65" O_E="0.0" SE="0.03465678404519463" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.001201092680355257" WEIGHT="15.418893645494414"/>
<DICH_DATA CI_END="0.07867247430191125" CI_START="-0.08799222394785215" EFFECT_SIZE="-0.00465987482297045" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="66" O_E="0.0" SE="0.04251728592065805" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.0018077196020589875" WEIGHT="17.408793493217438"/>
<DICH_DATA CI_END="0.06867421599019687" CI_START="-0.07131971863569951" EFFECT_SIZE="-0.0013227513227513227" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67" O_E="0.0" SE="0.0357133946669813" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.0012754465586395684" WEIGHT="5.673737203138785"/>
<DICH_DATA CI_END="0.043249393910038944" CI_START="-0.07605482377429233" EFFECT_SIZE="-0.016402714932126694" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68" O_E="0.0" SE="0.030435308665207043" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="9.26308013546427E-4" WEIGHT="22.959392660558276"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Urgency to defecate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Healthy volunteers. Naloxone: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Naloxone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors naloxone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5128037817118108" CI_START="-0.012803781711810847" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" O_E="0.0" SE="0.13408602596005514" STUDY_ID="STD-Hawkes-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.017979062357760582" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2008-04-11 22:42:15 +0100" MODIFIED_BY="Ewan McNicol" NO="11">
<NAME>Abdominal pain/distension/cramping</NAME>
<DICH_OUTCOME CHI2="157.84697623503598" CI_END="0.01069335836483793" CI_START="-0.039481785714877767" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.014394213675019918" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="171" I2="94.29827532039708" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-1.9708858784898684" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-04-11 22:42:15 +0100" MODIFIED_BY="Ewan McNicol" NO="1" P_CHI2="2.220446049250313E-16" P_Q="0.0" P_Z="0.2607812897210866" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1568" TOTAL_2="1258" WEIGHT="100.0" Z="1.1245464624472616">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8870501974779214" CI_END="0.010897732543362619" CI_START="-0.0575134110212828" DF="3.0" EFFECT_SIZE="-0.02330783923896009" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="89" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="-1.9626638549350401" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.8285518251609111" P_Z="0.18170334312018052" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="53.80316940270329" Z="1.3355287774905658">
<NAME>Alvimopan 12 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.0907963767113629" CI_START="-0.07575474361977011" EFFECT_SIZE="0.007520816545796394" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="70" O_E="0.0" SE="0.04248831142941069" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0018052566081225908" WEIGHT="11.307926205361738"/>
<DICH_DATA CI_END="0.04237245636439567" CI_START="-0.08527071576409416" EFFECT_SIZE="-0.021449129699849245" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.03256263205225272" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.001060325006170396" WEIGHT="12.76728127657904"/>
<DICH_DATA CI_END="0.02916697585239838" CI_START="-0.08900052465653546" EFFECT_SIZE="-0.02991677440206854" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.030145324465404466" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="9.08740587124513E-4" WEIGHT="16.837986167793687"/>
<DICH_DATA CI_END="0.027818215247597408" CI_START="-0.11493942736880954" EFFECT_SIZE="-0.043560606060606064" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="73" O_E="0.0" SE="0.03641843517086564" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0013263024202945432" WEIGHT="12.88997575296882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.13022096665101573" CI_START="-0.06276064919069828" DF="0.0" EFFECT_SIZE="0.033730158730158735" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="-0.885319085139914" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4719816150672513" MODIFIED="2008-04-11 22:42:15 +0100" MODIFIED_BY="Ewan McNicol" NO="2" P_CHI2="1.0" P_Z="0.49325438153915635" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="4.161012007528613" Z="0.6851419086277585">
<NAME>Alvimopan, constipation</NAME>
<DICH_DATA CI_END="0.13022096665101573" CI_START="-0.06276064919069828" EFFECT_SIZE="0.033730158730158735" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="74" O_E="0.0" SE="0.049230908670753235" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.002423682368548046" WEIGHT="4.161012007528613"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1598914135979508" CI_START="0.8401085864020492" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="0.06441733346606887" LOG_CI_START="-0.07566457652454038" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-04-11 22:42:15 +0100" MODIFIED_BY="Ewan McNicol" NO="3" P_CHI2="1.0" P_Z="1.520338078859471E-34" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.8324776007125696" Z="12.258094042925979">
<NAME>Methylnaltrexone, constipation</NAME>
<DICH_DATA CI_END="1.1598914135979508" CI_START="0.8401085864020492" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="75" O_E="0.0" SE="0.08157875086438007" STUDY_ID="STD-Yuan-2000a" TOTAL_1="11" TOTAL_2="11" VAR="0.006655092592592593" WEIGHT="0.8324776007125696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.44445947671376507" CI_START="-0.7777928100470983" DF="0.0" EFFECT_SIZE="-0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-011.01.04" LOG_CI_END="-0.35216782938862956" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-04-11 22:42:15 +0100" MODIFIED_BY="Ewan McNicol" NO="4" P_CHI2="1.0" P_Z="0.5929801002813471" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="3" WEIGHT="0.3027191275318435" Z="0.5345224838248488">
<NAME>Naloxone, constipation</NAME>
<DICH_DATA CI_END="0.44445947671376507" CI_START="-0.7777928100470983" EFFECT_SIZE="-0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76" O_E="0.0" SE="0.31180478223116176" STUDY_ID="STD-Liu-2002" TOTAL_1="6" TOTAL_2="3" VAR="0.09722222222222221" WEIGHT="0.3027191275318435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.45841206535855195" CI_END="0.01301889623184756" CI_START="-0.06718735149643515" DF="2.0" EFFECT_SIZE="-0.027084227632293793" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="78" I2="0.0" ID="CMP-011.01.05" LOG_CI_END="-1.8854258345649006" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-04-11 22:42:15 +0100" MODIFIED_BY="Ewan McNicol" NO="5" P_CHI2="0.7951648522464034" P_Z="0.18560596559777576" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="40.90062186152369" Z="1.3236901665869008">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.03324389648306171" CI_START="-0.12030272001247348" EFFECT_SIZE="-0.043529411764705886" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="77" O_E="0.0" SE="0.039170775000635545" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0015343496141504147" WEIGHT="11.464362998111895"/>
<DICH_DATA CI_END="0.04997522288389797" CI_START="-0.07254015794883306" EFFECT_SIZE="-0.011282467532467547" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78" O_E="0.0" SE="0.03125449799055409" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="9.768436446415498E-4" WEIGHT="16.799547978343746"/>
<DICH_DATA CI_END="0.0400721465561677" CI_START="-0.10641605905392637" EFFECT_SIZE="-0.033171956248879336" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="79" O_E="0.0" SE="0.03737012689150779" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0013965263838873936" WEIGHT="12.636710885068046"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6604559877776475" CI_END="0.26184950068263635" CI_START="-0.12851616734930305" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06666666666666665" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="39.775579276967235" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-0.5819482499121325" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.1760912590556813" METHOD="MH" NO="2" P_CHI2="0.1975418398370331" P_Q="0.0" P_Z="0.5032113536296783" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6694454781065057">
<NAME>Incidence vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors anatagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.355250540325063" CI_START="-0.021917206991729637" DF="0.0" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="-0.44946525285154165" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.7781512503836436" NO="1" P_CHI2="1.0" P_Z="0.08324203811983712" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="60.0" Z="1.732177082552282">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.355250540325063" CI_START="-0.021917206991729637" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="80" O_E="0.0" SE="0.09621803009949255" STUDY_ID="STD-Gonenne-2005" TOTAL_1="18" TOTAL_2="18" VAR="0.009257909316226855" WEIGHT="60.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3026011843763214" CI_START="-0.4692678510429881" DF="0.0" EFFECT_SIZE="-0.08333333333333337" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="-0.5191293764876693" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.6721439715904448" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="40.0" Z="0.42320736951515914">
<NAME>Naloxone, healthy volunteers</NAME>
<DICH_DATA CI_END="0.3026011843763214" CI_START="-0.4692678510429881" EFFECT_SIZE="-0.08333333333333337" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" O_E="0.0" SE="0.196908984427192" STUDY_ID="STD-Hawkes-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.03877314814814815" WEIGHT="40.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>VAS maximum vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.469260718081966" CI_START="-23.469260718081966" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="30.0" ORDER="82" SD_1="24.0" SD_2="29.0" SE="7.3824115301167" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2008-04-11 22:41:40 +0100" MODIFIED_BY="Ewan McNicol" NO="12">
<NAME>Diarrhea</NAME>
<DICH_OUTCOME CHI2="11.230954248674678" CI_END="0.02591887567792216" CI_START="-0.02023613966290202" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0028413680075100706" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="70" I2="37.67225967618875" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-1.5863838414382" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.5464725138024145" METHOD="MH" MODIFIED="2008-04-11 22:41:40 +0100" MODIFIED_BY="Ewan McNicol" NO="1" P_CHI2="0.12885743281128825" P_Q="0.0" P_Z="0.8093099721510317" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1223" TOTAL_2="928" WEIGHT="100.0" Z="0.24131630854938976">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7988426463517757" CI_END="0.023378467204465896" CI_START="-0.0358201925327736" DF="2.0" EFFECT_SIZE="-0.006220862664153851" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="37" I2="47.35238634006852" ID="CMP-012.01.01" LOG_CI_END="-1.631183966504567" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.14965531244936792" P_Z="0.6803953179290516" STUDIES="3" TAU2="0.0" TOTAL_1="780" TOTAL_2="483" WEIGHT="54.93671733240039" Z="0.41192374383575864">
<NAME>Alvimopan 12 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.01116009303152967" CI_START="-0.1107213787330249" EFFECT_SIZE="-0.04978064285074761" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="83" O_E="0.0" SE="0.031092783522028992" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="9.667611871477576E-4" WEIGHT="15.183863447033369"/>
<DICH_DATA CI_END="0.06574915969340984" CI_START="-0.02015548250395395" EFFECT_SIZE="0.022796838594727947" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84" O_E="0.0" SE="0.02191485223069624" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="4.802607482932519E-4" WEIGHT="17.143431251039065"/>
<DICH_DATA CI_END="0.05039595367543837" CI_START="-0.04833551411499879" EFFECT_SIZE="0.0010302197802197904" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85" O_E="0.0" SE="0.025187061744302033" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="6.343880793112831E-4" WEIGHT="22.609422634327963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.19338710378513124" CI_START="0.020898610500583018" DF="0.0" EFFECT_SIZE="0.10714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="-0.7135724906547586" LOG_CI_START="-1.679882588146841" LOG_EFFECT_SIZE="-0.9700367766225568" MODIFIED="2008-04-11 22:41:40 +0100" MODIFIED_BY="Ewan McNicol" NO="2" P_CHI2="1.0" P_Z="0.014895893769180447" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="5.58725242598623" Z="2.434900290470934">
<NAME>Alvimopan, constipation</NAME>
<DICH_DATA CI_END="0.19338710378513124" CI_START="0.020898610500583018" EFFECT_SIZE="0.10714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86" O_E="0.0" SE="0.04400297521921715" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.0019362618281430386" WEIGHT="5.58725242598623"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3095318907584216" CI_START="-0.12771370894023973" DF="0.0" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-012.01.03" LOG_CI_END="-0.5092945994163771" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2008-04-11 22:41:40 +0100" MODIFIED_BY="Ewan McNicol" NO="3" P_CHI2="1.0" P_Z="0.4150697984897519" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="11" WEIGHT="1.117820012474097" Z="0.815004401059231">
<NAME>Methylnaltrexone, constipation</NAME>
<DICH_DATA CI_END="0.3095318907584216" CI_START="-0.12771370894023973" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="87" O_E="0.0" SE="0.11154429447367369" STUDY_ID="STD-Yuan-2000a" TOTAL_1="11" TOTAL_2="11" VAR="0.01244212962962963" WEIGHT="1.117820012474097"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6110049318613127" CI_START="-0.2776715985279793" DF="0.0" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-012.01.04" LOG_CI_END="-0.21395528423942733" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2008-04-11 22:41:40 +0100" MODIFIED_BY="Ewan McNicol" NO="4" P_CHI2="1.0" P_Z="0.4622407671418838" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="3" WEIGHT="0.4064800045360352" Z="0.7351621268695206">
<NAME>Naloxone, constipation</NAME>
<DICH_DATA CI_END="0.6110049318613127" CI_START="-0.2776715985279793" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="88" O_E="0.0" SE="0.22670736232886393" STUDY_ID="STD-Liu-2002" TOTAL_1="6" TOTAL_2="3" VAR="0.05139622813411079" WEIGHT="0.4064800045360352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6943242059578054" CI_END="0.03636272506840078" CI_START="-0.04385172658263312" DF="1.0" EFFECT_SIZE="-0.003744500757116172" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" I2="0.0" ID="CMP-012.01.05" LOG_CI_END="-1.4393435776551764" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-04-11 22:41:40 +0100" MODIFIED_BY="Ewan McNicol" NO="5" P_CHI2="0.40469784923934315" P_Z="0.8548084988960104" STUDIES="2" TAU2="0.0" TOTAL_1="370" TOTAL_2="377" WEIGHT="37.95173022460324" Z="0.18298664325373015">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.040508850783046446" CI_START="-0.08965917758043207" EFFECT_SIZE="-0.024575163398692812" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="89" O_E="0.0" SE="0.03320673986619839" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0011026875725413693" WEIGHT="15.393920963864701"/>
<DICH_DATA CI_END="0.06126952337398192" CI_START="-0.040327964932423466" EFFECT_SIZE="0.010470779220779228" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="90" O_E="0.0" SE="0.025918202861836596" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="6.717532395873148E-4" WEIGHT="22.557809260738534"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Incidence vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.14294845785696952" CI_START="-0.1487964110733438" EFFECT_SIZE="-0.0029239766081871343" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="91" O_E="0.0" SE="0.0744260790584826" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.005539241244019503" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Constipation</NAME>
<DICH_OUTCOME CHI2="4.974942965136586" CI_END="-0.017582172168126606" CI_START="-0.07556496544032618" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.04657356880422639" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="111" I2="19.59706818688763" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.28987824509328897" P_Q="0.0" P_Z="0.0016405059316569291" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1150" TOTAL_2="860" WEIGHT="99.99999999999999" Z="3.148607106913845">
<NAME>Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6620294710994903" CI_END="-0.005091866209095963" CI_START="-0.08284156488855528" DF="1.0" EFFECT_SIZE="-0.04396671554882562" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="39" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.41584468052417534" P_Z="0.026644829295329218" STUDIES="2" TAU2="0.0" TOTAL_1="370" TOTAL_2="377" WEIGHT="40.85731996038912" Z="2.216682005405161">
<NAME>Postoperative ileus, 6 mg</NAME>
<DICH_DATA CI_END="0.006749888922785663" CI_START="-0.13433158826919087" EFFECT_SIZE="-0.0637908496732026" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="92" O_E="0.0" SE="0.03599083409307753" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0012953401387154318" WEIGHT="16.5724816903822"/>
<DICH_DATA CI_END="0.013837551135661277" CI_START="-0.07471417451228464" EFFECT_SIZE="-0.03043831168831168" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.022590141029741013" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="5.103144717435884E-4" WEIGHT="24.284838270006922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.358642298267034" CI_END="-0.00736627126996188" CI_START="-0.0893826320168253" DF="2.0" EFFECT_SIZE="-0.04837445164339359" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="72" I2="54.11415153762019" ID="CMP-013.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.11311837764763799" P_Z="0.0207759767564975" STUDIES="3" TAU2="0.0" TOTAL_1="780" TOTAL_2="483" WEIGHT="59.142680039610866" Z="2.3120309686882035">
<NAME>Postoperative ileus, 12 mg</NAME>
<DICH_DATA CI_END="-0.00623371940888888" CI_START="-0.1443616785676533" EFFECT_SIZE="-0.0752976989882711" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94" O_E="0.0" SE="0.035237371770170306" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0012416723692691952" WEIGHT="16.34634214089471"/>
<DICH_DATA CI_END="0.013261919113983722" CI_START="-0.18069761740993145" EFFECT_SIZE="-0.08371784914797387" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="95" O_E="0.0" SE="0.049480382816685216" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.002448308283685718" WEIGHT="18.45593472807101"/>
<DICH_DATA CI_END="0.045188675147090435" CI_START="-0.05217800934230696" EFFECT_SIZE="-0.0034946670976082617" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="96" O_E="0.0" SE="0.02483889634131376" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="6.169707714545301E-4" WEIGHT="24.340403170645143"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Alvimopan: incidence vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Healthy volunteers</NAME>
<DICH_DATA CI_END="0.07619543047031141" CI_START="-0.4212246702363933" EFFECT_SIZE="-0.17251461988304095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="97" O_E="0.0" SE="0.12689521456268865" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.01610239547891079" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Postoperative ileus</NAME>
<DICH_OUTCOME CHI2="11.163887825652367" CI_END="-0.016135490815639034" CI_START="-0.05879726993064771" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.03746638037314337" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="123" I2="46.2552822663337" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.08344155517939955" P_Q="0.0" P_Z="5.76247107820828E-4" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="1190" WEIGHT="100.0" Z="3.4425547966238135">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.369175506422808" CI_END="-4.710811669041137E-4" CI_START="-0.06949483426648134" DF="2.0" EFFECT_SIZE="-0.03498295771669273" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" I2="62.75033294017814" ID="CMP-014.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.06824949340614062" P_Z="0.04695374965200398" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="43.187945609705835" Z="1.9867171551361291">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.09119352144979609" CI_START="-0.03498437112299868" EFFECT_SIZE="0.028104575163398704" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="98" O_E="0.0" SE="0.032188829378516616" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0010361207367592543" WEIGHT="12.105495297570412"/>
<DICH_DATA CI_END="0.0016719640062092464" CI_START="-0.097938197772443" EFFECT_SIZE="-0.04813311688311688" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="99" O_E="0.0" SE="0.0254112224929551" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="6.457302285864672E-4" WEIGHT="17.739044819728925"/>
<DICH_DATA CI_END="-0.0053270166535345775" CI_START="-0.14414402512519947" EFFECT_SIZE="-0.07473552088936702" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="100" O_E="0.0" SE="0.03541315288613356" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0012540913973366698" WEIGHT="13.343405492406497"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.947178942983168" CI_END="-0.012494846083124553" CI_START="-0.0662136599258093" DF="3.0" EFFECT_SIZE="-0.039354253004466926" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="63" I2="49.55591501850509" ID="CMP-014.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.11420860194604643" P_Z="0.004082338096385429" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="56.812054390294165" Z="2.8717282832460054">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.06267833854234162" CI_START="-0.05578425670869492" EFFECT_SIZE="0.003447040916823352" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="101" O_E="0.0" SE="0.030220605119648723" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="9.132849737977385E-4" WEIGHT="11.940309943677143"/>
<DICH_DATA CI_END="0.011576613179983264" CI_START="-0.053652541728569314" EFFECT_SIZE="-0.021037964274293025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="102" O_E="0.0" SE="0.016640396309083184" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="2.7690278932334923E-4" WEIGHT="13.481277894100213"/>
<DICH_DATA CI_END="0.01177215983110795" CI_START="-0.09043247010906529" EFFECT_SIZE="-0.03933015513897867" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="103" O_E="0.0" SE="0.026073088777740384" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="6.798059584119315E-4" WEIGHT="17.779632624015125"/>
<DICH_DATA CI_END="-0.028974158173346698" CI_START="-0.16117735697816843" EFFECT_SIZE="-0.09507575757575756" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="104" O_E="0.0" SE="0.033725925539352684" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0011374380534859615" WEIGHT="13.610833928501684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>Insomnia</NAME>
<DICH_OUTCOME CHI2="6.950954130026061" CI_END="0.020246161016383567" CI_START="-0.03607186198662744" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.007912850485121938" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="95" I2="42.453943369857875" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-1.6936573135583899" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.13850305584772493" P_Q="0.0" P_Z="0.5817971198125691" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1150" TOTAL_2="860" WEIGHT="99.99999999999999" Z="0.5507615906566934">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.499341087234439" CI_END="0.04725030979866206" CI_START="-0.04302574484191561" DF="1.0" EFFECT_SIZE="0.0021122824783732256" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" I2="81.81600333317587" ID="CMP-015.01.01" LOG_CI_END="-1.3255953396751763" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.675248003469957" NO="1" P_CHI2="0.019023735576167655" P_Z="0.9269216030021505" STUDIES="2" TAU2="0.0" TOTAL_1="370" TOTAL_2="377" WEIGHT="40.85731996038912" Z="0.09171862016499034">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.00868700891001313" CI_START="-0.1360072703479216" EFFECT_SIZE="-0.06366013071895424" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="105" O_E="0.0" SE="0.03691248420870606" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0013625314904579743" WEIGHT="16.5724816903822"/>
<DICH_DATA CI_END="0.10469895819959978" CI_START="-0.010705451706093314" EFFECT_SIZE="0.04699675324675323" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="106" O_E="0.0" SE="0.02944044146116672" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="8.667395934283844E-4" WEIGHT="24.284838270006922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1531473712686404" CI_END="0.021141402923513165" CI_START="-0.050818355303420444" DF="2.0" EFFECT_SIZE="-0.014838476189953641" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="53" I2="0.0" ID="CMP-015.01.02" LOG_CI_END="-1.6748661967010539" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.5618202263870884" P_Z="0.41891242931616346" STUDIES="3" TAU2="0.0" TOTAL_1="780" TOTAL_2="483" WEIGHT="59.142680039610866" Z="0.8083095228321353">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.02746258132832209" CI_START="-0.1226367240447694" EFFECT_SIZE="-0.047587071358223654" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="107" O_E="0.0" SE="0.03829134273819714" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.001466226928694083" WEIGHT="16.34634214089471"/>
<DICH_DATA CI_END="0.057763424169988406" CI_START="-0.07160599349704767" EFFECT_SIZE="-0.006921284663529634" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="108" O_E="0.0" SE="0.03300300890411394" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.001089198596725024" WEIGHT="18.45593472807101"/>
<DICH_DATA CI_END="0.05308567832864303" CI_START="-0.050782834114034114" EFFECT_SIZE="0.0011514221073044562" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="109" O_E="0.0" SE="0.026497556399499866" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="7.021204951446762E-4" WEIGHT="24.340403170645143"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>Fatigue</NAME>
<DICH_OUTCOME CHI2="1.7408907780629357" CI_END="0.027357970956368036" CI_START="-0.14387347514343496" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.05825775209353347" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="42.55814249802129" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="-1.562916115838249" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.1870261066100013" P_Q="0.0" P_Z="0.18231212820339268" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="72" WEIGHT="100.0" Z="1.3336697029006743">
<NAME>Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.05822901380021514" CI_START="-0.09791155348275482" DF="0.0" EFFECT_SIZE="-0.01984126984126984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-016.01.01" LOG_CI_END="-1.2348605652887046" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.618401230433751" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="74.8374668914038" Z="0.4981174972414888">
<NAME>Sub-category</NAME>
<DICH_DATA CI_END="0.05822901380021514" CI_START="-0.09791155348275482" EFFECT_SIZE="-0.01984126984126984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="110" O_E="0.0" SE="0.03983250929981031" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.001586628797119475" WEIGHT="74.8374668914038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.07619543047031141" CI_START="-0.4212246702363933" DF="0.0" EFFECT_SIZE="-0.17251461988304095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-016.01.02" LOG_CI_END="-1.1180710730309311" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.17398676588559592" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="25.162533108596197" Z="1.359504536696421">
<NAME>Healthy volunteers</NAME>
<DICH_DATA CI_END="0.07619543047031141" CI_START="-0.4212246702363933" EFFECT_SIZE="-0.17251461988304095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="111" O_E="0.0" SE="0.12689521456268865" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.01610239547891079" WEIGHT="25.162533108596197"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" NO="17">
<NAME>Anxiety/jitteriness</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="3" WEIGHT="0.0" Z="0.0">
<NAME>Constipation. Naloxone: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Naloxone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors naloxone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9921735948933954" CI_START="0.00782640510660454" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="112" O_E="0.0" SE="0.25111359125759347" STUDY_ID="STD-Liu-2002" TOTAL_1="6" TOTAL_2="3" VAR="0.06305803571428571" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" NO="18">
<NAME>Headache</NAME>
<DICH_OUTCOME CHI2="1.6807797993693985" CI_END="0.03727020423580997" CI_START="-0.018535517954346173" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0093673431407319" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-1.4286382273630842" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.0283835705784337" METHOD="MH" NO="1" P_CHI2="0.8913123039539058" P_Q="0.0" P_Z="0.5105479782320654" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1169" TOTAL_2="878" WEIGHT="100.0" Z="0.6579846820762547">
<NAME>Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5881049270793447" CI_END="0.03633419282015469" CI_START="-0.03481781002663637" DF="2.0" EFFECT_SIZE="7.581913967591612E-4" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="48" I2="0.0" ID="CMP-018.01.01" LOG_CI_END="-1.4396844834037483" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-3.1202211478457764" NO="1" P_CHI2="0.7452374218026134" P_Z="0.9666816416792878" STUDIES="3" TAU2="0.0" TOTAL_1="780" TOTAL_2="483" WEIGHT="57.97027618415515" Z="0.04177051303069804">
<NAME>Alvimopan 12 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.07168332505925275" CI_START="-0.07410073037754446" EFFECT_SIZE="-0.001208702659145855" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="113" O_E="0.0" SE="0.03719049344445184" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0013831328026418154" WEIGHT="16.02230348495711"/>
<DICH_DATA CI_END="0.08860787288697748" CI_START="-0.04867914156074056" EFFECT_SIZE="0.01996436566311846" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="114" O_E="0.0" SE="0.035022841116117566" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.001226599399844815" WEIGHT="18.090076958069087"/>
<DICH_DATA CI_END="0.03616845101365199" CI_START="-0.061136130393096094" EFFECT_SIZE="-0.012483839689722054" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="115" O_E="0.0" SE="0.02482305342707167" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="6.161839814432545E-4" WEIGHT="23.85789574112896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.2959517040366384" CI_START="-0.34273532976763255" DF="0.0" EFFECT_SIZE="-0.023391812865497075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-018.01.02" LOG_CI_END="-0.5287791550954779" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.8858425985524576" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="1.9823312955559238" Z="0.1435667496688998">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.2959517040366384" CI_START="-0.34273532976763255" EFFECT_SIZE="-0.023391812865497075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="116" O_E="0.0" SE="0.1629333597051152" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.026547279704796457" WEIGHT="1.9823312955559238"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.462740881644137" CI_END="0.06763990982680546" CI_START="-0.020737876360837463" DF="1.0" EFFECT_SIZE="0.023451016732983995" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" I2="0.0" ID="CMP-018.01.03" LOG_CI_END="-1.169796980047491" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6298383234413374" NO="3" P_CHI2="0.49634582901997637" P_Z="0.2982694850584291" STUDIES="2" TAU2="0.0" TOTAL_1="370" TOTAL_2="377" WEIGHT="40.047392520288916" Z="1.040151607778594">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.12012356328411206" CI_START="-0.03541768093117087" EFFECT_SIZE="0.04235294117647059" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="117" O_E="0.0" SE="0.03967961795272067" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.001574472080873872" WEIGHT="16.24396019938348"/>
<DICH_DATA CI_END="0.06261353341520276" CI_START="-0.041509637311306656" EFFECT_SIZE="0.010551948051948049" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="118" O_E="0.0" SE="0.026562521441164146" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="7.055675453123049E-4" WEIGHT="23.803432320905436"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" NO="19">
<NAME>Dizziness/lightheadedness</NAME>
<DICH_OUTCOME CHI2="2.1600966402294337" CI_END="0.025293325889735707" CI_START="-0.041692104154890886" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.008199389132577587" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="-1.5969940603119668" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.5398508633552348" P_Q="0.0" P_Z="0.6313546939554269" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="664" TOTAL_2="359" WEIGHT="100.0" Z="0.47982098149925434">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3689450968067975" CI_END="0.03010272636515753" CI_START="-0.036503354079734936" DF="2.0" EFFECT_SIZE="-0.0032003138572887038" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="21" I2="0.0" ID="CMP-019.01.01" LOG_CI_END="-1.52139416913296" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.5043562320809749" P_Z="0.8506052987450313" STUDIES="3" TAU2="0.0" TOTAL_1="645" TOTAL_2="341" WEIGHT="95.60554660223823" Z="0.1883461647229029">
<NAME>Sub-category</NAME>
<DICH_DATA CI_END="0.06628401026988742" CI_START="-0.047735881072573705" EFFECT_SIZE="0.009274064598656859" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="119" O_E="0.0" SE="0.029087241460005252" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="8.460676157526486E-4" WEIGHT="40.102277723393705"/>
<DICH_DATA CI_END="0.02289471093072419" CI_START="-0.05751817570124779" EFFECT_SIZE="-0.017311732385261798" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="120" O_E="0.0" SE="0.020513868434894354" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="4.20818798164155E-4" WEIGHT="52.88844061438688"/>
<DICH_DATA CI_END="0.3095318907584216" CI_START="-0.12771370894023973" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="121" O_E="0.0" SE="0.11154429447367369" STUDY_ID="STD-Yuan-2000a" TOTAL_1="11" TOTAL_2="11" VAR="0.01244212962962963" WEIGHT="2.6148282644576577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.11953303269551849" CI_START="-0.35345116135048926" DF="0.0" EFFECT_SIZE="-0.11695906432748537" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-019.01.02" LOG_CI_END="-0.9225120617872092" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.3323876026623698" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="4.394453397761764" Z="0.9693159164006937">
<NAME>Healthy volunteers</NAME>
<DICH_DATA CI_END="0.11953303269551849" CI_START="-0.35345116135048926" EFFECT_SIZE="-0.11695906432748537" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="122" O_E="0.0" SE="0.12066145035746745" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.014559185602367582" WEIGHT="4.394453397761764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" NO="20">
<NAME>Hypotension</NAME>
<DICH_OUTCOME CHI2="1.4282834623723781" CI_END="0.016176547766080383" CI_START="-0.033396988654292956" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.008610220444106285" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="-1.7911141555365606" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9641153336424967" P_Q="0.0" P_Z="0.49597532754994245" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="1190" WEIGHT="100.0" Z="0.6808359131894952">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3979762429392109" CI_END="0.018897799964723218" CI_START="-0.044416697652852034" DF="3.0" EFFECT_SIZE="-0.012759448844064407" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="75" I2="0.0" ID="CMP-020.01.01" LOG_CI_END="-1.7235887523767492" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.9406602501864155" P_Z="0.42954929245010653" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="56.812054390294165" Z="0.7899631565584929">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.04301332540619393" CI_START="-0.11079020784866864" EFFECT_SIZE="-0.03388844122123735" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="123" O_E="0.0" SE="0.039236316194594695" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0015394885085222138" WEIGHT="11.940309943677143"/>
<DICH_DATA CI_END="0.03781015100474205" CI_START="-0.059008012944529155" EFFECT_SIZE="-0.010598930969893554" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="124" O_E="0.0" SE="0.02469896506082778" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="6.100388750759914E-4" WEIGHT="13.481277894100213"/>
<DICH_DATA CI_END="0.047795105210181" CI_START="-0.06310699919854558" EFFECT_SIZE="-0.007655946994182289" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="125" O_E="0.0" SE="0.028291873035297645" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="8.00430079845402E-4" WEIGHT="17.779632624015125"/>
<DICH_DATA CI_END="0.07020497435148088" CI_START="-0.07626558041208698" EFFECT_SIZE="-0.00303030303030305" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="126" O_E="0.0" SE="0.03736562404179589" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0013961898600328352" WEIGHT="13.610833928501684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8731370086259218" CI_END="0.036341224101435234" CI_START="-0.04264536942576721" DF="2.0" EFFECT_SIZE="-0.003152072662165989" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="69" I2="0.0" ID="CMP-020.01.02" LOG_CI_END="-1.4396004482017577" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.6462502476641218" P_Z="0.8756938426136711" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="43.187945609705835" Z="0.15643031604777294">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.04655846501853826" CI_START="-0.10721205978978009" EFFECT_SIZE="-0.030326797385620913" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="127" O_E="0.0" SE="0.03922789551778518" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0015388277867542707" WEIGHT="12.105495297570412"/>
<DICH_DATA CI_END="0.07381090682619094" CI_START="-0.042804413319697435" EFFECT_SIZE="0.015503246753246755" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="128" O_E="0.0" SE="0.02974935281100447" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="8.850239926736197E-4" WEIGHT="17.739044819728925"/>
<DICH_DATA CI_END="0.07062926287217877" CI_START="-0.07722779254763154" EFFECT_SIZE="-0.0032992648377263845" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="129" O_E="0.0" SE="0.037719329688220775" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.001422747832128693" WEIGHT="13.343405492406497"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" NO="21">
<NAME>Hypertension</NAME>
<DICH_OUTCOME CHI2="3.6148291109188753" CI_END="0.027851761734788115" CI_START="-0.018489639572718534" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0046810610810347885" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="116" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="-1.555147328766792" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.3296556919246223" METHOD="MH" NO="1" P_CHI2="0.7286348446326436" P_Q="0.0" P_Z="0.6921332485648821" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="1190" WEIGHT="100.0" Z="0.3959617477848752">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6034297021488686" CI_END="0.04043470450969147" CI_START="-0.03214146550940375" DF="2.0" EFFECT_SIZE="0.004146619500143859" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="55" I2="0.0" ID="CMP-021.01.01" LOG_CI_END="-1.3932457262958988" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.3823058143030664" NO="1" P_CHI2="0.448559275911363" P_Z="0.8227853112643542" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="43.187945609705835" Z="0.22396400569870592">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.10530759240346625" CI_START="-0.034980795017845304" EFFECT_SIZE="0.035163398692810474" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="130" O_E="0.0" SE="0.03578851155630625" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0012808175594158661" WEIGHT="12.105495297570412"/>
<DICH_DATA CI_END="0.032915271484856075" CI_START="-0.07463605070563528" EFFECT_SIZE="-0.020860389610389607" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="131" O_E="0.0" SE="0.02743706594581392" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="7.52792587714942E-4" WEIGHT="17.739044819728925"/>
<DICH_DATA CI_END="0.07732869214391004" CI_START="-0.058824119793183846" EFFECT_SIZE="0.009252286175363097" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="132" O_E="0.0" SE="0.034733498424218474" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.001206415912785187" WEIGHT="13.343405492406497"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.007211057702419" CI_END="0.03512771597714166" CI_START="-0.024953039712785445" DF="3.0" EFFECT_SIZE="0.005087338132178109" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="61" I2="0.0" ID="CMP-021.01.02" LOG_CI_END="-1.4543500873492043" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.2935093958345765" NO="2" P_CHI2="0.5709114073258532" P_Z="0.7399497362926065" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="56.812054390294165" Z="0.33191991018575223">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.10200648626333335" CI_START="-0.038437679745292344" EFFECT_SIZE="0.0317844032590205" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="133" O_E="0.0" SE="0.03582825172208044" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0012836636214607602" WEIGHT="11.940309943677143"/>
<DICH_DATA CI_END="0.06142296093815938" CI_START="-0.039037287768987655" EFFECT_SIZE="0.011192836584585864" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="134" O_E="0.0" SE="0.02562808538819199" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="6.567987606644599E-4" WEIGHT="13.481277894100213"/>
<DICH_DATA CI_END="0.027294534387815553" CI_START="-0.07880552339880455" EFFECT_SIZE="-0.025755494505494497" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="135" O_E="0.0" SE="0.02706683863160849" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="7.326137535095339E-4" WEIGHT="17.779632624015125"/>
<DICH_DATA CI_END="0.08410005655817615" CI_START="-0.05228187473999432" EFFECT_SIZE="0.015909090909090914" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="136" O_E="0.0" SE="0.0347919483148501" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0012104796675432006" WEIGHT="13.610833928501684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" NO="22">
<NAME>Tachycardia</NAME>
<DICH_OUTCOME CHI2="5.329903097584487" CI_END="0.0103699220536947" CI_START="-0.03230300878166187" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.010966543363983583" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="-1.9842245080060892" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.5022488948062203" P_Q="0.0" P_Z="0.31374992723328465" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="1190" WEIGHT="100.0" Z="1.0073847569192844">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0999291065467103" CI_END="0.025165222654964486" CI_START="-0.04369029413838908" DF="2.0" EFFECT_SIZE="-0.0092625357417123" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="53" I2="0.0" ID="CMP-022.01.01" LOG_CI_END="-1.5991992227317864" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.5769703892265439" P_Z="0.5979756069808526" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="43.187945609705835" Z="0.5273139264571893">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.0845306221539731" CI_START="-0.05394238685985546" EFFECT_SIZE="0.01529411764705882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="137" O_E="0.0" SE="0.03532539630985211" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0012478836244481132" WEIGHT="12.105495297570412"/>
<DICH_DATA CI_END="0.015856527450367405" CI_START="-0.06796691706075701" EFFECT_SIZE="-0.026055194805194803" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="138" O_E="0.0" SE="0.021383924697676346" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="4.5727223547589247E-4" WEIGHT="17.739044819728925"/>
<DICH_DATA CI_END="0.06404161733173135" CI_START="-0.08247446653381134" EFFECT_SIZE="-0.009216424601039996" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="139" O_E="0.0" SE="0.03737723882205052" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0013970579819606004" WEIGHT="13.343405492406497"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.3794086894895985" CI_END="0.014673492697633562" CI_START="-0.039197317933439266" DF="3.0" EFFECT_SIZE="-0.012261912617902854" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="56" I2="31.497601326866867" ID="CMP-022.01.02" LOG_CI_END="-1.8334664997376562" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.22330251594955108" P_Z="0.3722631011712447" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="56.812054390294165" Z="0.8922422674220759">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.06494274307979246" CI_START="-0.06924035253453327" EFFECT_SIZE="-0.002148804727370404" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="140" O_E="0.0" SE="0.03423101053711825" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.001171762082392301" WEIGHT="11.940309943677143"/>
<DICH_DATA CI_END="0.06056581517582146" CI_START="-0.015474673506489824" EFFECT_SIZE="0.022545570834665817" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="141" O_E="0.0" SE="0.01939844029842103" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="3.76299486011405E-4" WEIGHT="13.481277894100213"/>
<DICH_DATA CI_END="0.010197418812544795" CI_START="-0.07172780019586734" EFFECT_SIZE="-0.030765190691661275" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="142" O_E="0.0" SE="0.02089967459979566" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="4.3679639837734395E-4" WEIGHT="17.779632624015125"/>
<DICH_DATA CI_END="0.03852366836561742" CI_START="-0.10140245624440532" EFFECT_SIZE="-0.03143939393939395" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="143" O_E="0.0" SE="0.035696095875674794" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0012742112607653671" WEIGHT="13.610833928501684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" NO="23">
<NAME>Hypokalemia</NAME>
<DICH_OUTCOME CHI2="6.665718208165532" CI_END="0.004419660978051899" CI_START="-0.05430821325301828" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.024944276137483193" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="86" I2="54.99359699416954" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-2.3546110430962024" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.08335120595170487" P_Q="0.0" P_Z="0.09592004257334252" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="786" TOTAL_2="778" WEIGHT="100.0" Z="1.6649634773949844">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.539216061923442" CI_END="0.026382777430528945" CI_START="-0.05849211271852367" DF="1.0" EFFECT_SIZE="-0.01605466764399736" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" I2="71.74515535351254" ID="CMP-023.01.01" LOG_CI_END="-1.5786794863007154" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.05993392510570139" P_Z="0.45840169434487965" STUDIES="2" TAU2="0.0" TOTAL_1="389" TOTAL_2="389" WEIGHT="49.75348018322187" Z="0.7414812628501902">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.06888942269412877" CI_START="-0.03009072139542747" EFFECT_SIZE="0.019399350649350652" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="144" O_E="0.0" SE="0.02525050074141642" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="6.375877876922711E-4" WEIGHT="28.394776024562162"/>
<DICH_DATA CI_END="0.010592088504770919" CI_START="-0.1369682764194204" EFFECT_SIZE="-0.06318809395732473" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="145" O_E="0.0" SE="0.03764364194651754" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0014170437789976149" WEIGHT="21.358704158659705"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8062061354210224" CI_END="0.006866599173962734" CI_START="-0.07435991140564002" DF="1.0" EFFECT_SIZE="-0.033746656115838644" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="43" I2="64.3646991082511" ID="CMP-023.01.02" LOG_CI_END="-2.1632583030669568" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.09390030168768992" P_Z="0.10340042078308745" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="389" WEIGHT="50.24651981677813" Z="1.628587270676415">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.04224120785013154" CI_START="-0.04947294669951745" EFFECT_SIZE="-0.003615869424692955" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="146" O_E="0.0" SE="0.023396897920849192" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="5.474148323186372E-4" WEIGHT="28.459744664291495"/>
<DICH_DATA CI_END="-0.001099305174416934" CI_START="-0.14511281603770432" EFFECT_SIZE="-0.07310606060606062" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="147" O_E="0.0" SE="0.03673881561070702" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.00134974057247753" WEIGHT="21.786775152486634"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" NO="24">
<NAME>Hypomagnesemia</NAME>
<DICH_OUTCOME CHI2="0.6418116616889122" CI_END="0.017684560875718708" CI_START="-0.03863389069539093" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.01047466490983611" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="-1.7524057196558431" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.4230557791877487" P_Q="0.0" P_Z="0.4659606045287258" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="441" TOTAL_2="448" WEIGHT="100.0" Z="0.7290671316658067">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0430451145474511" CI_START="-0.04109706259939915" DF="0.0" EFFECT_SIZE="9.740259740259744E-4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-024.01.01" LOG_CI_END="-1.3660761321425632" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-3.0114294617807817" NO="1" P_CHI2="1.0" P_Z="0.9638068884082462" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="224" WEIGHT="49.94286413908501" Z="0.045376905942560795">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.0430451145474511" CI_START="-0.04109706259939915" EFFECT_SIZE="9.740259740259744E-4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="148" O_E="0.0" SE="0.02146523553763054" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="4.60756336685957E-4" WEIGHT="49.94286413908501"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2966627434173007E-32" CI_END="0.015554440474090585" CI_START="-0.059348881327354955" DF="0.0" EFFECT_SIZE="-0.021897220426632186" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="100.0" ID="CMP-024.01.02" LOG_CI_END="-1.808145606759423" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.0" P_Z="0.25181550033181854" STUDIES="1" TAU2="0.0" TOTAL_1="221" TOTAL_2="224" WEIGHT="50.05713586091499" Z="1.1459508701496768">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.015554440474090582" CI_START="-0.05934888132735496" EFFECT_SIZE="-0.02189722042663219" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="149" O_E="0.0" SE="0.01910834137572766" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="3.651287101313457E-4" WEIGHT="50.05713586091499"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" NO="25">
<NAME>Oliguria</NAME>
<DICH_OUTCOME CHI2="0.39038719177238007" CI_END="-0.006095610426351122" CI_START="-0.06912670282377431" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.03761115662506272" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9422210499010278" P_Q="0.0" P_Z="0.01933272432275009" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="786" TOTAL_2="778" WEIGHT="100.0" Z="2.339052350139235">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1005931808530039" CI_END="0.002795558562681724" CI_START="-0.0858458289120451" DF="1.0" EFFECT_SIZE="-0.04152513517468169" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="52" I2="0.0" ID="CMP-025.01.01" LOG_CI_END="-2.5535314055039953" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.7511189780835713" P_Z="0.06630769866124774" STUDIES="2" TAU2="0.0" TOTAL_1="389" TOTAL_2="389" WEIGHT="49.75348018322187" Z="1.8363378939378299">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.006922700146336523" CI_START="-0.10253958326321966" EFFECT_SIZE="-0.047808441558441564" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150" O_E="0.0" SE="0.027924565010627924" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="7.797813310327854E-4" WEIGHT="28.394776024562162"/>
<DICH_DATA CI_END="0.0400721465561677" CI_START="-0.10641605905392637" EFFECT_SIZE="-0.033171956248879336" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151" O_E="0.0" SE="0.03737012689150779" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0013965263838873936" WEIGHT="21.358704158659705"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23963437932639287" CI_END="0.01107587483292144" CI_START="-0.07854704213637782" DF="1.0" EFFECT_SIZE="-0.03373558365172819" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="52" I2="0.0" ID="CMP-025.01.02" LOG_CI_END="-1.9556219608064458" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.6244703368771825" P_Z="0.1400708425910523" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="389" WEIGHT="50.24651981677813" Z="1.475527268934471">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.011633968397981413" CI_START="-0.09885924312325614" EFFECT_SIZE="-0.04361263736263736" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="152" O_E="0.0" SE="0.028187561708478803" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="7.945386350693005E-4" WEIGHT="28.459744664291495"/>
<DICH_DATA CI_END="0.05314379316581272" CI_START="-0.0948104598324794" EFFECT_SIZE="-0.020833333333333343" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="153" O_E="0.0" SE="0.03774412544448173" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.001424619005568773" WEIGHT="21.786775152486634"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" NO="26">
<NAME>Liver function tests increase</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Healthy volunteers. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.05557511124631065" CI_START="-0.27779733346853286" EFFECT_SIZE="-0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="154" O_E="0.0" SE="0.08504555373069168" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.007232746209359965" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" NO="27">
<NAME>Pruritus</NAME>
<DICH_OUTCOME CHI2="7.782369818738635" CI_END="0.0013023148209600696" CI_START="-0.05051879371020548" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.024608239444622704" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="162" I2="22.902661531799595" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-2.885284016936417" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.2544851782893446" P_Q="0.0" P_Z="0.06268031876439618" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="1190" WEIGHT="100.0" Z="1.861452385002218">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.39828808057186" CI_END="0.007631268109541633" CI_START="-0.06138950193531717" DF="3.0" EFFECT_SIZE="-0.02687911691288777" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="89" I2="31.791643815883393" ID="CMP-027.01.01" LOG_CI_END="-2.1174032880981453" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.2215444101439651" P_Z="0.12687098106225975" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="56.812054390294165" Z="1.5265579057220513">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.08859262909499065" CI_START="-0.05179434813877255" EFFECT_SIZE="0.018399140478109047" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="155" O_E="0.0" SE="0.035813662480820505" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0012826184202901305" WEIGHT="11.940309943677143"/>
<DICH_DATA CI_END="0.057847590318447537" CI_START="-0.09339055710541815" EFFECT_SIZE="-0.017771483393485304" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="156" O_E="0.0" SE="0.038581869008005476" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.0014885606161508932" WEIGHT="13.481277894100213"/>
<DICH_DATA CI_END="0.0422758224810441" CI_START="-0.08364621679261487" EFFECT_SIZE="-0.020685197155785387" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="157" O_E="0.0" SE="0.032123559480407786" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="0.0010319230736912971" WEIGHT="17.779632624015125"/>
<DICH_DATA CI_END="-0.016009628584035693" CI_START="-0.1514146138402067" EFFECT_SIZE="-0.0837121212121212" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="158" O_E="0.0" SE="0.0345427228061914" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0011931996988653755" WEIGHT="13.610833928501684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3230224480058155" CI_END="0.017602624028605907" CI_START="-0.060844601819481176" DF="2.0" EFFECT_SIZE="-0.021620988895437634" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="73" I2="39.8138281852347" ID="CMP-027.01.02" LOG_CI_END="-1.7544225869472516" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.18985205536833416" P_Z="0.2799735525074205" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="43.187945609705835" Z="1.0803787919093522">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.10726318567935166" CI_START="-0.03667495038523401" EFFECT_SIZE="0.03529411764705882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="159" O_E="0.0" SE="0.03671958699240172" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0013483280688925577" WEIGHT="12.105495297570412"/>
<DICH_DATA CI_END="0.022799383720528553" CI_START="-0.09942276034390518" EFFECT_SIZE="-0.03831168831168831" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="160" O_E="0.0" SE="0.0311796913179289" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="9.721731506813308E-4" WEIGHT="17.739044819728925"/>
<DICH_DATA CI_END="0.021415330659849796" CI_START="-0.12354909433207498" EFFECT_SIZE="-0.05106688183611259" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="161" O_E="0.0" SE="0.036981400203112316" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0013676239609827557" WEIGHT="13.343405492406497"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.06315789473684211" CI_END="21.925614140589616" CI_START="-1.2940351932211893" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.315789473684212" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.02" NO="2" P_CHI2="0.8015726347619013" P_Q="0.8015726347619013" P_Z="0.08159497489965441" Q="0.06315789473684211" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="1.741505700611732">
<NAME>Postoperative ileus. Alvimopan: VAS maximum vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.49487580761404" CI_START="-6.49487580761404" DF="0.0" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-027.02.01" NO="1" P_CHI2="1.0" P_Z="0.25494518331179783" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="56.14035087719298" Z="1.1384199576606167">
<NAME>6 mg</NAME>
<CONT_DATA CI_END="24.49487580761404" CI_START="-6.49487580761404" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="16.0" ORDER="162" SD_1="29.0" SD_2="28.0" SE="7.905694150420948" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="56.14035087719298"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.944304526105059E-32" CI_END="29.530450811531637" CI_START="-5.530450811531631" DF="0.0" EFFECT_SIZE="12.000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-027.02.02" NO="2" P_CHI2="0.0" P_Z="0.1797124948858607" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="43.859649122807014" Z="1.341640786499874">
<NAME>12 mg</NAME>
<CONT_DATA CI_END="29.530450811531633" CI_START="-5.530450811531633" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="16.0" ORDER="163" SD_1="36.0" SD_2="28.0" SE="8.94427190999916" STUDY_ID="STD-Taguchi-2001" TOTAL_1="26" TOTAL_2="26" WEIGHT="43.859649122807014"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" NO="28">
<NAME>Nasal congestion</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Constipation. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0419776322595708" CI_START="-0.08033742061935917" EFFECT_SIZE="-0.01917989417989418" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="164" O_E="0.0" SE="0.03120339298164035" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="9.736517335666821E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" NO="29">
<NAME>Pyrexia</NAME>
<DICH_OUTCOME CHI2="0.5806203366006071" CI_END="0.0112005627115244" CI_START="-0.04033059665098011" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.014565016969727857" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="156" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="-1.9507601580109781" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9967147179487394" P_Q="0.0" P_Z="0.2678845226391027" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="1190" WEIGHT="100.0" Z="1.107947465107988">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.200248848130113" CI_END="0.014706763387421058" CI_START="-0.05275613838830861" DF="3.0" EFFECT_SIZE="-0.019024687500443775" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="84" I2="0.0" ID="CMP-029.01.01" LOG_CI_END="-1.832482894753518" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.9775491253254197" P_Z="0.2689740398218693" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="56.812054390294165" Z="1.1054283565197518">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.050363637033226966" CI_START="-0.09325019805032789" EFFECT_SIZE="-0.02144328050855046" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="165" O_E="0.0" SE="0.036636855630093834" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0013422591904603384" WEIGHT="11.940309943677143"/>
<DICH_DATA CI_END="0.0529235289463726" CI_START="-0.08079140778962722" EFFECT_SIZE="-0.013933939421627309" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="166" O_E="0.0" SE="0.034111580057267936" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="0.0011635998940033995" WEIGHT="13.481277894100213"/>
<DICH_DATA CI_END="0.05031874681294243" CI_START="-0.07383199826737036" EFFECT_SIZE="-0.011756625727213962" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="167" O_E="0.0" SE="0.03167169041359893" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="0.001003095973654854" WEIGHT="17.779632624015125"/>
<DICH_DATA CI_END="0.03852366836561742" CI_START="-0.10140245624440532" EFFECT_SIZE="-0.03143939393939395" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="168" O_E="0.0" SE="0.035696095875674794" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="0.0012742112607653671" WEIGHT="13.610833928501684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24061781698630536" CI_END="0.031180182892246167" CI_START="-0.048577172289898746" DF="2.0" EFFECT_SIZE="-0.00869849469882629" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="72" I2="0.0" ID="CMP-029.01.02" LOG_CI_END="-1.5061213417174035" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.8866465055735189" P_Z="0.6690041997038134" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="43.187945609705835" Z="0.4275150872412272">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.06954030465825255" CI_START="-0.07790631773014799" EFFECT_SIZE="-0.00418300653594772" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="169" O_E="0.0" SE="0.03761462546032495" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0014148600485205261" WEIGHT="12.105495297570412"/>
<DICH_DATA CI_END="0.04092812573012409" CI_START="-0.08151254131453967" EFFECT_SIZE="-0.020292207792207792" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="170" O_E="0.0" SE="0.031235438000509222" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="9.756525870836556E-4" WEIGHT="17.739044819728925"/>
<DICH_DATA CI_END="0.07720021181852185" CI_START="-0.0719644219673474" EFFECT_SIZE="0.0026178949255872275" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="171" O_E="0.0" SE="0.03805290172739419" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="0.0014480233298747192" WEIGHT="13.343405492406497"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" NO="30">
<NAME>Postoperative wound infection</NAME>
<DICH_OUTCOME CHI2="0.7839676226012119" CI_END="-4.956175365635924E-4" CI_START="-0.060759272535206035" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.030627445035884816" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.3759304847853301" P_Q="0.0" P_Z="0.04634889088761002" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="441" TOTAL_2="448" WEIGHT="100.0" Z="1.9922020730460694">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="-0.004147289468048224" CI_START="-0.08416439884364009" DF="0.0" EFFECT_SIZE="-0.04415584415584416" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" ID="CMP-030.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.030530876035472318" STUDIES="1" TAU2="0.0" TOTAL_1="220" TOTAL_2="224" WEIGHT="49.94286413908501" Z="2.1631339829133345">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="-0.004147289468048224" CI_START="-0.08416439884364009" EFFECT_SIZE="-0.04415584415584416" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="172" O_E="0.0" SE="0.02041290299381943" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="4.1668660863508226E-4" WEIGHT="49.94286413908501"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.027926010402567945" CI_START="-0.06218586819183749" DF="0.0" EFFECT_SIZE="-0.01712992889463477" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" ID="CMP-030.01.02" LOG_CI_END="-1.553991104539256" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.4561728606974239" STUDIES="1" TAU2="0.0" TOTAL_1="221" TOTAL_2="224" WEIGHT="50.05713586091499" Z="0.7451635503535182">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.027926010402567945" CI_START="-0.06218586819183749" EFFECT_SIZE="-0.01712992889463477" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="173" O_E="0.0" SE="0.02298814654381316" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="5.284548815198288E-4" WEIGHT="50.05713586091499"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2008-04-11 22:42:02 +0100" MODIFIED_BY="Ewan McNicol" NO="31">
<NAME>Treatment-related withdrawals</NAME>
<DICH_OUTCOME CHI2="13.528348795703945" CI_END="-0.006339815013541514" CI_START="-0.048157489568403385" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.02724865229097245" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="125" I2="40.86491913528667" I2_Q="0.0" ID="CMP-031.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-04-11 22:42:02 +0100" MODIFIED_BY="Ewan McNicol" NO="1" P_CHI2="0.09491784510917889" P_Q="0.0" P_Z="0.010641711838085736" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1558" TOTAL_2="1247" WEIGHT="100.0" Z="2.5542490196338106">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.534744981030518" CI_END="-0.018220961590382563" CI_START="-0.0831424769131921" DF="2.0" EFFECT_SIZE="-0.05068171925178733" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="59" I2="43.41883188933984" ID="CMP-031.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.1707811803151611" P_Z="0.002212362475732535" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="41.228059970402015" Z="3.0601363481475405">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="-0.01437484660672217" CI_START="-0.15294541483118632" EFFECT_SIZE="-0.08366013071895424" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="174" O_E="0.0" SE="0.035350284320908726" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0012496426015690854" WEIGHT="11.55614324908964"/>
<DICH_DATA CI_END="0.004180429620770934" CI_START="-0.10856354650388784" EFFECT_SIZE="-0.052191558441558455" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="175" O_E="0.0" SE="0.0287617469029964" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="8.27238084912023E-4" WEIGHT="16.93404011977533"/>
<DICH_DATA CI_END="0.01959889083758407" CI_START="-0.05711009757956005" EFFECT_SIZE="-0.01875560337098799" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="176" O_E="0.0" SE="0.019568979078752168" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="3.8294494218464E-4" WEIGHT="12.737876601537051"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4421604197313553" CI_END="0.010972216286174539" CI_START="-0.046209907828679175" DF="3.0" EFFECT_SIZE="-0.01761884577125232" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="64" I2="0.0" ID="CMP-031.01.02" LOG_CI_END="-1.9597056400971922" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.4858349539322505" P_Z="0.22712397598259393" STUDIES="4" TAU2="0.0" TOTAL_1="957" TOTAL_2="648" WEIGHT="54.272473602141396" Z="1.207800643832684">
<NAME>Alvimopan 12mg, postoperative ileus</NAME>
<DICH_DATA CI_END="0.09664688160968551" CI_START="-0.06853335309325612" EFFECT_SIZE="0.014056764258214699" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="177" O_E="0.0" SE="0.042138589281706766" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0017756607066523726" WEIGHT="11.398454070306075"/>
<DICH_DATA CI_END="0.03601423223522958" CI_START="-0.052872014683034416" EFFECT_SIZE="-0.008428891223902418" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="178" O_E="0.0" SE="0.02267547965661292" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="5.141773776574664E-4" WEIGHT="12.869492300432775"/>
<DICH_DATA CI_END="0.0032940664579108464" CI_START="-0.10906948473332916" EFFECT_SIZE="-0.052887709137709155" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="179" O_E="0.0" SE="0.028664697942806436" STUDY_ID="STD-Viscusi-2006" TOTAL_1="222" TOTAL_2="224" VAR="8.216649081523315E-4" WEIGHT="17.011358199409035"/>
<DICH_DATA CI_END="0.03246517251457724" CI_START="-0.04913183918124392" EFFECT_SIZE="-0.008333333333333338" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="180" O_E="0.0" SE="0.020815946706023165" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="4.3330363726799674E-4" WEIGHT="12.993169031993512"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.17725410645532302" CI_START="-5.4292066457711785E-6" DF="0.0" EFFECT_SIZE="0.08862433862433862" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-031.01.03" LOG_CI_END="-0.75140369470496" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0524469928003801" NO="3" P_CHI2="1.0" P_Z="0.05001403569383367" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="4.194323821402203" Z="1.9598439227397049">
<NAME>Alvimopan, constipation</NAME>
<DICH_DATA CI_END="0.17725410645532302" CI_START="-5.4292066457711785E-6" EFFECT_SIZE="0.08862433862433862" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="181" O_E="0.0" SE="0.04522010023147603" STUDY_ID="STD-Paulson-2005" TOTAL_1="56" TOTAL_2="54" VAR="0.0020448574649447387" WEIGHT="4.194323821402203"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.44445947671376507" CI_START="-0.7777928100470983" DF="0.0" EFFECT_SIZE="-0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-031.01.04" LOG_CI_END="-0.35216782938862956" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-04-11 22:42:02 +0100" MODIFIED_BY="Ewan McNicol" NO="4" P_CHI2="1.0" P_Z="0.5929801002813471" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="3" WEIGHT="0.3051426060543931" Z="0.5345224838248488">
<NAME>Naloxone, constipation</NAME>
<DICH_DATA CI_END="0.44445947671376507" CI_START="-0.7777928100470983" EFFECT_SIZE="-0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="182" O_E="0.0" SE="0.31180478223116176" STUDY_ID="STD-Liu-2002" TOTAL_1="6" TOTAL_2="3" VAR="0.09722222222222221" WEIGHT="0.3051426060543931"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10021460131223853" CI_END="0.06030893014542091" CI_START="-0.18944010561390473" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.06456558773424191" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-031.02" LOG_CI_END="-1.2196183756587322" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="2" P_CHI2="0.7515722818130802" P_Q="0.0" P_Z="0.3108753084802146" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="1.0133871085029804">
<NAME>Incidence vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.08158059222556101" CI_START="-0.181580592225561" DF="0.0" EFFECT_SIZE="-0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-031.02.01" LOG_CI_END="-1.0884131462932607" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.45640654492208277" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="64.39522998296422" Z="0.7447770037317515">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.08158059222556101" CI_START="-0.181580592225561" EFFECT_SIZE="-0.05" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="183" O_E="0.0" SE="0.06713418882359672" STUDY_ID="STD-Gonenne-2005" TOTAL_1="18" TOTAL_2="20" VAR="0.004506999309002338" WEIGHT="64.39522998296422"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.13306759784501235" CI_START="-0.3148857796631942" DF="0.0" EFFECT_SIZE="-0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-031.02.02" LOG_CI_END="-0.8759276829945928" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.42630950882483953" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="11" WEIGHT="35.60477001703578" Z="0.7955227172981036">
<NAME>Naloxone, healthy volunteers</NAME>
<DICH_DATA CI_END="0.13306759784501235" CI_START="-0.3148857796631942" EFFECT_SIZE="-0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="184" O_E="0.0" SE="0.11427592063976828" STUDY_ID="STD-Murphy-1997" TOTAL_1="10" TOTAL_2="11" VAR="0.013058986038066617" WEIGHT="35.60477001703578"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" NO="32">
<NAME>Serious adverse events</NAME>
<DICH_OUTCOME CHI2="28.97615299621497" CI_END="-0.01839375359151809" CI_START="-0.05813530772212338" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.038264530656820735" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="119" I2="75.84220375660502" I2_Q="0.0" ID="CMP-032.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="1.4614336475859968E-4" P_Q="0.0" P_Z="1.6049553634277594E-4" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1545" TOTAL_2="1242" WEIGHT="100.0" Z="3.7742410237017663">
<NAME>Incidence vs. placebo</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.05134876143288" CI_END="-0.013330341976450277" CI_START="-0.07669407266004111" DF="2.0" EFFECT_SIZE="-0.04501220731824569" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="56" I2="88.92049549076883" ID="CMP-032.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.2028230011762453E-4" P_Z="0.005358866489731239" STUDIES="3" TAU2="0.0" TOTAL_1="539" TOTAL_2="542" WEIGHT="41.497363820098954" Z="2.784631026507994">
<NAME>Alvimopan 6 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="-0.020306228162089324" CI_START="-0.17237351040000215" EFFECT_SIZE="-0.09633986928104574" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="185" O_E="0.0" SE="0.03879338687787126" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="0.0015049268654561943" WEIGHT="11.631628582788661"/>
<DICH_DATA CI_END="-0.004727934583855127" CI_START="-0.10923310437718384" EFFECT_SIZE="-0.056980519480519486" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="186" O_E="0.0" SE="0.026659971973376082" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="7.107541056211983E-4" WEIGHT="17.04465415784677"/>
<DICH_DATA CI_END="0.047983179385932405" CI_START="-0.01305400599522056" EFFECT_SIZE="0.017464586695355923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="187" O_E="0.0" SE="0.015570996677134501" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="2.4245593751933369E-4" WEIGHT="12.82108107946352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.359915323929368" CI_END="-0.010296731493114893" CI_START="-0.06432951121958166" DF="3.0" EFFECT_SIZE="-0.037313121356348275" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="63" I2="64.11446906151286" ID="CMP-032.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.03913054575806796" P_Z="0.006790177732513306" STUDIES="4" TAU2="0.0" TOTAL_1="956" TOTAL_2="648" WEIGHT="54.58816012474239" Z="2.7069632315582193">
<NAME>Alvimopan 12 mg, postoperative ileus</NAME>
<DICH_DATA CI_END="-0.0016572918090577704" CI_START="-0.15887632803157253" EFFECT_SIZE="-0.08026680992031515" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="188" O_E="0.0" SE="0.04010763398272582" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="0.0016086223036923032" WEIGHT="11.472909370020172"/>
<DICH_DATA CI_END="0.04184737917331519" CI_START="-0.06254270559297803" EFFECT_SIZE="-0.010347663209831423" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="189" O_E="0.0" SE="0.02663061300863406" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="7.091895492156296E-4" WEIGHT="12.953556499006263"/>
<DICH_DATA CI_END="0.0052735007422969465" CI_START="-0.10166975155031248" EFFECT_SIZE="-0.048198125404007766" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="190" O_E="0.0" SE="0.027281943223488838" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="7.443044260496685E-4" WEIGHT="17.083653162252876"/>
<DICH_DATA CI_END="0.007988494296535564" CI_START="-0.032230918538959805" EFFECT_SIZE="-0.012121212121212121" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="191" O_E="0.0" SE="0.010260242829138944" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="1.0527258291289714E-4" WEIGHT="13.078041093463074"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.07317463982858703" CI_START="-0.033174639828587024" DF="0.0" EFFECT_SIZE="0.02" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-032.01.03" LOG_CI_END="-1.135639406520985" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6989700043360187" NO="3" P_CHI2="1.0" P_Z="0.46101291480131135" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="52" WEIGHT="3.9144760551586595" Z="0.7371799755891774">
<NAME>Alvimopan, constipation</NAME>
<DICH_DATA CI_END="0.07317463982858703" CI_START="-0.033174639828587024" EFFECT_SIZE="0.02" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="192" O_E="0.0" SE="0.027130416807666775" STUDY_ID="STD-Paulson-2005" TOTAL_1="50" TOTAL_2="52" VAR="7.360595161577277E-4" WEIGHT="3.9144760551586595"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.08946394721363131" CI_START="-0.08946394721363131" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-032.02" LOG_CI_END="-1.0483519443560583" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Incidence vs. placebo, healthy volunteers</NAME>
<GROUP_LABEL_1>Opioid antagonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.09930932864748786" CI_START="-0.09930932864748786" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-032.02.01" LOG_CI_END="-1.0030099540238744" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="60.63829787234043" Z="0.0">
<NAME>Alvimopan, healthy volunteers</NAME>
<DICH_DATA CI_END="0.09930932864748786" CI_START="-0.09930932864748786" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="193" O_E="0.0" SE="0.05066895587410134" STUDY_ID="STD-Gonenne-2005" TOTAL_1="19" TOTAL_2="18" VAR="0.0025673430893716287" WEIGHT="60.63829787234043"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.14783867756078112" CI_START="-0.14783867756078112" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-032.02.02" LOG_CI_END="-0.8302119309360907" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="39.361702127659576" Z="0.0">
<NAME>Naloxone, healthy volunteers</NAME>
<DICH_DATA CI_END="0.14783867756078112" CI_START="-0.14783867756078112" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="194" O_E="0.0" SE="0.07542928274545539" STUDY_ID="STD-Hawkes-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.005689576695493855" WEIGHT="39.361702127659576"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" NO="33">
<NAME>Rehospitalization</NAME>
<DICH_OUTCOME CHI2="6.56008690177582" CI_END="-0.007133565827406506" CI_START="-0.051770335914181585" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.029451950870794046" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="77" I2="39.025197990636414" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.16104365245131802" P_Q="0.0" P_Z="0.009697810564355003" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1199" TOTAL_2="884" WEIGHT="100.0" Z="2.586422040348391">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0016660473511624023" CI_END="-6.129173443852332E-4" CI_START="-0.0758485537971985" DF="1.0" EFFECT_SIZE="-0.03823073557079187" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="38" I2="0.0" ID="CMP-033.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.9674415986662684" P_Z="0.04638222732697651" STUDIES="2" TAU2="0.0" TOTAL_1="389" TOTAL_2="389" WEIGHT="40.92262502533303" Z="1.99189821084911">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.014766416492039455" CI_START="-0.09252615675177973" EFFECT_SIZE="-0.03887987012987014" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="195" O_E="0.0" SE="0.02737105734853531" STUDY_ID="STD-Viscusi-2006" TOTAL_1="220" TOTAL_2="224" VAR="7.491747803768088E-4" WEIGHT="23.35492447266686"/>
<DICH_DATA CI_END="0.013546759560624407" CI_START="-0.08828228044999142" EFFECT_SIZE="-0.03736776044468351" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="196" O_E="0.0" SE="0.025977273259567602" STUDY_ID="STD-Wolff-2004" TOTAL_1="169" TOTAL_2="165" VAR="6.748187260022459E-4" WEIGHT="17.567700552666178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9117809694932175" CI_END="0.003982158574671647" CI_START="-0.050724013014388517" DF="2.0" EFFECT_SIZE="-0.023370927219858433" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" I2="48.872393020023665" ID="CMP-033.01.02" LOG_CI_END="-2.3998814497999104" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.14143863337811036" P_Z="0.09400772810426378" STUDIES="3" TAU2="0.0" TOTAL_1="810" TOTAL_2="495" WEIGHT="59.07737497466696" Z="1.6746255241662502">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.0149914985917309" CI_START="-0.02417419309581971" EFFECT_SIZE="-0.004591347252044405" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="197" O_E="0.0" SE="0.009991431474375189" STUDY_ID="STD-Herzog-2006" TOTAL_1="413" TOTAL_2="106" VAR="9.982870290713517E-5" WEIGHT="17.749221010004483"/>
<DICH_DATA CI_END="0.029739835609728427" CI_START="-0.08100841996654809" EFFECT_SIZE="-0.02563429217840983" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="198" O_E="0.0" SE="0.028252625162973558" STUDY_ID="STD-Viscusi-2006" TOTAL_1="221" TOTAL_2="224" VAR="7.982108285994867E-4" WEIGHT="23.40836168494344"/>
<DICH_DATA CI_END="0.011217865512413758" CI_START="-0.08924816854271678" EFFECT_SIZE="-0.03901515151515151" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="199" O_E="0.0" SE="0.025629561269389076" STUDY_ID="STD-Wolff-2004" TOTAL_1="176" TOTAL_2="165" VAR="6.568744108613686E-4" WEIGHT="17.91979227971904"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" NO="34">
<NAME>Death</NAME>
<DICH_OUTCOME CHI2="0.9000035710289521" CI_END="0.014799164534945468" CI_START="-0.014266534097713108" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RD" EFFECT_SIZE="2.663152186161809E-4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-034.01" LOG_CI_END="-1.8297628013688636" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-3.5746040150399185" METHOD="MH" NO="1" P_CHI2="0.34278087384185063" P_Q="0.0" P_Z="0.9713489856430441" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="306" WEIGHT="100.00000000000001" Z="0.035916441825082135">
<NAME>Postoperative ileus. Alvimopan: incidence vs. placebo</NAME>
<GROUP_LABEL_1>Alvimopan</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors alvimopan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.011479590286867021" CI_START="-0.024551485711703624" DF="0.0" EFFECT_SIZE="-0.006535947712418301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-034.01.01" LOG_CI_END="-1.9400736118795174" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.47704383907860826" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="153" WEIGHT="50.343480603448285" Z="0.7110651994786393">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.011479590286867021" CI_START="-0.024551485711703624" EFFECT_SIZE="-0.006535947712418301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="200" O_E="0.0" SE="0.009191769920972828" STUDY_ID="STD-Delaney-2005" TOTAL_1="150" TOTAL_2="153" VAR="8.448863428010084E-5" WEIGHT="50.343480603448285"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.5735252656288467E-33" CI_END="0.02993374853059433" CI_START="-0.01560838368145833" DF="0.0" EFFECT_SIZE="0.007162682424567999" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="100.0" ID="CMP-034.01.02" LOG_CI_END="-1.5238388941115297" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.1449243039461114" NO="2" P_CHI2="0.0" P_Z="0.53755769868064" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="153" WEIGHT="49.65651939655173" Z="0.6165104224582624">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.02993374853059433" CI_START="-0.01560838368145833" EFFECT_SIZE="0.007162682424568" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="201" O_E="0.0" SE="0.011618104355815511" STUDY_ID="STD-Delaney-2005" TOTAL_1="146" TOTAL_2="153" VAR="1.3498034882261937E-4" WEIGHT="49.65651939655173"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Combined hazard ratios for alvimopan studies in postoperative ileus</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAugAAAHhCAIAAACz39ySAAAs0UlEQVR42u3dMXabzNcH4Gww+/Ai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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-04-11 22:23:09 +0100" MODIFIED_BY="Ewan McNicol">
<APPENDIX ID="APP-01" MODIFIED="2008-04-11 22:23:09 +0100" MODIFIED_BY="Ewan McNicol" NO="1">
<TITLE MODIFIED="2008-04-11 22:23:02 +0100" MODIFIED_BY="Ewan McNicol">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-04-11 22:23:09 +0100" MODIFIED_BY="Ewan McNicol">
<P>1. constipation.mp. or exp Constipation/<BR/>2. exp ileus/<BR/>3. exp Gastrointestinal motility/ or Gastrointestinal Transit/ or exp Gastrointestinal Tract/ or exp Gastric emptying/<BR/>4. exp Colonic Diseases, Functional/<BR/>5. 1 or 2 or 3 or 4<BR/>6. exp Narcotic antagonists/<BR/>7. exp Opioid antagonist/ or Receptors, opioid, mu.mp. or Receptors, opioid, kappa.mp. or Receptors, opioid delta.mp. or exp Receptors, Opioid, mu/ai or mu opioid receptors.mp. or kappa opioid receptors.mp. or delta opioid receptors.mp.<BR/>8. (Naltrexone or Naloxone or Methylnaltrexone or nalmefene or Alvimopan or ADL 8-2698 or LY246736).mp.<BR/>9. (pentazocine or nalbuphine or buprenorphine or dezocine or butorphanol).mp.<BR/>10. 6 or 7 or 8 or 9<BR/>11. randomized controlled trial.pt.<BR/>12. meta-analysis.pt.<BR/>13. controlled-clinical-trial.pt.<BR/>14. clinical-trial.pt.<BR/>15. random:.ti,ab,sh.<BR/>16. (meta-anal: or metaanaly: or meta analy:).ti,ab,sh.<BR/>17. ((doubl: or singl:) and blind:).ti,ab,sh.<BR/>18. exp clinical trials/<BR/>19. crossover.ti,ab,sh.<BR/>20. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19<BR/>21. 5 and 10 and 20<BR/>22. limit 21 to humans</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>